Feeds:
Posts
Comments

Archive for the ‘Conference Coverage with Social Media’ Category

Tweets and Re-Tweets of Tweets by @pharma_BI@AVIVA1950 at 2021 Virtual World Medical Innovation Forum, Mass General Brigham, Gene and Cell Therapy, VIRTUAL May 19–21, 2021

REAL TIME EVENT COVERAGE as PRESS by invitation from 2021 Virtual World Medical Innovation Forum at #WMIF2021 @MGBInnovation:

Aviva Lev-Ari, PhD, RN

Tweet Collection Curator:

Aviva Lev-Ari, PhD, RN

UPDATED Twitter Analytics

May 2021  31 days

TWEET HIGHLIGHTS

Top Tweet earned 611 impressions

@MGBInnovation#WMIF Best Global event on Gene Cell Therapy covered in real time @AVIVA1950@pharma_BI Disruptive Dozen technologies four are based on Gene Editing, AAV and non viral vector for drug delivery are included pic.twitter.com/9Q2dWikhNd 1  2

View all Tweet activity View Tweet activity

Top Follower followed by 7,598 people

Ryan Gravatt@gravatt FOLLOWS YOU

Christian, father, husband. Owner @RaconteurMC. Strategist for comms, digital. Former award-winning journalist. Proverbs 3:5-6 View profile

Top mention earned 15 engagements

#COVID#vaccines by @Pfizer, @AstraZeneca are probed in @Europe after reports of #heart#inflammation, rare #nerve#disorderpharmaceuticalintelligence.com/2021/05/14/cov… via @pharma_BI@AVIVA1950 1  3View all Tweet activityView Tweet activity

MAY 2021 SUMMARY

Tweets

213

Tweet impressions

17.6K

Profile visits

861

Mentions

211

New followers

2

These are the Tweets and the Re-Tweets

by Day, 5/21, 5/20, 5/19 for

2021 Virtual World Medical Innovation Forum, Mass General Brigham, Gene and Cell Therapy, VIRTUAL May 19–21, 2021

Real Time coverage: Aviva Lev-Ari, PhD, RN

LPBI Group’s Logo
Aviva Lev-Ari, PhD, RN, Founder, 1.0 LPBI Group and 2.0 LPBI Group

May 21, 2021

TWEETS AND RE-TWEETS for 2021 World Medical Innovation Forum, Mass General Brigham, Gene and Cell Therapy, VIRTUAL May 19–21, 2021

PART 1: ALL THE TWEETS PRODUCED by @AVIVA1950 on May 21, 2021

Part 2: ALL THE RE-TWEETS by @AVIVA1950 on

May 21, 2021

Tweets Originator for Part 1: Aviva Lev-Ari, PhD, RN

From: Mass General Brigham <innovations@partners.org>
Reply-To: <innovations@partners.org>
Date: Monday, May 24, 2021 at 9:31 AM
To: “Aviva Lev-Ari, PhD, RN” <AvivaLev-Ari@alum.berkeley.edu>
Subject: RECAP | World Forum | Day 3 | GCT | CEOs | Harvard | Investors

Notable Tweets
@mandywoodland Fascinating #WMIF2021 panel on mRNA yesterday -“mRNA is the message, and we just have to decide what message we want to deliver to the cell,” said moderator Lindsey Baden, MD. “The promise of this technology could not be more front and center for all of us.”   @LeapsByBayer Congratulations to the 2021 Innovation Discovery Grants winners: @lynchielydia, Peter Sage, @GrishchukL, Benjamin Kleinstiver, Petr Baranov, announced at the #WMIF2021. It’s exciting to see the range of breakthrough research in #geneticdisease at @MassGenBrigham@DrLilitGaribyan Gene and cell therapy have scalability problems that we need to solve. This is what is echoed this week at @MGBInnovation World Medical Innovation Forum. #gct #celltherapy #healthcare #innovation   @MPDexpert “imagine how the future could look if gene therapy cost 1/100th what it does today” @VCAmir @PolarisVC #wmif2021  
@AVIVA1950 #WMIF2021 @MGBInnovation Roger Kitterman VP, Venture, Mass General Brigham Saturation reached or more investment is coming in CGT Multi OMICS and academia originated innovations are the most attractive areas @pharma_BI @AVIVA1950
Notable Tweets

 

Disruptive Dozen

2021 World Medical Innovation Forum on

YouTube

https://www.youtube.com/results?search_query=Disruptive+Dozen+2021+World+Medical+Innovation+Forum

Example for a TWEET

Aviva Lev-Ari

@AVIVA1950

·

May 21

@MGBInnovation

#WMIF Best Global event on Gene Cell Therapy covered in real time

@AVIVA1950

@pharma_BI

Disruptive Dozen technologies four are based on Gene Editing, AAV and non viral vector for drug delivery are included

2

2

Example for a RE-TWEET

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

May 21

Thanks

@AVIVA1950

for sharing this screen capture of the impressive lineup of #GCT “Disruptive Dozen” panelists at #WMIF2021

Quote Tweet

Aviva Lev-Ari

@AVIVA1950

 · May 21

@MGBInnovation #WMIF Best Global event on Gene Cell Therapy covered in real time @AVIVA1950 @pharma_BI Disruptive Dozen technologies four are based on Gene Editing, AAV and non viral vector for drug delivery are included

 PART 1: ALL THE TWEETS PRODUCED by @AVIVA1950 on May 21, 2021

Aviva Lev-Ari

@AVIVA1950

·

4h

#WMIF2021

@MGBInnovation

Erwan Bezard, PhD INSERM Research Director, Institute of Neurodegenerative Diseases Cautious on reversal

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

4h

#WMIF2021

@MGBInnovation

Nikola Kojic, PhD CEO and Co-Founder, Oryon Cell Therapies Autologus cell therapy placed focal replacing missing synapses reestablishment of neural circutary

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

4h

#WMIF2021

@MGBInnovation

Bob Carter, MD, PhD Chairman, Department of Neurosurgery, MGH William and Elizabeth Sweet, Professor of Neurosurgery, HMS Neurogeneration REVERSAL or slowing down? 

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

4h

#WMIF2021

@MGBInnovation

Penelope Hallett, PhD NRL, McLean Assistant Professor Psychiatry, HMS efficacy Autologous cell therapy transplantation approach program T cells into dopamine genetating cells greater than Allogeneic cell transplantation 

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

4h

#WMIF2021

@MGBInnovation

Penelope Hallett, PhD NRL, McLean Assistant Professor Psychiatry, HMS Pharmacologic agent in existing cause another disorders locomo-movement related 

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

4h

#WMIF2021

@MGBInnovation

Roger Kitterman VP, Venture, Mass General Brigham Saturation reached or more investment is coming in CGT Multi OMICS and academia originated innovations are the most attractive areas

@pharma_BI

@AVIVA1950

1

3

Aviva Lev-Ari

@AVIVA1950

·

4h

#WMIF2021

@MGBInnovation

Roger Kitterman VP, Venture, Mass General Brigham Saturation reached or more investment is coming in CGT 

@pharma_BI

@AVIVA1950

1

Aviva Lev-Ari

@AVIVA1950

·

4h

#WMIF2021

@MGBInnovation

Oleg Nodelman Founder & Managing Partner, EcoR1 Capital Invest in company next round of investment will be IPO 20% discount

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

4h

#WMIF2021

@MGBInnovation

Peter Kolchinsky, PhD Founder and Managing Partner, RA Capital Management Future proof for new comers disruptors  Ex Vivo gene therapy to improve funding products what tool kit belongs to 

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

4h

#WMIF2021

@MGBInnovation

Deep Nishar Senior Managing Partner, SoftBank Investment Advisors Young field vs CGT started in the 80s  high payloads is a challenge 

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

5h

#WMIF2021

@MGBInnovation

Bob Carter, MD, PhD MGH, HMS cells producing dopamine transplantation fibroblast cells metabolic driven process lower mutation burden  Quercetin inhibition elimination undifferentiated cells graft survival oxygenation increased 

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

5h

#WMIF2021

@MGBInnovation

Chairman, Department of Neurosurgery, MGH, Professor of Neurosurgery, HMS Cell therapy for Parkinson to replace dopamine producing cells lost ability to produce dopamine skin cell to become autologous cells reprogramed  

@pharma_BI

@AVIVA1950

#WMIF2021

@MGBInnovation

Kapil Bharti, PhD Senior Investigator, Ocular and Stem Cell Translational Research Section, NIH Off-th-shelf one time treatment becoming cure  Intact tissue in a dish is fragile to maintain metabolism to become like semiconductors

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

5h

#WMIF2021

@MGBInnovation

Ole Isacson, MD, PhD Director, Neuroregeneration Research Institute, McLean Professor, Neurology and Neuroscience, MGH, HMS Opportunities in the next generation of the tactical level Welcome the oprimism and energy level of all

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

5h

#WMIF2021

@MGBInnovation

Erin Kimbrel, PhD Executive Director, Regenerative Medicine, Astellas In the ocular space immunogenecity regulatory communication use gene editing for immunogenecity Cas1 and Cas2 autologous cells

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

5h

#WMIF2021

@MGBInnovation

Nabiha Saklayen, PhD CEO and Co-Founder, Cellino scale production of autologous cells foundry using semiconductor process in building cassettes by optic physicists

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

5h

#WMIF2021

@MGBInnovation

Joe Burns, PhD VP, Head of Biology, Decibel Therapeutics Ear inside the scall compartments and receptors responsible for hearing highly differentiated tall ask to identify cell for anticipated differentiation control by genomics

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

5h

#WMIF2021

@MGBInnovation

Kapil Bharti, PhD Senior Investigator, Ocular and Stem Cell Translational Research Section, NIH first drug required to establish the process for that innovations design of animal studies not done before 

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

5h

#WMIF2021

@MGBInnovation

Meredith Fisher, PhD Partner, Mass General Brigham Innovation Fund Strategies, success what changes are needed in the drug discovery process@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

5h

#WMIF2021

@MGBInnovation

Robert Nelsen Managing Director, Co-founder, ARCH Venture Partners Manufacturing change is not a new clinical trial FDA need to be presented with new rethinking for big innovations Drug pricing cheaper requires systematization

@pharma_BI

@AVIVA1950

1

Aviva Lev-Ari

@AVIVA1950

·

5h

#WMIF2021

@MGBInnovation

Kush Parmar, MD, PhD Managing Partner, 5AM Ventures Responsibility mismatch should be and what is “are”

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

5h

#WMIF2021

@MGBInnovation

David Berry, MD, PhD CEO, Valo Health GP, Flagship Pioneering Bring disruptive frontier platform reliable delivery CGT double knockout disease cure all change efficiency scope human centric vs mice centered right scale acceleration

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

6h

#WMIF2021

@MGBInnovation

Kush Parmar, MD, PhD Managing Partner, 5AM Ventures build it yourself, benefit for patients FIrst Look at MGB shows MEE innovation on inner ear worthy investment  

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

6h

#WMIF2021

@MGBInnovation

Robert Nelsen Managing Director, Co-founder, ARCH Venture Partners Frustration with supply chain during the Pandemic, GMC anticipation in advance CGT rapidly prototype rethink and invest proactive investor .edu and Pharma

@pharma_BI

@AVIVA1950

Part 2: ALL THE RE-TWEETS by @AVIVA1950 on

May 21, 2021

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

4h

The # of US patients with Parkinson’s Disease is expected to double over next 30 years. Penelope Hallett PhD, Co-Director of the Neuroregeneration Research Inst

@McLeanHospital

, presents a #regenerativemedicine approach that could alter that trajectory. #WMIF2021

1

1

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

4h

Our “Capital Formation ’21-30 | Investing Modes Driving GCT Technology and Timing” panelists have taken the stage. #WMIF2021

1

1

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

3h

CAR-T therapies have proven remarkably effective. Now,

@MassGenBrigham

researchers including

@MGHCancerCenter

Marcela Maus, MD PhD, are working to expand the reach of this transformative technology. #WMIF2021

Quote Tweet

Mass General Brigham Innovation

@MGBInnovation

 · 3h

Disruptive Dozen: 12 Technologies that Will Reinvent GCT #9. Building the Next Wave of CAR-T-cell Therapies #WMIF2021 #GCT #GeneAndCellTherapy #CellTherapy #CarT #DisruptiveDozen

1

2

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

3h

Disruptive Dozen: 12 Technologies that Will Reinvent GCT #6. Eyes and Ears: Expanding Gene Therapy’s Reach #WMIF2021 #GCT #GeneAndCellTherapy #GeneTherapy #DisruptiveDozen

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

May 20

If you’ve missed some First Look sessions, don’t worry! We’ve got you covered. Our First Look On-Demand videos, featuring 18

@MassGenBrigham

investigators giving previews of their #GCT research, are available to view on the #WMIF2021 conference platform. https://worldmedicalinnovation.org/register/

5

7

You Retweeted

REGENXBIO

@REGENXBIO

·

May 19

This morning at 10:20 a.m. ET, our CEO, Ken Mills, will be participating live on the AAV Success Studies virtual panel at the #WMIF2021, hosted by

@MGBInnovation

. Click here to register: https://bit.ly/33tHTti #Genetherapy

Register | World Medical Innovation Forum – Gene and Cell Therapy

Hear from industry-leading experts discuss the advances and future of GCT in health care. May 19-21, 2021; Mass General Brigham. Register!

worldmedicalinnovation.org

2

3

You Retweeted

Brett P. Monia, Ph.D.

@BPMonia

·

May 20

Looking forward to joining

@MGBInnovation

and global colleagues at #WMIF2021. On Thursday, May 20, my colleagues and I will discuss the advantages of RNA-targeted medicines and how they might shape the future of medicine for patients.

Quote Tweet

Mass General Brigham Innovation

@MGBInnovation

 · May 10

Are you part of the @MassGenBrigham network and interested in #GeneAndCellTherapy? Join us at the World Medical Innovation Forum on 5/19-5/21. Register today! https://worldmedicalinnovation.org/register/ #WMIF2021

1

5

You Retweeted

Maria Luiza Gutierrez de Andrade Seixas

@MLGASeixas

·

May 16

Incredible opportunity to get up to speed with the most innovative technologies in medicine ! Gene and cell therapy are revolutionizing healthcare ! #WMIF2021 #MedTwitter

Quote Tweet

Mass General Brigham Innovation

@MGBInnovation

 · May 11

#WMIF2021 is an opportunity for innovators from around the globe to meet, explore, challenge, and reflect on the issues influencing the adoption of novel technologies in #healthcare. Register now to join the conversation: https://worldmedicalinnovation.org/register/

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

3h

Currently, the only cure for some common blood disorders is a bone marrow transplant, which can be risky. Now, gene therapies are also in the works, including a CRISPR-based #genetherapy being tested in clinical trials with encouraging early results. #WMIF2021

Quote Tweet

Mass General Brigham Innovation

@MGBInnovation

 · 3h

Disruptive Dozen: 12 Technologies that Will Reinvent GCT #2. A Genetic Fix for Two Common Blood Disorders #WMIF2021 #GCT #GeneAndCellTherapy #BloodDisorders #DisruptiveDozen

2

1

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

3h

Researchers have pinpointed key genes involved in cholesterol and lipid metabolism that represent promising targets for new cholesterol-lowering treatments. #WMIF2021

Quote Tweet

Mass General Brigham Innovation

@MGBInnovation

 · 3h

Disruptive Dozen: 12 Technologies that Will Reinvent GCT #1. A New Generation of Cholesterol-Loweing Therapies #WMIF2021 #GCT #GeneAndCellTherapy #DisruptiveDozen

2

1

You Retweeted

Harvard Ophthalmology

@HMSeye

·

May 19

The

@MGBInnovation

#WMIF2021 event kicks of this morning! Congratulations to faculty member and event Co-Chair

@VandenbergheLuk

on putting together such a terrific program. Register: https://bit.ly/3uWYB0E

4

9

You Retweeted

Yulia Grishchuk Lab

@GrishchukL

·

4h

I really enjoyed this remarkable panel #WMIF2021. Thank you Meredith Fisher for moderating and thank you David, Bob and Kush for openly sharing your big picture view

1

4

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

2h

Thank you to our World Medical Innovation Forum Collaborators

@Amplify_Bio

@bostonsci

@CanonUSA

@CatalentPharma

@InterSystems

@nlvcofficial

@onemedical

@ReconStrategy

@SiemensHealth

@thermofisher

@VertexPharma

#WMIF2021

You Retweeted

Tracy Doyle

@doylet

·

5h

Variability, delays, manufacturing as an afterthought make #GCT challenging from an investment POV — need to rethink the ecosystem and drive efficiency, invest in tech innovation says Bob Nelson ARCH Venture Partners

@MGBInnovation

#WMIF2021

1

You Retweeted

Tracy Doyle

@doylet

·

5h

We need to change the scale and scope of how #GCT is advancing from discovery to development — systematization critical. Can’t have thousands of one-off therapies say early-stage investors. Major mis-match between where things are now and what could be.

@MGBInnovation

#WMIF202

2

2

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

3h

Disruptive Dozen: 12 Technologies that Will Reinvent GCT #8. Replacing What’s Lost: Stem Cell Therapies for Diabetes #WMIF2021 #GCT #GeneAndCellTherapy #StemCell #StemCellResearch #Diabetes #DisruptiveDozen

3

2

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

21h

An overview of our CEO Panel featuring Lisa Deschamps of

@NovartisGene

, Kieran Murphy of

@GEHealthcare

and Christian Rommel PhD, of

@Bayer

#WMIF2021

4

7

You Retweeted

Mass General Brigham

@MassGenBrigham

·

4h

Gene and cell therapies could change the future of medicine for patients w chronic disease or rare/ultra-rare disease – hear how

@MassGenBrigham

is working w the GCT ecosystem to drive new discoveries from bench to bedside #GCT #WMIF2021

5

11

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

2h

That’s a wrap! Thank you to everyone who helped make #WMIF2021 such a success, especially our incredible sponsors:

@NovartisGene

@Bayer

@GEHealthcare

@AstellasUS

@biogen

@FujifilmHealth

and more. Full list: https://worldmedicalinnovation.org/sponsors/

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

3h

Disruptive Dozen: 12 Technologies that Will Reinvent GCT #1. A New Generation of Cholesterol-Loweing Therapies #WMIF2021 #GCT #GeneAndCellTherapy #DisruptiveDozen

5

2

You Retweeted

Natalie Artzi

@NatalieArtzi

·

17h

Today I moderated a panel on Gene and Cell Therapy Delivery, Perfecting the Technology. We highlighted non-viral delivery technologies as key enablers of gene therapy and editing. Learn more: https://lnkd.in/d-Xqzqh #WMIF2021

3

12

You Retweeted

Yulia Grishchuk Lab

@GrishchukL

·

5h

Thank you

@MGBInnovation

and

@LeapsByBayer

for this award! Congratulations to

@BKleinstiver

and all other winners!

@MGH_RI

@CGM_MGH

! #WMIF2021

Quote Tweet

Leaps by Bayer

@LeapsByBayer

 · 6h

Congratulations to the 2021 Innovation Discovery Grants winners: @lynchielydia, Peter Sage, @GrishchukL, Benjamin Kleinstiver, Petr Baranov, announced at the #WMIF2021. It’s exciting to see the range of breakthrough research in #geneticdisease at @MassGenBrigham…

Show this thread

2

5

You Retweeted

Natalie Artzi

@NatalieArtzi

·

17h

An artistic description of an exciting panel I led today, at the World Biomedical Innovation Forum, discussing the future of non-viral delivery systems for gene therapy. #MatthewStanton #LauraSeppLorenzino #DouglasWilliams #SonyaMontgomery #WMIF2021

May 20, 2021

TWEETS AND RE-TWEETS for 2021 World Medical Innovation Forum, Mass General Brigham, Gene and Cell Therapy, VIRTUAL May 19–21, 2021

PART 1: ALL THE TWEETS PRODUCED by @AVIVA1950 on May 20, 2021

Part 2: ALL THE RE-TWEETS by @AVIVA1950 on

May 20, 2021

Tweets Originator for Part 1: Aviva Lev-Ari, PhD, RN

Example for a TWEET

Aviva Lev-Ari

@AVIVA1950

·

May 21

@MGBInnovation

#WMIF Best Global event on Gene Cell Therapy covered in real time

@AVIVA1950

@pharma_BI

Disruptive Dozen technologies four are based on Gene Editing, AAV and non viral vector for drug delivery are included

2

2

Example for a RE-TWEET

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

May 21

Thanks

@AVIVA1950

for sharing this screen capture of the impressive lineup of #GCT “Disruptive Dozen” panelists at #WMIF2021

Quote Tweet

Aviva Lev-Ari

@AVIVA1950

 · May 21

@MGBInnovation #WMIF Best Global event on Gene Cell Therapy covered in real time @AVIVA1950 @pharma_BI Disruptive Dozen technologies four are based on Gene Editing, AAV and non viral vector for drug delivery are included

PART 1: ALL THE TWEETS PRODUCED by @AVIVA1950 on May 20, 2021

Aviva Lev-Ari

@AVIVA1950

·

2h

#WMIF2021

@MGBInnovation

Bob Brown, PhD CSO, EVP of R&D, Dicerna small molecule vs capacity of nanoparticles to deliver therapeutics quantity for more molecule is much larger CNS delivery most difficult

@pharma_BI

@AVIVA1950



Aviva Lev-Ari

@AVIVA1950

·

9h

#WMIF2021

@MGBInnovation

Jeannie Lee, MD, PhD Molecular Biologist, MGH Prof Genetics, HMS 200 disease X chromosome unlock for neurological genetic diseases: Rett Syndrome, autism spectrum disorders female model vs male mice model restore own protein

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

9h

#WMIF2021

@MGBInnovation

Suneet Varma Global President of Rare Disease, Pfizer review of protocols and CGT for Hemophilia Pfizer: You can’t buy Time With MIT Pfizer is developing a model for Hemophilia CGT treatment

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

9h

#WMIF2021

@MGBInnovation

Gallia Levy, MD, PhD CMO, Spark Therapeutics Hemophilia CGT is the highest potential for Global access logistics in underdev countries working with NGOs practicality of the Tx Roche reached 120 Counties great to be part of the Roche

@pharma_BI

@AVIVA1950

1

1

Aviva Lev-Ari

@AVIVA1950

·

9h

#WMIF2021

@MGBInnovation

Theresa Heggie CEO, Freeline Therapeutics Safety concerns, high burden of treatment CGT has record of safety and risk/benefit adoption of Tx functional cure CGT is potent Tx relative small quantity of protein needs be delivered 

@pharma_BI

@AVIVA1950

1

1

Aviva Lev-Ari

@AVIVA1950

·

9h

#WMIF2021

@MGBInnovation

Suneet Varma Global President of Rare Disease, Pfizer Gene therapy at Pfizer small, large molecule and CGT – spectrum of choice allowing Hemophilia patients to marry 1/3 internal 1/3 partnership 1/3 acquisitions  review of protocols

@pharma_BI

@AVIVA1950

1

1

Aviva Lev-Ari

@AVIVA1950

·

9h

#WMIF2021

@MGBInnovation

Ron Renaud CEO, Translate Bio What strain of Flu vaccine will come back in the future when people do not use masks. AAV vectors small transcript size fit reach cytoplasm more development coming

@pharma_BI

@AVIVA1950

1

1

Aviva Lev-Ari

@AVIVA1950

·

9h

#WMIF2021

@MGBInnovation

Melissa Moore Chief Scientific Officer, Moderna Flu vaccine knowing the virus variant 45 days for Personalized cancer vaccine one per patient

@pharma_BI

@AVIVA1950

1

1

Aviva Lev-Ari

@AVIVA1950

·

9h

#WMIF2021

@MGBInnovation

Melissa Moore Chief Scientific Officer, Moderna Many years of mRNA pivoting for new diseases, DARPA, nucleic Acids global deployment of a manufacturing unit on site where the need arise Elan Musk funds new directions at Moderna

@pharma_BI

@AVIVA1950

1

1

Aviva Lev-Ari

@AVIVA1950

·

9h

#WMIF2021

@MGBInnovation

Melissa Moore Chief Scientific Officer, Moderna How many mRNA can be put in one vaccine: Dose and tolerance to achieve efficacy and the 

@pharma_BI

@AVIVA1950

1

2

Aviva Lev-Ari

@AVIVA1950

·

9h

#WMIF2021

@MGBInnovation

Lindsey Baden, MD Director, Clinical Research, Division of Infectious Diseases, BWH Associate Professor, HMS In vivo delivery process regulatory for new opportunities for same platform new indication using multi valence vaccines

@pharma_BI

@AVIVA1950

1

1

Aviva Lev-Ari

@AVIVA1950

·

10h

#WMIF2021

@MGBInnovation

Ron Renaud CEO, Translate Bio Platform allowing to swap cargo reusing same nanoparticles address disease beyond Big Pharma options for biotech

@pharma_BI

@AVIVA1950

#WMIF2021

@MGBInnovation

Melissa Moore Chief Scientific Officer, Moderna Many years of mRNA pivoting for new diseases, DARPA, nucleic Acids global deployment of a manufacturing unit on site where the need arise Elan Musk funds new directions at Moderna

@pharma_BI

@AVIVA1950

1

1

Aviva Lev-Ari

@AVIVA1950

·

10h

#WMIF2021

@MGBInnovation

Ron Renaud CEO, Translate Bio 1.6 Billion doses produced rare disease monogenic correct mRNA like CF multiple mutation infection disease and oncology applications

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

10h

#WMIF2021

@MGBInnovation

Kate Bingham, UK Vaccine Taskforce July 2020, AAV vs mRNA delivery across UK local centers administered both types supply and delivery uplift 

@pharma_BI

@AVIVA1950

1

1

1

Aviva Lev-Ari

@AVIVA1950

·

10h

#WMIF2021

@MGBInnovation

Melissa Moore CSO, Moderna mRNA vaccine 98% efficacy for Pfizer and Moderna more then 10 years 2015 mRNA was ready (ZIKA, RSV), as the proteine is identify manufacturing temp less of downside in the future ability to store at Ref

@pharma_BI

@AVIVA1950

1

1

Aviva Lev-Ari

@AVIVA1950

·

10h

#WMIF2021

@MGBInnovation

Shunfei Yan, PhD Investment Manager, InnoStar Capital Indication driven: Hymophilia,  Allogogenic efficiency therapies Licensing opportunities 

@pharma_BI

@AVIVA1950

1

1

Aviva Lev-Ari

@AVIVA1950

·

10h

#WMIF2021

@MGBInnovation

Richard Wang, PhD CEO, Fosun Kite Biotechnology Co. Ltd Possibilities to be creative and capitalize the new technologies for new drug Support of the ecosystem by funding new companies Autologous in patients differences cost challenge

@pharma_BI

@AVIVA1950

1

1

Aviva Lev-Ari

@AVIVA1950

·

10h

#WMIF2021

@MGBInnovation

Tian Xu, PhD Vice President, Westlake University ICH Chinese FDA -r regulation similar to the US Difference is the population recruitment, in China patients are active participants Dev of transposome non-viral methods, price

@pharma_BI

@AVIVA1950

1

1

Aviva Lev-Ari

@AVIVA1950

·

10h

#WMIF2021

@MGBInnovation

Alvin Luk, PhD CEO, Neuropath Therapeutics Monogenic rare disease with clear genomic target Increase of 30% in patient enrollment  Regulatory reform approval is 60 days no delay

@pharma_BI

@AVIVA1950

Part 2: ALL THE RE-TWEETS by @AVIVA1950 on

May 20, 2021

You Retweeted

Vertex Pharmaceuticals

@VertexPharma

·

May 19

We’re excited to attend this week’s #WMIF2021 to talk all things cell and genetic therapies. Join our Chief of VCGT Bastiano Sanna tomorrow at 9:50am EDT for a discussion on the promise of cell therapies for type 1 diabetes. Register now! https://bit.ly/3otngYd

2

4

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

8h

John Fish, Board Chair, Brigham Health, Chairman & CEO, Suffolk on the Novartis Main Stage to introduce the “Collaboration is Key: GCT R&D of the Future” fireside chat with Jay Bradner, MD, President, NIBR

@NovartisScience

. #WMIF2021

2

2

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

4h

In our next First Look presentation we’ll hear from Xandra Breakefield PhD & Koen Breyne PhD

@MGHNeurology

@MGHNeurosurg

about their work focused on developing non-viral vectors to enhance #genedelivery. #WMIF2021 #GCT #genetherapy

More Topics

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

May 19

Thomas VanCott, PhD, Chief Technology & Strategy Officer, Catalent Cell & Gene Therapy, says that time, improvements and scaling up in manufacturing will lead to allogeneic cell therapies. He recognizes that upfront costs are high, but will decrease in the long term #WMIF2021

2

1

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

4h

Ravi Thadhani, CAO

@MassGenBrigham

and Juergen Eckhardt, Head of

@LeapsbyBayer

, are announcing the 2021 Innovation Discovery Grants this afternoon at #WMIF2021.

1

3

You Retweeted

Editas Medicine

@editasmed

·

10h

Today Lisa Michaels, Editas CMO, will participate in the panel “Gene Editing – Achieving Therapeutic Mainstream” at the World Medical Innovation Forum #WMIF2021 in Boston. For those attending, be sure to tune in!

@MassGenBrigham

https://bit.ly/3hx1XTV #geneediting #biotechnology

Gene Editing | Achieving Therapeutic Mainstream – 2021 World Medical Innovation Forum

Gene editing was recognized by the Nobel Committee as “one of gene technology’s sharpest tools, having a revolutionary impact on life sciences.” Introduced in 2011, gene editing is used to modify…

worldmedicalinnovation.org

1

1

7

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

3h

A behind the scenes peek at our “Gene Editing | Achieving Therapeutic Mainstream” moderator & panelists preparing to go live. #WMIF2021

1

1

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

2h

Thank you to the “Common Blood Disorders | Gene Therapy” moderator David Scadden, MD

@ScaddenLab

@harvardstemcell

and panelists Leslie Kean, MD PhD

@DanaFarberNews

, Samarth Kulkarni, PhD

@CRISPRTX

, Nick Leschly

@bluebirdbio

, Mike McCune, MD PhD

@gatesfoundation

. #WMIF2021

1

1

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

6h

Kieran Murphy, CEO,

@GEHealthcare

, views GCT as the ultimate precision medicine. AI, machine learning, and data science comprise one of the big disruptive forces that will address misdiagnosis, smooth out workflow, reduce cost and enhance recovery. #WMIF2021

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

2h

Wrapping up Day 2 of #WMIF2021 with the “Gene Expression | Modulating with Oligonucleotide-Based Therapies” panel.

1

1

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

4h

Juergen Eckhardt, Head of

@LeapsbyBayer

, announces new Bayer mentoring program for Innovation Discovery Grant winners at #WMIF2021.

3

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

2h

In our final First Look session of the day, Pierpaolo Peruzzi, MD PhD,

@BWHNeurosurgery

presents “RNA Therapy for Brain Cancer” #WMIF2021

1

1

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

6h

Hear from

@intelliatweets

CSO Laura Sepp-Lorenzino, PhD, in our “GCT Delivery | Perfecting the Technology” panel this afternoon! #WMIF2021

Quote Tweet

Intellia Therapeutics

@intelliatweets

 · 6h

Today, Intellia CSO, @LauraSeppLore will be participating in the World Medical Innovation Forum’s panel on Gene and Cell Therapy Delivery, Perfecting the Technology. #WMIF2021 @MGBInnovation. Click here to learn more: https://worldmedicalinnovation.org

1

1

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

4h

Natalie Artzi, PhD, Assistant Professor

@BrighamWomens

is back with us this afternoon sharing a First Look at “Versatile Polymer-Based Nanocarriers for Targeted Therapy and Immunomodulation.” #WMIF2021 #GCT #geneandcelltherapy

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

8h

We look forward to hearing from

@ViaCyte

VP of Clinical Development, Manasi Jaiman, during the “Diabetes | Grand Challenge” panel today. #WMIF2021

Quote Tweet

ViaCyte

@ViaCyte

 · 8h

Join us at #WMIF2021 today! Our own Manasi Jaiman, VP, Clinical Development, will participate in the Diabetes: Grand Challenge panel to discuss regenerative medicine approaches for T1D utilizing stem-cell derived islet cell replacement therapy.

1

1

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

5h

We’ll see you back here after the break for the “GCT Delivery | Perfecting the Technology” panel, featuring moderator Natalie Artzi, PhD,

@BrighamWomens

and panelists from

@EvOx_Ltd

,

@intelliatweets

,

@generationbio

and

@codiakbio

. #WMIF2021

1

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

6h

Christian Rommel, PhD,EVP, Head, Pharmaceuticals Research & Development,

@Bayer

, discusses how GCT is in the embryonic phase. Bayer is ready to treat its first Parkinson’s patient, and is exploring therapeutic technologies to treat diseases with single gene defects #WMIF2021

1

2

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

8h

Next up is the #Diabetes | Grand Challenge panel at #WMIF2021 featuring speakers from

@BrighamWomens

@armi_usa

@ViaCyte

@VertexPharma

@Sigilon_Inc

3

5

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

10h

The “Gene Editing | Achieving Therapeutic Mainstream” panel today at 2:55 pm Eastern will discuss the movement of #geneediting technology into the therapeutic mainstream. Join us! #WMIF2021 https://worldmedicalinnovation.org/register/

Quote Tweet

Editas Medicine

@editasmed

 · 10h

Today Lisa Michaels, Editas CMO, will participate in the panel “Gene Editing – Achieving Therapeutic Mainstream” at the World Medical Innovation Forum #WMIF2021 in Boston. For those attending, be sure to tune in! @MassGenBrigham https://bit.ly/3hx1XTV #geneediting #biotechnology

You Retweeted

Atara Bio

@Atarabio

·

2h

Global Head of R&D

@jdupontmd

joined this week’s World Medical Innovation Forum hosted by

@MGBInnovation

to discuss the current state of CAR-T and its future prospects. These conversations are important for the development of potential #CART therapies. #WMIF2021

1

8

You Retweeted

Tracy Doyle

@doylet

·

9h

“We can get to an “n of 1” with mRNA technology says Melissa Moore, PhD, CSO Platform Research,

@moderna_tx

@MGBInnovation

#WMIF2021 #GCT

1

1

You Retweeted

Intellia Therapeutics

@intelliatweets

·

6h

Today, Intellia CSO,

@LauraSeppLore

will be participating in the World Medical Innovation Forum’s panel on Gene and Cell Therapy Delivery, Perfecting the Technology. #WMIF2021

@MGBInnovation

. Click here to learn more: https://worldmedicalinnovation.org

3

4

You Retweeted

TranslateBio

@TranslateBio

·

7h

Graphical representation of this morning’s #mRNA #vaccines panel at

@MGBInnovation

‘s #WMIF2021 — Thanks to the MGB team for facilitating a great discussion!

Quote Tweet

Mass General Brigham Innovation

@MGBInnovation

 · 7h

Overview of our #mRNA Vaccines panel today, highlighting improved manufacturing capabilities & potential for #personalizedmedicine. Thank you to Lindsey Baden @bwh_id & panelists Kate Bingham, SV Health Investors, Melissa Moore @moderna_tx and Ron Renaud @TranslateBio #WMIF2021

1

3

You Retweeted

Tracy Doyle

@doylet

·

May 19

18

@MassGenBrigham

investigators are ready to give you an early preview of their #GCT research in the First Look sessions at #WMIF2021. Exciting opportunities to dramatically change how disease is treated!

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

7h

Please welcome Marc Casper, CEO

@thermofisher

to the stage for a Fireside Chat moderated by Erin Harris

@ErinHarris_1

, Editor in Chief

@_CellandGene

“Partnering Across the GCT Spectrum” #WMIF2021 #GCT #geneandcelltherapy

4

3

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

6h

The “CEO Panel | Anticipating Disruption | Planning for Widespread GCT” panelists have joined the stage. #WMIF2021

1

1

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

7h

Our “Rare and Ultra Rare Diseases | GCT Breaks Through” panelists on the role of family organizations & patient advocacy groups in moving us forward on the regulatory side – “It’s absolutely essential” #WMIF2021

2

1

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

4h

Congratulations! Lydia Lynch PhD, Brigham and Women’s Hospital receives an Innovation Discovery Grant for “Generating Superior ‘Killers’ for Adoptive Cell Therapy in Cancer” at #WMIF2021.

@BrighamWomens

@BrighamResearch

2

You Retweeted

Tracy Doyle

@doylet

·

10h

Looking forward to the Diabetes Grand Challenge and how #GCT could help millions of people. Read about what facing this disease and how cell therapies could lessen the burden from Manasi Jaiman, MD, VP, Clinical Development

@ViaCyte

here http://bit.ly/T1Dcelltherapies… #WMIF2021

Quote Tweet

Mass General Brigham Innovation

@MGBInnovation

 · 11h

Today is Day 2 of the World Medical Innovation Forum. Which panel you are most excited to see today? Reply and let us know! #WMIF2021 https://worldmedicalinnovation.org/agenda/

2

2

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

6h

Coming up at 12:05 pm Eastern: “CEO Panel | Anticipating Disruption | Planning for Widespread GCT” featuring panelists from

@NovartisGene

@GEHealthcare

@Bayer

and moderated by

@CNBC

Senior Health and Science Reporter

@megtirrell

#WMIF2021

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

10h

Join us at #WMIF2021 to hear from Suneet Varma, Global President of Rare Disease

@Pfizer

, during the “Benign Blood Disorders” today at 9:00 am Eastern. https://worldmedicalinnovation.org/register/

Quote Tweet

Pfizer Inc.

@pfizer

 · May 19

Cell and gene therapies hold promising potential for rare disease, blood cancers, and viral diseases. Register for #WMIF21 to hear about our work to pioneer cutting-edge science across our pipeline to advance breakthroughs that change patients’ lives: https://on.pfizer.com/3f3CGzj

2

1

You Retweeted

Pearl Freier

@PearlF

·

9h

Melissa Moore/Moderna said they are working with Merck on developing personalized cancer vaccines, n of 1 #wmif2021

1

1

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

4h

Congratulations! Peter Sage PhD, Brigham and Women’s Hospital receives an Innovation Discovery Grant for “Novel Strategies to Enhance Tfr Treatment of Autoimmunity” at #WMIF2021

@BrighamWomens

@BrighamResearch

2

1

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

4h

Congratulations! Yulia Grishchuk PhD, Massachusetts General Hospital, receives an Innovation Discovery Grant for “AAV-Based Gene Replacement Therapy Improves Targeting and Clinical Outcomes in a Childhood CNS Disorder” at #WMIF2021

@MassGeneralNews

@MGH_RI

@CGM_MGH

2

1

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

4h

Congratulations! Jinjun Shi, PhD, Brigham and Women’s Hospital, receives an Innovation Discovery Grant for “Long-Lasting mRNA Therapy for Genetic Disorders” at #WMIF2021

@BrighamWomens

@BrighamResearch

2

2

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

9h

Final thoughts from “Benign Blood Disorders” panelists on academic/industry collaboration — the pace of #innovation is incredibly exciting, and I think it will be even faster together. #WMIF2021

2

1

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

4h

Congratulations! Benjamin Kleinstiver PhD, Massachusetts General Hospital, receives an Innovation Discovery Grant for “Towards a Permanent Genetic Cure for Spinal Muscular Atrophy” at #WMIF2021

@MassGeneralNews

@MGH_RI

@CGM_MGH

2

You Retweeted

Pearl Freier

@PearlF

·

10h

Listening to mRNA vaccines #wmif2021 panel w/ speakers incl SV Health managing partner & ex UK Vaccine Taskforce

@katebingham2

, Moderna CSO Platform Rsrch Melissa Moore,

@TranslateBio

CEO Ron Renaud

@biotech1969

, Brigham/BWH Dir Clinical Research Infectious Disease Lindsey Baden

2

2

You Retweeted

Ned Pagliarulo

@NedPagliarulo

·

May 19

FDA’s Peter Marks, at #WMIF2021, notes # of INDs for gene therapies was flat in 2020 vs. 2019. But the fact IND submissions didn’t decline, he said, is a sign of how strong the gene therapy field is, given pandemic’s disruption.

1

9

21



You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

5h

Coming up this afternoon: the 2021 Innovation Discovery Grants in #geneandcelltherapy. Who will secure additional funding for research to advance #GCT? Join us to watch live. #WMIF2021 https://worldmedicalinnovation.org/register/

2

1

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

1h

Thank you Jeannie Lee, MD PhD

@MGHPathology

, Bob Brown, PhD

@DicernaPharma

, Brett Monia, PhD

@ionispharma

, and Alfred Sandrock, MD PhD

@biogen

for sharing your perspectives on oligonucleotide-based therapies. #WMIF2021

1

2

You Retweeted

Pearl Freier

@PearlF

·

9h

Melissa Moore/Moderna- one advantage of mRNA is ability to do multivalent vaccines she said. She said they are already testing multivalent covid vaccines in clinical trials & testing flu vaccines. #wmif2021

1

3

You Retweeted

Pearl Freier

@PearlF

·

10h

Kate Bingham/SV Health & former head of UK Vaccine Taskforce: they haven’t seen escape variants in UK yet she said. mRNA is quickest platform to address escape variants probably. Needle delivery w/ supply cold chain has been the challenge. Deploying 3 vaccines in UK #WMIF2021

1

1

1

Show this thread

You Retweeted

Tracy Doyle

@doylet

·

6h

Marc Casper

@thermofisher

says gene and cell therapy represents a “phenomenal opportunity to improve patients’ lives” #WMIF2021 #GCT

1

2

You Retweeted

TranslateBio

@TranslateBio

·

7h

Today, our CEO Ron Renaud

@biotech1969

participated in

@MGBInnovation

‘s 2021 World Medical Innovation Forum to discuss the impact of #messengerRNA #vaccines on the industry #WMIF2021 #mRNA

2

10

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

6h

Lisa Deschamps, SVP & Chief Business Officer,

@NovartisGene

, notes that the science behind gene cell therapies is converging with technological development. How therapies are brought to market is still the question, as there is no roadmap when reimagining medicine #WMIF2021

3

4

You Retweeted

Pearl Freier

@PearlF

·

10h

Melissa Moore/Moderna: clear advantage of mRNA vaccine is how quickly we can manufacture the vaccines. Downsides- need 2store at low temperatures & limited shelflife 4storage in refrigerator. I know that both companies [Moderna, Pfizer/BioNTech] r working 2change this #wmif2021

You Retweeted

Novartis Gene Therapies

@NovartisGene

·

6h

We’re committed to addressing the unmet needs of people living with rare genetic diseases. Our SVP, External Innovation and Strategic Alliances, Leah Bloom, discusses the promise #genetherapy holds for communities impacted by rare diseases during #WMIF2021.

2

4

You Retweeted

Tracy Doyle

@doylet

·

6h

Diagnostics and data tools key part of precision medicine complementing gene and cell therapy says

@KieranMurphyCEO

@GEHealthcare

at

@MGBInnovation

#WMIF2021

Meg Tirrell and 2 others

2

2

You Retweeted

Tracy Doyle

@doylet

·

7h

Debating the value of natural history studies in rare/ultra rare disease — panel led by Susan Slaugenhaupt, PhD, scientific director,

@MGH_RI

at #WMIF2021. Challenges include costs, feasibility, timing, comparative data.

1

2

You Retweeted

Tracy Doyle

@doylet

·

8h

Rett’s Syndrome, which primarily affects young girls, has historically been studied in male mice! Jeannie Lee, MD, PhD,

@MassGeneralNews

, and team are exploring how to treat the disease w X chromosome reactivation… and using a female mouse model. Hear more on #GCT at #WMIF2021

2

5

You Retweeted

Tracy Doyle

@doylet

·

10h

Speed of vaccination is critical to prevent escape variants says Kate Bingham, SV Health Investors, UK, at #WMIF2021, exploring what’s next for the technology w panel led by Lindsey Baden MD,

@BrighamWomens

2

2

May 19, 2021

TWEETS AND RE-TWEETS for 2021 World Medical Innovation Forum, Mass General Brigham, Gene and Cell Therapy, VIRTUAL May 19–21, 2021

PART 1: ALL THE TWEETS PRODUCED by @AVIVA1950 on May 19, 2021

Part 2: ALL THE RE-TWEETS by @AVIVA1950 on

May 19, 2021

Tweets Originator for Part 1: Aviva Lev-Ari, PhD, RN

Example for a TWEET

Aviva Lev-Ari

@AVIVA1950

·

May 21

@MGBInnovation

#WMIF Best Global event on Gene Cell Therapy covered in real time

@AVIVA1950

@pharma_BI

Disruptive Dozen technologies four are based on Gene Editing, AAV and non viral vector for drug delivery are included

2

2

Example for a RE-TWEET

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

May 21

Thanks

@AVIVA1950

for sharing this screen capture of the impressive lineup of #GCT “Disruptive Dozen” panelists at #WMIF2021

Quote Tweet

Aviva Lev-Ari

@AVIVA1950

 · May 21

@MGBInnovation #WMIF Best Global event on Gene Cell Therapy covered in real time @AVIVA1950 @pharma_BI Disruptive Dozen technologies four are based on Gene Editing, AAV and non viral vector for drug delivery are included

 PART 1: ALL THE TWEETS PRODUCED by @AVIVA1950 on May 19, 2021



Aviva Lev-Ari

@AVIVA1950

·

17h

#WMIF2021

@MGBInnovation

Marcela Maus, MD, PhD Director, Cancer Center, MGH, HMS  Fit-to-purpose CAR-T cells: 3 lead programs Tr-fill CAR-T induce response myeloma and multiple myeloma GBM 27 patents on CAR-T +400 patients treaded 40 Clinical Trials 

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

17h

#WMIF2021

@MGBInnovation

Thomas VanCott, PhD Global Head of Product Dev, Gene & Cell Therapy, Catalent 2/3 autologous 1/3 allogeneic  CAR-T high doses scale up is not done today logistics issues centralized vs decentralized allogeneic are health donors

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

17h

#WMIF2021

@MGBInnovation

Ropa Pike, Director,  Enterprise Science & Partnerships, Thermo FIsher Scientific  Centralized biopharma industry is moving  to decentralized models site specific license 

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

17h

#WMIF2021

@MGBInnovation

Rahul Singhvi, ScD CEO and Co-Founder, National Resilience, Inc. Investment company in platforms to be shared by start ups in CGT. Production cost of allogeneic: cost of quality 30% reagents 30% cell 30% Test is very expensive 

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

18h

#WMIF2021

@MGBInnovation

Oladapo Yeku, MD, PhD Clinical Assistant in Medicine, MGH Outstanding moderator and most gifted panel on solid tumor success window of opportunities studies 

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

18h

#WMIF2021

@MGBInnovation

Knut Niss, PhD CTO, Mustang Bio tumor hot start in 12 month clinical trial solid tumors Combination therapy will be an experimental treatment long journey checkpoint inhibitors to be used in combination maintenance 

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

18h

#WMIF2021

@MGBInnovation

Barbra Sasu, PhD CSO, Allogene T cell response at prostate cancer  tumor specific  cytokine tumor specific signals move from solid to metastatic cell type for easier infiltration

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

18h

#WMIF2021

@MGBInnovation

Jennifer Brogdon Executive Director, Head of Cell Therapy Research, Exploratory Immuno-Oncology, NIBR 2017 CAR-T first approval M&A and research collaborations TCR tumor specific antigens avoid tissue toxicity 

@pharma_BI

@AVIVA1950

1

1

Aviva Lev-Ari

@AVIVA1950

·

18h

#WMIF2021

@MGBInnovation

Jay Short, PhD Chairman, CEO, Cofounder, BioAlta, Inc. Tumor type is not enough for R&D therapeutics other organs are involved in periphery difficult to penetrate solid tumors biologics activated in the tumor only, positive changes

@pharma_BI

@AVIVA1950

1

1

Aviva Lev-Ari

@AVIVA1950

·

18h

#WMIF2021

@MGBInnovation

Christi Shaw CEO, Kite CAR-T is priority 120 companies in the space Manufacturing consistency  Patients respond with better quality of life

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

18h

#WMIF2021

@MGBInnovation

Stefan Hendriks Global Head, Cell & Gene, Novartis Confirmation the effectiveness of CAR-T therapies, 1 year response to 5 years 26 months Patient not responding a lot to learn Patient after 8 months of chemo can be helped by CAR-T

@pharma_BI

@AVIVA1950



Aviva Lev-Ari

@AVIVA1950

·

19h

#WMIF2021

@MGBInnovation

Jeffrey Infante, MD , Oncology, Janssen R&D Direct effect with intra-tumor single injection with right payload Platform approach  Prime with 1 and Boost with 2 – not yet experimented with  Do not have the data at trial

@pharma_BI

@AVIVA1950

1

Aviva Lev-Ari

@AVIVA1950

·

19h

#WMIF2021

@MGBInnovation

Nino Chiocca, MD, PhD Neurosurgeon-in-Chief BWH, HMS Oncolytic therapy DID NOT WORK Pancreatic Cancer and Glioblastoma Intra-tumoral heterogeniety hinders success Oncolytic VIRUSES – “coldness” GADD-34 20,000 GBM 40,000 pancreatic

@pharma_BI

@AVIVA1950

1

Aviva Lev-Ari

@AVIVA1950

·

19h

#WMIF2021

@MGBInnovation

Loic Vincent, PhD Head of Oncology Drug Discovery Unit, Takeda Classification of Patients by prospective response type id UNKNOWN yet, population of patients require stratification

@pharma_BI

@AVIVA1950

1

Aviva Lev-Ari

@AVIVA1950

·

20h

#WMIF2021

@MGBInnovation

Loic Vincent, PhD Head of Oncology Drug Discovery Unit, Takeda R&D in collaboration with Academic Vaccine platform to explore different payload IV administration may not bring sufficient concentration to the tumor is administer IV

@pharma_BI

@AVIVA1950

1

Aviva Lev-Ari

@AVIVA1950

·

20h

#WMIF2021

@MGBInnovation

Nino Chiocca, MD, PhD Neurosurgeon-in-Chief and Chairman, Neurosurgery, BWH Harvey W. Cushing Professor of Neurosurgery, HMS Challenges of manufacturing at Amgen what are they?

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

20h

#WMIF2021

@MGBInnovation

David Reese, MD Executive Vice President, R&D , Amgen Inter lesion injection of agent vs systemic therapeutics cold tumors immune resistant render them immune susptible Oncolytic virus is a Mono therapy addressing the unknown 

@pharma_BI

@AVIVA1950

2

Aviva Lev-Ari

@AVIVA1950

·

20h

#WMIF2021

@MGBInnovation

David Reese, MD Executive Vice President, Research and Development, Amgen Inter lesion injection of agent vs systemic therapeutics  cold tumors immune resistant render them immune suseptible Oncolytic virus is a Mono therapy

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

20h

#WMIF2021

@MGBInnovation

Robert Coffin, PhD Chief R&D Officer, Replimune 2002 in UK promise in oncolytic therapy GNCSF Phase III melanoma 2015 M&A with Amgen oncolytic therapy remains non effecting on immune response data is key for commercialization 

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

20h

#WMIF2021

@MGBInnovation

Ann Silk, MD Physician, Dana Farber-Brigham and Women’s Cancer Center, HMS Which person gets oncolytics virus if patient has immune supression due to other indications Safety of oncolytic virus greater than Systemic treatment

@pharma_BI

@AVIVA1950

2

Aviva Lev-Ari

@AVIVA1950

·

21h

#WMIF2021

@MGBInnovation

@pharma_BI

@AVIVA1950

amazing Conference on the frontier od Science Cell & Gene Therapy

@MGB

top programs for ALS, Brain genetic vasculopathologies and Occular, MEE

@pharma_BI

@AVIVA1950

Quote Tweet

Pearl Freier

@PearlF

 · 21h

Marianne De Backer/Bayer on post M&A & company culture: They acquired AskBio & thought about how to preserve their freedom so they could continue to operate. Bayer decided to keep them independent & so they can operate at arm’s length. #wmif2021



Aviva Lev-Ari

@AVIVA1950

·

21h

#WMIF2021

@MGBInnovation

Merit Cudkowicz, MD Chief of Neurology, MGH ALS – Man 1in 300, Women 1 in 400, next decade increase 7%  10% ALS is heredity 160 pharma in ALS space diagnosis is late 1/3 of people are not diagnosed active community for clinical trials @pharma_BI@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

21h

#WMIF2021

@MGBInnovation

Adam Koppel, MD, PhD Managing Director, Bain Capital Life Sciences What acquirers are looking for?? What is the next generation vs what is real where is the industry going?

@pharma_BI

@AVIVA1950

2

Aviva Lev-Ari

@AVIVA1950

·

21h

#WMIF2021

@MGBInnovation

Debby Baron, Worldwide Business Development, Pfizer  Scalability and manufacturing regulatory conversations, clinical programs safety in parallel to planning getting drug to patients

@pharma_BI

@AVIVA1950

1

Aviva Lev-Ari

@AVIVA1950

·

21h

#WMIF2021

@MGBInnovation

Marianne De Backer, PhD Head of Strategy, BD & Licensing, Bayer Absolute Leadership: Gene editing, gene therapy, via acquisition and alliances Operating model of the acquired company discussed acquired continue independence

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

21h

#WMIF2021

@MGBInnovation

Sean Nolan Board Chairman, Encoded Therapeutics & Affinia Executive Chairman Jaguar Gene Therapy Istari Oncology As acquiree multiple M&A acquirer looks at integration and cultures companies  Traditional integration vs acquisition 

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

21h

#WMIF2021

@MGBInnovation

Debby Baron, Worldwide Business Development, Pfizer  CGT is an important area Pfizer is active looking for innovators, advancing forward programs of innovation with the experience Pfizer has internally 

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

21h

#WMIF2021

@MGBInnovation

Marianne De Backer, PhD Head of Strategy, Business Development & Licensing, and Member of the Executive Committee, Bayer Absolute Leadership in Gene editing, gene therapy, via acquisition and strategic alliance 

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

22h

2 people unfollowed me // automatically checked by

fllwrs – keep track of who follows and unfollows you on twitter

fllwrs is the easiest way to keep track of your twitter followers

fllwrs.com

Aviva Lev-Ari

@AVIVA1950

·

22h

#WMIF2021

@MGBInnovation

Manny Simons, PhD CEO, Akouos Biology across species nerve ending in the cochlea engineer out of the caspid, lowest dose possible, get desired effect by vector use, 2022 new milestones

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

22h

#WMIF2021

@MGBInnovation

Mathew Pletcher, PhD SVP, Head of Gene Therapy Research and Technical Operations, Astellas Continue to explore large animal guinea pig not the mice, not primates (ethical issues) for understanding immunogenicity and immune response 

@pharma_BI

@AVIVA1950

1

Aviva Lev-Ari

@AVIVA1950

·

22h

#WMIF2021

@MGBInnovation

Mathew Pletcher, PhD SVP, Head of Gene Therapy Research and Technical Operations, Astellas Work with diseases poorly understood, collaborations needs example of existing: DMD is a great example explain dystrophin share placedo data 

@pharma_BI

@AVIVA1950



Aviva Lev-Ari

@AVIVA1950

·

23h

#WMIF2021

@MGBInnovation

Rick Modi CEO, Affinia Therapeutics Speed R&D Speed better gene construct get to clinic with better design vs ASAP Data sharing clinical experience patients selection, vector selection, mitigation, patient type specific

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

23h

#WMIF2021

@MGBInnovation

Dave Lennon, PhD President, Novartis Gene Therapies big pharma therapeutics not one drug across Tx areas: cell, gene iodine therapy collective learning infrastructure development Acquisitions growth # applications for scaling 

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

23h

#WMIF2021

@MGBInnovation

Rick Modi CEO, Affinia Therapeutics Copy, paste EDIT from product A to B novel vectors variant of vector coder optimization choice of indication is critical exploration on larger populations Speed to R&D to better gene construct get

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

23h

#WMIF2021

@MGBInnovation

Louise Rodino-Klapac, PhD EVP, Chief Scientific Officer, Sarepta Therapeutics AV based platform 15 years in development 1 disease indication vs more than one indication stereotype, analytics as hurdle 1st was 10 years 2nd was 3 years

@pharma_BI

@AVIVA1950

1

Aviva Lev-Ari

@AVIVA1950

·

May 19

#WMIF2021

@MGBInnovation

Katherine High, MD President, Therapeutics, AskBio Three drugs approved in Europe in the CGT Regulatory Infrastructure CGT drug approval – as new class of therapeutics Participants investigators, regulators, patients i.e., MDM 

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

May 19

#WMIF2021

@MGBInnovation

Peter Marks, MD, PhD Director, Center for Biologics Evaluation and Research, FDA Immune modulators Immunotherapy Genome editing can make use of viral vectors future technologies nanoparticles and liposome encapsulation 50% more staff

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

May 19

#WMIF2021

@MGBInnovation

Peter Marks, MD, PhD Director, Center for Biologics Evaluation and Research, FDA Recover Work load for the pandemic Gene Therapies IND application remained flat Rare diseases urgency remains Guidance T-Cell therapy vs Regulation

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

May 19

#WMIF2021

@MGBInnovation

Peter Marks, MD, PhD Director, Center for Biologics Evaluation and Research, FDA June 2020 belief that vaccine challenge manufacture scaling up FDA did not predicted the efficacy of mRNA vaccine vs other approaches expected to work

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

May 19

#WMIF2021

@MGBInnovation

Jim Holland CEO, http://Backcountry.com Parkinson patient Constraints by regulatory on participation in clinical trial wish to take Information dissemination is critical 

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

May 19

#WMIF2021

@MGBInnovation

Patricia Musolino, MD, PhD Co-Director Pediatric Stroke and Cerebrovascular Program What is the Power of One – the impact that a patient can have on their own destiny connecting with other participants in same trial can be beneficial

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

May 19

#WMIF2021

@MGBInnovation

Barbara Lavery Chief Program Officer, ACGT Foundation Patient has the knowledge of the symptoms and recording all input needed for diagnosis by multiple clinicians Early application for CGT

@pharma_BI

@AVIVA1950

1

Aviva Lev-Ari

@AVIVA1950

·

May 19

#WMIF2021

@MGBInnovation

Sarah Beth Thomas, RN Professional Development Manager, BWH Outcome is unknown, hope for good, support with resources all advocacy groups, 

@pharma_BI

@AVIVA1950



Aviva Lev-Ari

@AVIVA1950

·

May 19

#WMIF2021

@MGBInnovation

Jack Hogan Patient, MEE Constraints by regulatory on participation in #clinicaltrials advance stage is approved participation Patients to determine the level of #risk they wish to take 

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

May 19

#WMIF2021

@MGBInnovation

Barbara Lavery Chief Program Officer, ACGT Foundation Advocacy agency beginning of work Global Genes educational content and out reach to access the information

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

May 19

#WMIF2021

@MGBInnovation

Dave Lennon, PhD President, Novartis Gene Therapies Modality one time intervention, long duration of impart, reimbursement, ecosystem FDA works by indications and risks involved, Standards manufacturing payments over time payers

@pharma_BI

@AVIVA1950

1

Aviva Lev-Ari

@AVIVA1950

·

May 19

#WMIF2021

@MGBInnovation

Dave Lennon, PhD President, Novartis Gene Therapies Promise of CGT realized, what part? #FDA role and interaction in CGT #Manufacturing aspects which is critical

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

May 19

#WMIF2021

@MGBInnovation

Julian Harris, MD Partner, Deerfield Hope that CGT emerging, how therapies work, #neuro, #muscular, #ocular, #genetic diseases of #liver and of #heart revolution for the industry 900 #IND application 25 approvals #Economic driver 

@pharma_BI

@AVIVA1950

1

Aviva Lev-Ari

@AVIVA1950

·

May 19

#WMIF2021

@MGBInnovation

Luk Vandenberghe, PhD Grousbeck Family Chair, Gene Therapy, MEE Associate Professor, Ophthalmology, HMS #Pharmacology #Gene-Drug, Interface academic centers and industry many CGT drugs emerged in Academic center

@pharma_BI

@AVIVA1950

1

Aviva Lev-Ari

@AVIVA1950

·

May 19

#WMIF2021

@MGBInnovation

Ravi Thadhani, MD CAO, Mass General Brigham Professor, Medicine and Faculty Dean, HMS Role of #academia special to spear head the #Polygenic #therapy – multiple #genes involved, #plug-play #delivery

@pharma_BI

@AVIVA1950

1

Aviva Lev-Ari

@AVIVA1950

·

May 19

#WMIF2021

@MGBInnovation

Nino Chiocca, MD, PhD Neurosurgeon-in-Chief and Chairman, Neurosurgery, BWH #Oncolytic #Viruses triple threats #Toxic, #braintumors #immunological requires #combination #therapies with #anticancer

@pharma_BI

@AVIVA1950

Part 2: ALL THE RE-TWEETS by @AVIVA1950 on

May 19, 2021

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

17h

Will point of care production become a reality? “Short answer is yes” says Rupa Pike PhD, Director, Enterprise Science & Innovation Partnerships,

@thermofisher

. #WMIF2021 #GCTManufacturing

2

2

You Retweeted

Novartis Gene Therapies

@NovartisGene

·

May 18

The field of #genetherapy is growing. New therapies will come to market for rare and chronic diseases, and new therapies will drive scientific innovation and economic growth. #WMIF2021 (2/6)

1

1

1

Show this thread

Aviva Lev-Ari

@AVIVA1950

·

15h

Very creative two targets

@ScaddenLab

@pharma_BI

@AVIVA1950

Quote Tweet

Mass General Brigham Innovation

@MGBInnovation

 · 16h

A behind the scenes look at David Scadden, MD @ScaddenLab presenting his FIRST LOOK: Regenerating T Cell Immunity #WMIF2021 #GCT #Tcells

1

1

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

16h

In our First Look sessions clinicians/researchers from Harvard-affiliated hospitals highlight the potential of their research & new technologies. Next we’ll hear from Khalid Shah PhD, Vice Chair of Research

@BWHNeurosurgery

#WMIF2021 https://bwhclinicalandresearchnews.org/2021/05/11/look-whos-talking-world-medical-innovation-forum-first-look-speakers/…

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

19h

“Entrepreneurial Growth | Oncolytic Virus” panel, moderated by Reid Huber PhD, Partner

@ThirdRockV

, discusses how small companies can address the challenges of developing #oncolyticvirus therapies. #WMIF2021

3

3

You Retweeted

Novartis Gene Therapies

@NovartisGene

·

May 19

The World Medical Innovation Forum is here! During his fireside chat, our President Dave Lennon shares the immense promise ahead for #genetherapy.

@MGBInnovation

#WMIF2021

1

3

6

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

May 18

Tomorrow is Day 1 of #WMIF2021! Hear from the world-renowned CEOs, investors, clinicians and scientists bringing game-changing discoveries and insights to #GCT. Register to attend today: https://worldmedicalinnovation.org/register/

2

1

You Retweeted

Novartis Gene Therapies

@NovartisGene

·

May 18

We’re at

@MGBInnovation

‘s World Medical Innovation Forum this week, discussing the future of #genetherapy. Here are our five predictions for where the industry is headed. #WMIF2021 (1/6)

1

1

4

Show this thread

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

23h

Some incredible #visualnotes from this morning’s co-chair’s panel “The Grand Challenge of Widespread GCT Patient Benefits” #WMIF2021 #GCT #geneandcelltherapy

1

2

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

May 17

The World Medical Innovation Forum #WMIF2021 is just two days away! Join us to hear the latest in #geneandcelltherapy #healthcare innovation. https://worldmedicalinnovation.org/register/

You Retweeted

BrighamResearch

@BrighamResearch

·

May 16

“We anticipate that our engineered tumor cell platform will have major contributions in finding a cure for #glioblastoma patients,” says

@khalidshahs

 of

@BWHNeurosurgery

. Catch a preview of his #WMIF2021 First Look talk here: https://fal.cn/3fpUL

8

16

You Retweeted

Mass Eye and Ear

@MassEyeAndEar

·

22h

Dr. Eric Pierce

@MassEyeAndEar

@HMSeye

explains at #WMIF2021 why the first FDA-approved gene therapy for inherited disease was for an inherited retinal degeneration, and what lessons have been learned from the success of that treatment.

Mass General Brigham Innovation

6

11

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

22h

Ravi Thadhani, CAO @MassGeneralBrigham and Juergen Eckhardt, Head of

@LeapsbyBayer

, will be announcing the 2021 Innovation Discovery Grants at #WMIF2021 tomorrow, 5/20 @ 2:00 pm Eastern. https://worldmedicalinnovation.org

Quote Tweet

Leaps by Bayer

@LeapsByBayer

 · 22h

Together with @BayerPharma, we are pleased to be part of #WMIF2021, organized by @MassGenBrigham. This year’s event focuses on the transformative potential of #cellandgene therapy (#GCT).

Show this thread

 

1

3

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

20h

Welcome back! Our next #WMIF2021 panel, Oncolytic Viruses in #Cancer | Curing #Melanoma and Beyond, features panelists from

@BrighamWomens

@Replimune

@EikonTX

@Amgen

and

@DanaFarber

2

6

You Retweeted

Novartis Gene Therapies

@NovartisGene

·

22h

“We are more committed to our mission than ever before – laser-focused on realizing the transformative potential of #genetherapy for patients.” – Dave Lennon, President, during #WMIF2021

Outstanding researcher and speaker

@pharma_BI

@AVIVA1950

Quote Tweet

Mass General Brigham Innovation

@MGBInnovation

 · 21h

Patricia Musolino, MD PhD, Co-Director Pediatric Stroke and Cerebrovascular Program at MGH, discusses her work developing #genetherapy treatments for cerebral genetic vasculopathies #GCT #geneandcelltherapy #WMIF2021

1

You Retweeted

Mass Eye and Ear

@MassEyeAndEar

·

23h

Happening now at #WMIF2021.

@MassEyeAndEar

chief and

@HMSeye

chair Dr. Joan Miller moderates a panel on AAV gene therapy featuring director of Inherited Retinal Disorders Service and Ocular Genomics Institute, Dr. Eric Pierce.

Quote Tweet

Mass General Brigham Innovation

@MGBInnovation

 · 23h

Our “AAV Success Studies | Retinal Dystrophy | Spinal Muscular Atrophy” panelists have taken the stage. #WMIF2021 @MassEyeAndEar @REGENXBIO @spark_tx @NovartisGene

1

3

You Retweeted

CRISPR Therapeutics

@CRISPRTX

·

19h

Attending

@MGBInnovation

World Medical Innovation Forum? Tune in to hear our CEO

@CRISPRSam

speak tomorrow at 3:25pm ET on innovations in cell and gene therapy, followed by a Q&A. Learn more: https://bit.ly/3eWb66R #WMIF2021

4

22

You Retweeted

Biogen

@biogen

·

15h

We are proud sponsors of the Virtual World Medical Innovation Forum (#WMIF2021). This year’s program will focus on the impact of gene and cell therapy as a way to potentially advance quality patient care, reduce cost and improve outcomes. Learn more:

World Medical Innovation Forum

worldmedicalinnovation.org

You Retweeted

Pearl Freier

@PearlF

·

16h

Jonathan Kraft introducing #wmif2021 session with Pfizer CSO & president of R&D Mikael Dolsten and MGH oncologist & chair of MGH Cancer Center Daniel Haber.

1

1

Aviva Lev-Ari

@AVIVA1950

·

15h

MEE is the leader in cell therapy for retina genetic disease

Quote Tweet

Tracy Doyle

@doylet

 · May 19

Great discussion to open #WMIF2021 on the patient impact of #GCT @MGBInnovation World Medical Innovation Forum twitter.com/AVIVA1950/stat…

You Retweeted

Pearl Freier

@PearlF

·

May 19

Tuning into

@MGBInnovation

#WMIF2021 cell & gene therapy meeting.

@NovartisGene

president Dave Lennon & Deerfield partner Julian Harris having a “fireside chat.” Dave/Novartis: sees gene therapy as driver for economy generating need for highly skilled workers Incl manufacturing

2

5

You Retweeted

Pearl Freier

@PearlF

·

17h

Kite Pharma CEO (Gilead subsidiary) Christi Shaw said there are 120 biopharma companies working on CAR-T cell therapy & they are continuing to look for new partnerships. She also mentioned logistical challenges currently getting to Israel & helping patients there. #WMIF2021

2

3

You Retweeted

Pearl Freier

@PearlF

·

15h

Dolsten/Pfizer discussing their partnership with Ionis.https://ir.ionispharma.com/news-releases/news-release-details/ionis-and-akcea-announce-pfizer-has-initiated-phase-2b-clinical… #wmif2021

Ionis and Akcea announce that Pfizer has initiated a Phase 2b clinical study of vupanorsen (AKCEA…

The Investor Relations website contains information about Ionis Pharmaceuticals, Inc.’s business for stockholders, potential investors, and financial analysts.

ir.ionispharma.com

1

1

You Retweeted

Pearl Freier

@PearlF

·

23h

FDA’s Dir of Center for Biologics Evaluation & Research Peter Marks interviewed by Vicki Sato- chairwoman of Vir Biotechnology, ex Vertex president & ex Biogen VP Research. Around June ’20, started 2c progress in covid vaccines w/ enough candidates moving forward #WMIF2021 1/n

1

2

You Retweeted

Tracy Doyle

@doylet

·

23h

FDA staffing up on gene therapies personnel by 50% says Peter Marks, MD, PhD, Center for Biologics Evaluation and Research

@US_FDA

at #WMIF2021

1

1

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

18h

“Once you work on cell and gene therapy, its really hard to go back and work on anything else” says moderator Marcela Maus, MD PhD in our “CAR-T | Lessons Learned | What’s Next” panel #WMIF2021 #GCT #geneandcelltherapy

2

1

You Retweeted

Pearl Freier

@PearlF

·

20h

Ex Merck president R&D Roger Perlmutter is now Eikon Therapeutics CEO & is on #WMIF2021 oncolytic virus in cancer panel w/Amgen EVP R&D David Reese, ex BioVex CTO (T-VEC inventor

@robertcoffin3

now

@Replimune

founder/president, Dana-Farber physician Ann Silk, BWH’s Nino Chiocca

You Retweeted

Novartis Gene Therapies

@NovartisGene

·

May 18

During this week’s World Medical Innovation Forum with

@MassGenBrigham

, join our leaders for panels and presentations discussing what’s next for #genetherapy and the key trends shaping the industry as it evolves. #WMIF2021 https://bit.ly/3eYYls4

59 views

0:24 / 0:36

1

4

You Retweeted

Pearl Freier

@PearlF

·

16h

Dolsten/Pfizer discussed covid vaccines and real world evidence study in Israel. Was sole provider of vaccines in Israel. 95%-98% efficacy replicated in real world. Well above 90% efficacy in asymptomatic disease. #wmif2021

2

4

You Retweeted

Tracy Doyle

@doylet

·

18h

Is CART-T therapy still an industry priority? Panelists say yes! Join us to hear more at the

@MGBInnovation

#WMIF2021

2

2

You Retweeted

Pearl Freier

@PearlF

·

18h

CAR-T #WMIF2021 panel w/ MGH’s

@MarcelaMaus

,

@Atarabio

EVP R&D

@jdupontmd

, BMS SVP Hematology/Oncology & Cell Therapy

@KristenHege

,

@KitePharma

CEO Christi Shaw, Novartis Global Head Cell & Gene

@Stefanhendriks5

1

3

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

16h

ICYMI: An illustration depicting the “AAV Delivery” panel discussion about advances in the area of #AAVGeneTherapy delivery. Thank you to the panelists from

@MGHNeurology

,

@CureFA_org

,

@AstellasUS

and

@AkouosInc

. #geneandcelltherapy #GCT #WMIF2021



Aviva Lev-Ari

@AVIVA1950

·

16h

Like that presentation a lot

@pharma_BI

@AVIVA1950

Quote Tweet

Mass General Brigham Innovation

@MGBInnovation

 · 22h

Casey Maguire PhD, Associate Professor of Neurology, at the podium to present his work developing improved #genetherapy vectors. #WMIF2021 “First Look: Enhanced Gene Delivery and Immunoevasion of AAV Vectors without Capsid Modification”

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

22h

Casey Maguire PhD, Associate Professor of Neurology, at the podium to present his work developing improved #genetherapy vectors. #WMIF2021 “First Look: Enhanced Gene Delivery and Immunoevasion of AAV Vectors without Capsid Modification”

3

3

Aviva Lev-Ari

@AVIVA1950

·

16h

Best interview of a CSO in the history of Big Pharma

@Pharma_BI

@AVIVA1950

Quote Tweet

Mass General Brigham Innovation

@MGBInnovation

 · 16h

Mikael Dolsten, MD PhD, CSO & President, Worldwide Research, Development and Medical @pfizer takes the stage for a Fireside Chat, moderated by @MGHCancerCenter Daniel Haber, MD, PhD. “Pfizer’s Future in Cell and Gene Therapy” #WMIF2021

You Retweeted

Pearl Freier

@PearlF

·

May 19

Dave Lennon/Novartis: manufacturing has been a roadblock for many cell & gene therapy companies. Expects to see more investments earlier. Engineering advances will unlock scale & address bigger & bigger patient populations. Oppty to ID patients early #WMIF2021

3

5

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

19h

Nino Chiocca, MD PhD,

@BWHNeurosurgery

presents FIRST LOOK: Oncolytic Viruses: Turning Pathogens into Anticancer Agents #WMIF2021

You Retweeted

Pearl Freier

@PearlF

·

22h

M&A cell & gene therapy #WMIF2021 panel incl Bain Capital’s Adam Koppel, Bayer’s Head Strategy Business Development & Licensing

@MDDBacker

, Pfizer’s SVP Worldiwde BD Debbie Baron, Eli Lilly VP BD Ken Custer, ex AveXis CEO Sean Nolan now Affinia & Encoded Therapeutics Board Chair

2

6

You Retweeted

Pearl Freier

@PearlF

·

21h

Marianne De Backer/Bayer on post M&A & company culture: They acquired AskBio & thought about how to preserve their freedom so they could continue to operate. Bayer decided to keep them independent & so they can operate at arm’s length. #wmif2021

3

4

You Retweeted

Resilience

@IncResilience

·

17h

Happening now: our CEO, Rahul Singhvi, speaking at the virtual 2021 World Medical Innovation Forum: http://worldmedicalinnovation.org #WMIF2021 https://pic.twitter.com/Nyc2lXbvUR

3

6

You Retweeted

Pearl Freier

@PearlF

·

21h

Ken Custer/Eli Lilly-said they’re relatively new in cell & gene therapy. They invested in 1 of Sean Nolan’s (ex AveXis CEO) new companies,Jaguar Gene Therapy. Lilly’s legacy in neuroscience is noted & bought Prevail last yr. Clinical trial w/ Parkinson’s w/GBA1 mutation #wmif2021

2

2

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

May 19

Jack Hogan, a patient

@MassEyeAndEar

, was the first in the U.S. to be approved for FDA gene therapy surgery. In 2018 he underwent therapy to treat retinitis pigmentosa by having a synthetic gene inserted into his retina. With improved eyesight he can now play sports #WMIF2021

3

11

You Retweeted

Tracy Doyle

@doylet

·

21h

The acquisition market in #GCT: looking for breakthroughs for patients, technologies for intractable diseases, manufacturing expertise, pioneering companies with deep experience — all for “the modality of the future”. M&A panel at #WMIF2021

2

2

You Retweeted

Pearl Freier

@PearlF

·

18h

Christi Shaw/Kite Pharma: Only 4 out of 10 patients eligible for CAR-T are being referred for CAR-T cell therapy by oncologists. The other 6 out of 10, referred to palliative care only. Consistency of manufacturing is also very important. #wmif2021 1/n

1

10

20

Show this thread

You Retweeted

Mass Eye and Ear

@MassEyeAndEar

·

22h

AAV gene therapy expert

@VandenbergheLuk

@HMSeye

@MassEyeAndEar

presents on the future potential of this revolutionary technology at #WMIF2021

Aviva Lev-Ari

@AVIVA1950

·

21h

#WMIF2021

@MGBInnovation

@pharma_BI

@AVIVA1950

amazing Conference on the frontier od Science Cell & Gene Therapy

@MGB

top programs for ALS, Brain genetic vasculopathologies and Occular, MEE

@pharma_BI

@AVIVA1950

Quote Tweet

Pearl Freier

@PearlF

 · 21h

Marianne De Backer/Bayer on post M&A & company culture: They acquired AskBio & thought about how to preserve their freedom so they could continue to operate. Bayer decided to keep them independent & so they can operate at arm’s length. #wmif2021

Read Full Post »


EmTech MIT 2021 – Day 3: Leading with innovation, Virtual MIT Technology Review’s flagship event, September 28-30, 2021

EmTech MIT hosted by MIT Technology Review 

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Covering the event in REAL TIME with

Social Media @pharma_BI @AVIVA1950 #EmTechMIT

In attendance

Aviva Lev-Ari, PhD, RN, Founder, LPBI Group: 1.0 & 2.0

AGENDA Overview

https://event.technologyreview.com/emtech-mit-2021/agenda

SPEAKERS on the AGENDA

Day 3: THURSDAY, SEPTEMBER 30

Day 3: Powering Our World (11:30 a.m. – 5:00 p.m.)

11:30 a.m .Welcome RemarksJames TempleSenior Editor for Energy, MIT Technology Review

Ensuring Energy Resilience (11:35 a.m. – 1:05 p.m.)

From next-generation power grids to nuclear power and renewable energy, understanding the impact, scalability, and tradeoffs of different energy technologies is critical to powering our future.

11:35 a.m.Transitioning toward Renewable Energy Solutions

With energy demands increasing dramatically in India, we examine the critical steps that renewable energy companies need to take to compete and continue to grow. Learn how these lessons can apply to other regions and what it will take to reliably meet regional electricity needs when it matters most, while actively transitioning toward cleaner and smarter energy choices.

Sumant Sinha Founder, Chairman & Managing Director, Renew Power

>>>India exceeded Paris Guidelines, Government involved in Renewable energies. Faster adoption. cost of renewal energy is plummeting. Demand increased by 5%-10% in coming 3 years, In 10 years 10%-15% – compromise of economic growth not favorable to all stakeholders. Intermittency regarding transmission and distribution of clean energy sources. Renewable only 15%, 2030 35%. Government GRID Management solar resource, storage cost will solve intermittency.

12:00 p.m.Cleaning Up the Power Sector

Today’s carbon-based power sources won’t safely sustain our growing electricity needs as climate change accelerates. The path forward requires decarbonizing the grid as rapidly as possible. We take a deep dive into the technologies, policies, and strategies needed to keep the lights on as rising demands and shifting climate conditions put ever greater strains on our power grids. What choices will have the greatest impact in delivering the clean energy required to run our world?

Jesse Jenkins Assistant Professor, Princeton University

>>> Cleaners energies 2030 50% lower emission Presidential mandate. Cost of batteries of electric cars, cost of Wind decreased by energy policy, push from oil energy to zero emission cars, accelerate clean energy is on the way.

Bill McKibben Cofounder & Senior Advisor, 350.org

>>> Washington Clean Energy Incentives, Utilities are engaged, Demand from the Public, investment $50Trillion divestment by Universities from Oil related investment. Climate change challenging fossil fuel energy industry. Changing is hard against Utilities and Oil interests

Leah Stokes Associate Professor, UC Santa Barbara

>>> Clean Energy to power homes and cars, pollution is draining the Power potential. FOssil fuel infrastructure IMPEDE decrease of Temperature by 5 degrees Celcius. Let’s make Clean energy cheaper by policy incentives to use and afford then deal with incease tax of fossil fuel.

Julian Brave NoisenCat Vice President, Policy & Strategy, Data for ProgressModerator

>>>

12:45 p.m.Transforming Clean Energy with Green Hydrogen

Hydrogen is energy-dense and burns cleanly, emitting no carbon dioxide. But until now, most hydrogen has been made from natural gas using a polluting and energy-intensive process. Get an early look at a transformational clean approach to producing hydrogen that has the potential to revolutionize the global energy sector. As featured in the 10 Breakthrough Technologies 2021

.Christoph Noeres Head of Green Hydrogen, thyssenkrupp Uhde Chlorine Engineers

@pharma_BI@AVIVA1950 #EmTechMIT Christoph Noeres Head of Green Hydrogen (GH) Electrolysis process of production of GH de-carbonizing by CO2 free for green housing low cost renewable industry at scale to push forward transport supply chain Green Hydrogen industry transformation

MIT Inside Track (1:05 p.m. – 1:45 p.m.)

Join the Inside Track sessions to engage more deeply with our content, speakers, and your fellow attendees during mainstage programming breaks.

1:05 p.m.Networking Break

1:20 p.m.Scaling Solutions for Emerging Economies

Creating scalable technology solutions in developing countries comes with its own unique constraints and opportunities. Gain insight into entrepreneurship in emerging economies including lessons in adapting existing technology and creating unique design assembly methods.

Harald Quintus Bosz CTO, Scaletech Countering Climate Change

>>> Building blocks of economic complexity

(1:45 p.m. – 3:20 p.m.)

As climate change marches on, the financial costs to businesses and nations are set to soar. Adopting climate-smart strategies will help to reduce risk while making a positive impact using the latest in green building technologies and more.

1:45 p.m. Weathering the Storm

Wildfires, heatwaves, and other extreme weather events are becoming more common and severe as the planet warms. Investigate the science behind climate change, how humans are influencing it, and what we can still do to address the rising dangers.

Kate Marvel NASA’s Goddard Institute for Space Studies; Professor, Columbia University

>>> Problem Space, Physical Climate Scientist Human are causing ALL the climate change, volcanos not responsible for warming TEMP altering the weather Heat waves, sea level rise, transfer of water from continents to oceans stronger hurricanes, tropical cyclone are stronger, increase in FIRES, Evaporation leads to droughts, Cold snaps like TX, cold air and Jet stream, Air quality particle level Ozon, high Probabilities based of 1988 projections of Temp getting it right for 2010 Warming is expected How bad gets. Climate sensitivity, cutting CO2 cutting Emission, Actions do matters, uncertainty is human behavior, sensitive climate What humans do? 5 degree Celcius is in Humans actions. 2020 – COVID Pandemic, 7% decrease in CO2 pollution caused increase in warming by clearing the sky. Avoid catastrophic effect. Positive view, under Human control are policies and effects behavior. Next year stop burn fossil fuel,

2:15 p.m.Creating Climate-Smart Buildings

The spaces where we live and work must adapt to the changing climate. Before investing in new spaces, discover how climate-smart innovations can boost our buildings’ efficiencies, including cooling, water recycling, and sustainable design.

Mircea Dinca Professor, MIT; Cofounder, Transaera

>>> AC new generation 50% more efficient than 2021 technology in AC

Meagan Mauter Associate Professor, Stanford University

>>> Automation, Precision preparation of resilient systems manage separation processing margilarity in water consumption electrify smart. Upgrading water and road infrastructure. Budget issues, achieve low carbon future. large centralized infrastructure become in adequate, build new small scale hybrid systems at the edge. Better use existing sunk costs. Water desalination manufacturing to save water and energy. Municipal treatment efficiencies next generation systems. Reuse of desalinated water. Retrofit buildings.

Anthony Brower Director of Sustainable Design, Gensler

>>> Building geometry, low tech shift from Rectangular to Square foot print. move stairs outside the building. Roof design Green rook sun is absorbed, eliminate lighting by sensor lighting reduce energy construction. 2030-2050 Building code in CA GREEN in 2045. Retrofitting buildings: this is the best 1st step.

Innovators Under 35 (2:50 p.m. – 3:20 p.m.)

2:50 p.m.Corporate Citizenship and the Risk We are not Thinking about – Presented by JPMorgan Chase

Awareness of the impending climate change challenges is growing in leadership circles, and the stakes are high. The imperative to integrate sustainability in business practices not only bolsters customer loyalty and attracts talent, it addresses climate change as an increasing risk to business as usual – worldwide.

Lori Beer Global CIO, JPMorgan Chase

2:55 p.m.Eliminating Carbon Emissions from Cement

Cement production accounts for approximately 7% of the planet’s carbon emissions. Learn how electrochemical synthesis of cement can eliminate carbon emissions for concrete production. As featured in the 2021 Innovators Under 35.

Leah Ellis CEO and Cofounder, Sublime Systems

>>> Patent-pending electrochemical system based on MIT research totally decarbonized cement commercially viable technology to scale cement made today. Green cement batch of tons of Cement not using fossil fuel.

3:10 p.m.Energy Transitions for Emerging Economies

Emerging economies require an intense amount of power. What does it take to create a scalable system that delivers reliable power as needed, where needed, and when needed? As featured in the 2021 Innovators Under 35.

Varun Sivaram Senior Director, Clean Energy & Innovation, U.S. Department of State

>>> Varun Sivaram Senior Director, Clean Energy & Innovation, U.S. Department of State Clean energy transition US will leverage technologies around the Global Drive down cost for Cleaner technologies National Labs lessons to be shared technical talent. Transportation and clean energy.

MIT Inside Track (3:20 p.m. – 3:55 p.m.)

Join the Inside Track sessions to engage more deeply with our content, speakers, and your fellow attendees during mainstage programming breaks.

3:20 p.m.Networking Break

3:30 p.m.Endless Ecosystems

Endless ecosystems is a framework for sustainable construction that combines design, digital fabrication, material development, and energy evaluation that uses 100% natural, recyclable materials. Inspired by nature, these modern materials and building practices bring the power and sustainability of the natural world to human systems.

Nic Lee Research Assistant, MIT Media Lab

Andy LippmanAssociate Director, MIT Media Lab

Turning Innovation Into Action (3:55 p.m. – 5:00 p.m.)

Research and innovation are only a few steps to achieving impactful change. Assess unique leadership approaches to chart the course for implementation from the lab to the real world.

3:55 p.m.Driving Innovation

The new era of autonomous vehicles is revolutionizing transportation. Take a deep dive into the process of changing an industry and reimagine the way we think about innovation, leadership, and design.

Jesse Levinson Co-Founder & CTO, Zoox

>>> Autonomous Vehicle for Urban Challenge Competition

History of Zoox, 2014 – Better way to create a new type of car optimize on Drivers experience vs autonomous vehicle Symmetrical and Bi-directional, shorter car, interior more space Passenger different experience add premium features, car is rented for few hours only.RObotTaxi like LIFT without a driver, each ride is in the same car. Expirience is UNIQUE to Zoox. 1/3 of Traffic is seeking for Parking this car will enable to convert Parking lots into Gardens, reduce road injuries. Congestion in Urban area requires a new vehicle. How to keep this car secure? AI driven. Zoox is not for sale. it is only for rent. so stealing, GPS knows where all Zoox are at any minute. AI ascertain safety. Passenger can stop the vehicle and can open the door and leave. TRUST is built over time. Zoox was acquired by Amazon. Amazon was attracted to Big Ideas will have Societal impact. Economic Opportunities of RoboTaxis and Societal Public good benefit.

4:25 p.m. The Future of Research and Innovation

The MIT Media Lab is the innovation center of MIT, bringing together researchers from across the globe to explore and develop new technologies that will transform the future of research as well as real-world applications. What are the issues, obstacles, and opportunities that will have the greatest impact on the world? Step with us into the lab where they lead with innovation. Dava Newman Director, MIT Media Lab

>>> Transition from a financial crisis and the Pandemic interruption – emergence into great opportunities with societal impact. New directions Bionics and prostetics for kids 3D Printing Assists Health and Wellness. Surgery and MGH collaboration Robotics Limbs. Videos using systemic view. Co-create the vision AI and data from Satellite Bridge ML and Data physics Predict crime in cities, inequality sensors in Urban environment to change behavior in Cities near Coast line floods. Buildings, manufacturing, Green and Clean. Responsibility and implementation equitable diversity challenging ideas: Art, design, Engineering, Science

4:50 p.m.Closing Remarks

Mat Honan Editor in Chief, MIT Technology Review

>>> James Temple, MIT TR Green Hydrogen was a surprise the need and the interest cost is deceasing it is in our capacity to overcome Amy Nordrum innovators under 35 small satellite hand size CRISPR as Diagnostics.

Read Full Post »

Day 2: Leading with innovation, Virtual MIT Technology Review’s flagship event, September 28-30, 2021

EmTech MIT hosted by MIT Technology Review 

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Covering the event in REAL TIME with Social Media

@pharma_BI @AVIVA1950 #EmTechMIT @EmtechMIT

In attendance

Aviva Lev-Ari, PhD, RN, Founder, LPBI Group: 1.0 & 2.0

AGENDA Overview

https://event.technologyreview.com/emtech-mit-2021/agenda

SPEAKERS on the AGENDA

WEDNESDAY, SEPTEMBER 29

Day 2: Mind, Body, Work (11:30 a.m. – 5:20 p.m.)

11:30 a.m.Welcome Remarks

Will Douglas Heaven Senior Editor for AI, MIT Technology Review

AI as a Global Disruptor (11:35 a.m. – 1:00 p.m.)

Artificial intelligence’s superhuman data processing capabilities have far-reaching implications. Unpack the oncoming effects on industry and society and explore the issues of ethics, inequity, and more that we’ll face as we strive to maintain control of algorithms that are controlling us.

11:35 a.m.Building a Better AI

To date, every major milestone in AI has been achieved by deep learning, but whether this approach will lead us to artificial general intelligence remains to be seen. To have true AI, must we first understand the brain? This session explores a neuroscience-based approach to AI that may lead to true machine intelligence.

Jeff Hawkins Cofounder and Chief Scientist, Numenta

>>> Model of the World, learning through movement, Current AI is pretty dump, machines that are truly intelligent, Road map for AI, his Thousand Brains Book, Not build the Brain, Two elements of new modeling: (1) fastest NN (2) Sparsity – existing NeuroNets and make them xxx times faster, learn new information Integration of these theoretical concept into companies building products. Add the thousands Brain model concept into AI to get Intelligent systems. The concept of competition, Structure of the Brain is known speculation of building AI to be human’s like in terms of Intelligence. The Goal is not Human’s Like bur Intelligent machine will act in the World, not have to be like Humans. Computing models can be smart not human but helping humans in Pattern recognition. Humans is the only species knowing about time, the universe, preserve and propagate, peer reviewed was also censored,

AI as a Global Disruptor

>>> Image processing and Computer Vision, finished PhD. Negative impact of AI, animate tools used for can be socially Bias. While at Google questioning AI experiences isolation. Labor rights and anti-discrimination rights, censoring research sounds like propaganda, outside the Tech company to impact the industry, to keep Tech companies accountable from the inside silencing. labor protection laws needed. Create own institute AI technologies to be built, critiquing AI. Ideas coming from the Researchers. AI to benefit Humanity vs Tech companies Profiting from Researchers work – Labor laws. Apples treatment of workers oppressive. Coalition of people around you: Scholars. Look at the marginalized group vs dominate group. Technology is built by both.

>>> Federated Learning beneficial – Distributed AI Learning Model. Where does the Data comes from Two canonical approaches in Federated Design: Centralized Learning vs Federated Learning – training at the Edge. Federate Learning (FL): (1) Cross Silo [high availability] vs (2) Cross device Federate Learning [communication bottleneck] – Distributive model [Privacy] different devices interoperability [heterogeniety}. Personalized FT: One for each device and among the devices improves Accuracy. Bias in Data. Privacy is Key. Google deploys Federated Design. FT design for Autonomous Vehicles construction behavior, rad conditions AI – work to be done for deployment. FT is not production ready. Centralized learning vs Federated Learning. Hospitals: FT is more expansive with greater benefits.

Challenge: Privacy [Criptographic technique] and secure the learned Model

Single Purpose Model vs Multi Purpose Model (1) General Models (2) Understand (3) Question and get answers. Learning Skills, Learning Concepts, Search Engine Data to teach after learning skills and concepts using richer vocabularies using Visual and Text data. Learn to interact, navigate. A game of Cache: Hide & Seek. AI agents, CEREBRA – Cognitive Rudiments for building AI Models – multi skills models simulators, robots, based on physical principles Multi modal AI Visual, Audio, Text. Building models that understand TEMPORAL behavior.

1:15 PM EDT

  • >>> Synthetic Biology – complexity biology: Pathways and Disease state (1) Sensing (2) Logic Processing (3) Therapeutics development. Controlling Stem cell differentiation. Programming a cell development for drug development via organelle development for building organelles for replacement: Liver vascularization dysfunction, Pancreas function by design mature Organoids Cyp3A4 – for druggability. Cancer immunotherapy will be first to benefit numeric synthetic Biology for therapeutic intervention to improve precision.

2:00 p.m.Can We Trust Tech to Police AI?

We are all subject to AI, even if it’s faulty, beyond our control, and biased. Massive AI models are being developed, but how do we ensure fair systems are created? Whether you’re building your own AI or working with vendors, learn the essential elements of fair and equitable AI.

Timnit Gebru Cofounder, Black in AI; Formerly, Google

12:25 p.m.AI Learning Models: Distributed vs Centralized

More secure methods of processing and storing massive volumes of data for AI are needed to alleviate privacy concerns. Is federated learning the best option? Examine how distributed learning works for AI and the potential benefits and risks for your organization.

Virginia Smith Assistant Professor, Carnegie Mellon University

12:45 p.m.New Advances in Multi-Skilled AI

AI robotics still struggle to match the skill level of a child. Human intelligence emerges from our combination of senses and language abilities; the same might be true for artificial intelligence. Is combining vision, audio, and language processing into a single AI system possible—and will it solve the problem? Explore the implications for AI and its potential use cases. As featured in the 10 Breakthrough Technologies 2021.

Ani Kembhavi Research Manager, Allen Institute for AI

MIT Inside Track (1:00 p.m. – 1:40 p.m.)

Join the Inside Track sessions to engage more deeply with our content, speakers, and your fellow attendees during mainstage programming breaks.

1:00 p.m.Networking Break

1:15 p.m.Programming DNA

Today with synthetic biology, we can assemble DNA for the purpose of modifying individual cells. But we’ve arrived at an age where it’s now possible to write DNA programs, analogous to writing to software, that impact cell information and behavior in a given sequence for even greater impact. We’ll talk about possibilities, limitations, and timelines for this amazing advancement.

Ron Weiss Professorr, Massachusetts Institute of Technology

AI as a Global Disruptor Cont’d (1:40 p.m. – 2:05 p.m.)

Artificial intelligence’s superhuman data processing capabilities have far-reaching implications. Unpack the oncoming effects on industry and society and explore the issues of ethics, inequity, and more that we’ll face as we strive to maintain control of algorithms that are controlling us.

1:40 p.m.Trustworthy AI in High-Stakes Environments – Presented by Raytheon Intelligence & Space

The high-stakes environment of intelligence and space is overflowing with data, where signals lurk in a sea of noise, best discoverable with AI. With no tolerance for error, engineering teams must drive trust and explainability in AI decisions so that human-machine teams, working in areas from synthetic biology to next-generation GPS, find the right solutions, every time, at speed.

Roy Azevedo President, Raytheon Intelligence & Space

Elizabeth Bramson-Boudreau CEO and Publisher, MIT Technology Review

>>> High-stake environments: National Security, Logistics, Cyber Satellite, Weather Storms, Deploy AI to explain the recommendation for trust into the decision making. AI is distrusted as it nears autonomy, edge or situation is unique, AI-ML recommendation require explainability for system automomy. Knowhow Satellite system for Weather prediction system data run through scenarios ethics applied before using AI-ML algorithm latency is not affordable, operator make decision at the edge Trust & Verify Modeling & Simulation perform.Education and Training 37,000 employees 5,000 were hired during the Pandemic. Three innovation new engine work, radio frequencies Radars, cyber technology

Biotech and Biothreats (2:05 p.m. – 3:20 p.m.)

Pandemic shutdowns focused a spotlight on biotech. Glimpse advances from drug development to gene editing, and which ones will help us through the next crisis.

2:05 p.m.Mitigating the Impact of Biological Threats

Our global society has become hyper-aware of biological pathogens and threats. We investigate some of the current and recent threat types, dispelling myths and confirming facts, while considering what comes next in the way of prevention, detection, and response for the next bio threat on the horizon.

Christina Rudzinski Assistant Division Head, Lincoln Laboratory, MIT

>>> Reducing Biological threats. COVID19 is a Global Pandemic by a pathogen, diagnostics deployed, genome of the virus gaps remain. Future pathogen will cause infections. Novel to genetically engineered pathogens, infectious agents, pathones evolve, can be used and have been used maliciously Infection progression: Pre-exposure Human transmission incubation symptoms onset illness early environmental detection population surveilence Bio-signal data for detection of host’s response to infection. Priority is both detection in advance and the vaccine capability virus detected as pathogen Active biological weapons Nation states as adversary Lab escape virus is a possibility Lab Survelience systems.

2:30 p.m.Turning CRISPR off

Genetic therapeutics has advanced to the point where we can turn genes off and on without altering DNA. Innovations like CRISPRoff affect cutting-edge research on viruses and the fight against diseases and other genetic disorders. Explore the possibilities and questions on how to manage ethical concerns and unintended consequences.

Jonathan Weissman Professor, MIT; Investigator, Howard Hughes Medical Institute

>>> CRISPR 2.0 under DARPA Chemical and BioChem funding. CRISPR gene editing correct the underlining genetics, where to cut the DNA for changing the sequence Cas9 – complicated technology. Turn up and down -Silence a gene, an existing gene programmable Epigenetic memory engineering (15 month) new opportunity in Medicine CRISP off Variant 1 vs CRISPR off Variant 2 only the targeted gene precision editing. Memorizing Gene Silencing. Silencing then reverse not permanent silencing. Germ line engineering. Motorneuron disease are good indications for Memorizing Gene Silencing

Innovators Under 35 (2:50 p.m. – 3:20 p.m.)

2:50 p.m.Scale Innovation and Ideas – Presented by JPMorgan Chase

Innovation drives results and creates value, and it must be supported by vision, leadership, purpose, and a clear path to scale. The right ecosystem is essential. From accelerator labs to automation, dynamic process transformation is built on collective intelligence put toward a common objective: to achieve real digital transformation for employees, customers, partners, and suppliers alike.

Lori Beer Global CIO, JPMorgan Chase

2:55 p.m.Next-Generation Disease Detection

New advances in CRISPR platforms are pushing biotechnology to the next level of disease detection and treatment. What does that mean for reducing human intervention, increasing diagnostics, and scalability? As featured in the 2021 Innovators Under 35.

Janice Chen Cofounder & CTO, Mammoth Biosciences

>>> On Demand DIagnostic Tool based on CRISPR: read, detect, Protein Discovery – Metagenomics – proteins Cas14, delivery advantages. Target proteins for diagnostics: detect DNA and RNA the exact sequence Future of CRISPR Diagnostics delivered to Mobile. Molecular lab accuracy in the mobile device for the results TEST to TREATMENT. CRISPR is a platform for Diagnostics it is also a therapeutics target via gene editing vs medicinal chemistry.

3:10 p.m.Microscopic Robots that Move

Programmable, autonomous, microscopic robots are coming, and now they can move. These tiny bots have the potential to revolutionize engineering new materials, rid crops of pests, act as cellular-level surgeons, and more. Get an early look at this emerging tech. As featured in the 2021 Innovators Under 35.

Marc Miskin Assistant Professor, University of Pennsylvania

>>> application of microelectronic CMOS for design of robots microorganism size not visible to eye laser spot is a control function parallel design of one robot allows deployment of an army of robots like microorganisms Repair of nerves. A factor of 10 in size power low, cost low,

MIT Inside Track (3:20 p.m. – 3:55 p.m.)

Join the Inside Track sessions to engage more deeply with our content, speakers, and your fellow attendees during mainstage programming breaks.

3:20 p.m.Networking Break

3:30 p.m.From a Mouse to a Bird

The ubiquitous computer mouse allows us to manipulate our 2D desktops. The jump to virtual worlds will require new tools to help us interact with 3D objects. Get an early look at the grasping technology called Bird.

Aubrey Simonson Graduate Student, MIT Media Lab

Andy Lippman Associate Director, MIT Media Lab

Extending the Workplace (3:55 p.m. – 5:15 p.m.)

The events of 2020 forced us to reimagine the workplace. Explore extended reality (XR) technology projects, including augmented reality (AR), virtual reality (VR), and mixed reality (MR), poised to change the way we work.

3:55 p.m.Planning for an Immersive Workplace

Extended reality (XR) technologies are transforming workspaces. Bridging the virtual and physical worlds with AR/VR/MR enables immersive experiences for team collaboration, staff training, and customer experience. Get industry insight on how these technologies are impacting work and generating surprising results.

Timoni West Vice President, XR Tools, Unity

4:20 p.m.Preparing for a New Reality

Immersion technologies are estimated to become a $57 billion industry by 2027. Get a look under the hood at how these systems work, what kind of infrastructure is needed, and tips for integrating immersion tech into existing workflow systems.

Urho Konttori Cofounder and CTO, Varjo

>>> VR and XR headsets: True Telepresence, device will be size of goggles. In 2025 standardization of the Industry.Human communication iwll be come Teleportation

4:40 p.m.Extended Reality Use Cases

Extended reality tools are already being incorporated into standard business operations in enterprise-level systems. Industry experts walkthrough real-world applications in health care, training, and construction to demonstrate the value immersion technologies can bring to the workplace.

Amitai Ziv Director, Extended Reality Hub, Sheba’s Innovation Center

>>>> Patients education with VR, Chemo Treatment VR can take patients to Paris or London. Used in Surgery CT overlaid on the Spine surgery site. Moving organ during surgery Heart, abdomen. Expectation. Assist device, not the only one. Simulation is not reality.

Will Adams Emerging Technologies Developer, M.A. Mortenson Company

>>> Rendering images of construction sites, technology is cool

Gordon Cooke Director, Research and Strategy, The U.S. Military Academy at West Point

>>> Training, new content creation is an issue.

Last Call with the Editors (5:15 p.m. – 6:20 p.m.)

Attendees and speakers are invited to attend our online EmTech MIT reception in virtual reality, which kicks off with a short talk on creating and navigating immersive spaces. Join us under the MIT Dome from your web browser or your VR headset as we mix and mingle in this unique networking session and hands on demo.

Before we send everyone home for the night, join our last call with all of our editors to get their analysis on the day’s topics, themes, and guests.

5:20 p.m.EmTech MIT VR Reception Under the MIT Dome

Read Full Post »

EmTech MIT 2021 – Agenda Overview & Speakers: Leading with innovation, Virtual MIT Technology Review’s flagship event, September 28-30, 2021

Day 1: Leading with innovation, Virtual MIT Technology Review’s flagship event, September 28-30, 2021

EmTech MIT hosted by MIT Technology Review 

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Covering the event in REAL TIME with Social Media

@pharma_BI @AVIVA1950 #EmTechMIT @EmtechMIT

In attendance

Aviva Lev-Ari, PhD, RN, Founder, LPBI Group: 1.0 & 2.0

Aviva Lev- Ari, Founder, 1.0 LPBI and 2.0 LPBI Group

AGENDA Overview & Speakers at EmTech MIT 2021

https://event.technologyreview.com/emtech-mit-2021/agenda

TUESDAY, SEPTEMBER 28

The digital future

The road to cyber-resiliency

The destructive rise of ransomware has quantified the cost of cybersecurity and elevated cyber-resilience from an IT concern to an executive mandate. Learn how we can defend against infinite threats with finite resources.

The business of blockchain

Digital value is changing the fundamental rules of business. Digital currencies, NFTs, and smart contracts are shifting power and creating new opportunities for those who understand their possibilities and potential.

Convergence in the cloud

Together, the cloud, edge computing, and 5G are altering what’s possible. Grasp the tangible benefits of real-world intelligent cloud computing and learn how it’s transforming business.

WEDNESDAY, SEPTEMBER 29

Mind, body, work

AI as a global disruptor

Artificial intelligence’s superhuman data processing capabilities have far-reaching implications. Unpack the oncoming effects on industry and society and explore the issues of ethics, inequity, and more that we’ll face as we strive to maintain control of algorithms that are controlling us.

Biotechnology for a post-pandemic world

The pandemic shutdowns focused a new spotlight on biotech. See the emerging advances in everything from drug development to vaccine next steps to gene editing, and glimpse which ones will help us through the next crisis.

Extending the workplace

The events of 2020 forced us to reimagine the workplace as never before, with remote workers, hybrid workplaces, and distributed teams. Explore real-world augmented reality (AR) and virtual reality (VR) projects poised to change the way we work when we’re no longer constrained by space and walls.

THURSDAY, SEPTEMBER 30

Powering our world

Ensuring energy resilience

As every aspect of our lives rapidly becomes digitized, ensuring energy resilience and efficiency is critical to powering the technologies we rely on in our businesses and our lives. From the future of the power grid to nuclear power and renewable energy, assess the knowledge needed for choosing the right energy source.

Countering climate change

As climate change marches on, affecting business, society, and the planet, the financial tipping point is around the corner. Adopt strategies to advance environmental responsibility and reduce risk with the latest in carbon capture technologies, green building, and more.

Turning innovation into action

Research and innovation are only a few steps to achieving impactful change. Assess unique leadership approaches to chart the course for implementation from the lab to the real world.

SPEAKERS at EmTech MIT 2021

Speakers

Will
Adams
Emerging Technologies Developer M.A. Mortenson Company

Roy
Azevedo
President Raytheon Intelligence & Space

Aamer
Baig
Senior Partner McKinsey Technology

Lori
Beer
Global CIO JPMorgan Chase

Elizabeth
Bramson-Boudreau
CEO and Publisher MIT Technology Review

Anthony
Brower
Director of Sustainable Design Gensler

Janice
Chen
Cofounder & CTO Mammoth Biosciences

Gordon
Cooke
Director, Research and Strategy The U.S. Military Academy at West Point

Mircea
Dinca
Professor, MIT; Cofounder Transaera

Leah
Ellis
CEO and Cofounder Sublime Systems

Timnit
Gebru
Cofounder, Black in AI; Formerly Google

Karen
Hao
Senior AI Reporter MIT Technology Review

Jeff
Hawkins
Cofounder and Chief Scientist Numenta

Will Douglas
Heaven
Senior Editor for AI MIT Technology Review

Mat
Honan
Editor in Chief MIT Technology Review

Charles
Hoskinson
CEO and Founder, Input Output Global; Founder, Cardano; Cofounder Ethereum

Ghada
Ijam
CIO Federal Reserve System

Jesse
Jenkins
Assistant Professor Princeton University

Bobbie
Johnson
Senior Editor MIT Technology Review

Ani
Kembhavi
Research ManagerAllen Institute for AI

Urho
Konttori
Cofounder and CTO Varjo

Jesse
Levinson
Co-Founder & CTO Zoox

Kate
Marvel
NASA’s Goddard Institute for Space Studies; Professor Columbia University

Meagan
Mauter
Associate Professor Stanford University

Bill
McKibben
Cofounder & Senior Advisor 350.org

Adnan
Mehonic
Assistant Professor University College London

Silvio
Micali
Founder Algorand

Marc
Miskin
Assistant Professor University of Pennsylvania

Wendy
Nather
Head of Advisory CISOs Cisco

Dava
Newman
Director MIT Media Lab

Christoph
Noeres
Head of Green Hydrogen thyssenkrupp Uhde Chlorine Engineers

Julian Brave
NoiseCat
Vice President, Policy & Strategy Data for Progress

Amy
Nordrum
Commissioning Editor MIT Technology Review

Judith
Olson
Head of Atomic Clock Division ColdQuanta

Patrick Howell
O’Neill
Senior Editor for Cybersecurity MIT Technology Review

Antonio
Regalado
Senior Editor, Biomedicine MIT Technology Review

Siobhan
Roberts
Senior editor, Computing MIT Technology Review

Christina
Rudzinski
Assistant Division Head, Lincoln Laboratory MIT

Kevin
Scott
CTO & EVP, Technology and Research Microsoft

Nick
Selby
Chief Security Officer Paxos Trust Company

Sumant
Sinha
Founder, Chairman & Managing Director Renew Power

Varun
Sivaram
Senior Director, Clean Energy & Innovation U.S. Department of State

Virginia
Smith
Assistant Professor Carnegie Mellon University

Sara
Spangelo
CEO & Cofounder Swarm Technologies

Leah
Stokes
Associate Professor UC Santa Barbara

Jennifer
Strong
Senior Editor for Podcasts and Live Journalism MIT Technology Review

James
Temple
Senior Editor for Energy MIT Technology Review

Daniel
Theobald
Founder and Chief Innovation Officer Vecna Robotics

Jonathan
Weissman
Professor, MIT; Investigator Howard Hughes Medical Institute

David
Wentzloff
Cofounder & Co-CTO Everactive

Timoni
West
Vice President, XR Tools Unity

Amitai
Ziv
Director, Extended Reality HubSheba’s Innovation Center

MIT Inside Track

Michael
Casey
Chief Content Officer CoinDesk

Charlotte
Jee
Reporter, News MIT Technology Review

Nic
Lee
Research Assistant MIT Media Lab

Andy
Lippman
Associate Director MIT Media Lab

Jacob
Loewenstein
VP, Business Development & Strategy Spatial

Michael
Potts
Metaverse Architect M2 Studio

Harald
Quintus Bosz
CTO Scaletech

Aubrey
Simonson
Graduate Student MIT Media Lab

Jake
Steinerman
Head of Community Spatial

Ron
Weiss
Professor Massachusetts Institute of Technology

Randi
Williams
Graduate Research Assistant MIT Media Lab

Day 1: The Digital Future (11:30 a.m. – 5:20 p.m.)

11:30 a.m.Welcome RemarksMat HonanEditor in Chief, MIT Technology Review

11:35 a.m.Leading with Innovation

Leadership requires innovation to succeed. On the most significant issues shaping the future, unpack what innovation must do, learn what to anticipate, and discover the technologies required to thrive and lead through the next 12-24 months. Kevin ScottCTO & EVP, Technology and Research, Microsoft

>>> start with function wish to write – micro-language representation model for code

writing. Compute is the only constraint. Open source version of OpenAI API no need to build OS. Responsible AI within Microsoft – Standard for the whole company to be rolled up soon. Regulation to consider where we are going to be. BioScience breakthroughs quick deployment of molecular innovations in Drug development – teach a machine how to solve a problem. Machines are excellent in doing functions that Human can’t and Humans are adept in reasoning an like machines. Technology can be harmful to society by intent , biases to overcome human in the loop for decision to deploy computer vision accomodation for gender and ethnicity if you do not use synthetic data – Face recognition need to be regulated.

The Road to Cyber Resiliency (12:05 p.m. – 1:00 p.m.)

>>> We get better at detection

The destructive rise of ransomware has quantified the cost of cybersecurity and elevated cyber-resilience from an IT concern to an executive mandate. Learn how we can defend against infinite threats with finite resources.12:05 p.m.Aftermath of a Breach

Go inside the war room to get a firsthand account of a cyberattack and what it’s like to discover your defenses have been breached and your data exposed. This first-person walkthrough prepares you for the technical, legal, and public-relations considerations to create your own response plan. Nick Selby Chief Security Officer, Paxos Trust Company

>>> at Timehop GDPR a bridge of security disclosure to US Citizens 5% of EU opt out 7/418 ADM password changed User database was compromised protect customers data Recovery architecture monitor Testing the backups – they need to be disconnected, security communication De-perimiterization for infection detection, pre-annuncement Challenges, De-activate all social media mobile phones numbers in Millions. Integrity & Transparency: Bring in MEDIA, NBC News, How you handle when you get a data breach. Threats had changed since 2018. Customers data can lead to Identity Theft, from phone numbers, e-mail to bank accounts.

12:35 p.m.Cyber Threat Analysis and Prevention

Before your defenses are breached, a strong cyber-resiliency plan is essential in protecting your infrastructure from attack. Understand the current attack vectors and what you can do to assess threats and implement preventive practices. Wendy Nather Head of Advisory CISOs, Cisco

>>>> mid 90s Two-way authentications Who are the attackers, changes, abuse of the platform by users Technology to buy Proactive Refresh Tech done by vendor is best security practice. Security poverty line – Incidence reporting is better than nothing. Evidence based security guidance BioMetrix on the Phone is easy to use Apple did beautiful design. Sterile Operating Theater HOW to do two way authentication? risk analyzed in design of products. Figuring out is there is a breach or not, it need to be reported anyway. Special Access privileges needed to investigate a breach. Mandatory Breach assigned.

MIT Inside Track (1:00 p.m. – 1:40 p.m.)

Join the Inside Track sessions to engage more deeply with our content, speakers, and your fellow attendees during mainstage programming breaks.

1:00 p.m.Networking Break

1:15 p.m.Demystifying Decentralized Finance

Views differ on Bitcoin, but few doubt the transformative potential of blockchain technology. Blockchain can restore personal control over our data, assets, and identities; grant billions of excluded people access to the global economy; and shift the balance of power to revive society’s faith in itself.We reveal the implications for industries including finance, tech, legal, and shipping as decentralization disrupts the money world. Michael CaseyChief Content Officer, CoinDesk

The Business of Blockchain (1:40 p.m. – 3:05 p.m.)

Bobbie Johnson, MIT Technology Review

>>> Emerging technologies

Is Blockchain that did not realized its potential will it work for you? What are Smart contract

Digital value is changing the fundamental rules of business. Digital currencies, NFTs, and smart contracts are shifting power and creating new opportunities for those who understand their possibilities and potential.1:40 p.m.Decentralized Digital Currencies and Contracts

Digital currencies and contracts are growing in number and scope, powered by Bitcoin and Ethereum. As these technologies mature, new options such as Ada and Cardano are challenging the status quo. Understand the technical, social, business, and global implications of a world where digital contracts and currencies exponentially facilitate the trade capabilities of our current financial system. Charles Hoskinson CEO and Founder, Input Output Global; Founder, Cardano; Cofounder, Ethereum

>>> Charles Hoskinson CEO and Founder, Input Output Global; Founder, Cardano, 2015 Nation scale [Ethiopia] and Global scale – records ledger and smart contracts, credentials identity, reversible auditable that operates at scale; Cofounder, Ethereum

Portability of credentials in Ethiopia for outside, Build reputation for credit scoring.

What is in El Salvador for crypto currency? Cardano ? Contract system, EDA is transaction system, consensus protocol, energy consumption comes from hash for every step, representation not actual, 2015 – decentralization of energy consumption, hardware with limited supply, 3rd generation systems become decentralized. Speed of Networks, base ledge proof of reserve, auction computation – hybrid model decentralized and centralized at the same time. Space is more inclusive, diverse industry. Mongolia has bitcoin and Nigeria and Vietnam had adopted bitcoin and microfinance in Kenia and Philippines

2:10 p.m.A National Digital Dollar

The role of digital currencies in business is rapidly changing from speculation to reality. Today, countries are already looking to adopt a national digital currency. Learn how to leverage digital currencies for real-world business impact and the implications of an economy based on a global digital dollar. Silvio Micali Founder, Algorand

>>> How one assesses scalability transactions on chain with interoperability, Consensus of teminology. El Salvador can’t afford VISA transaction fees. Blockchain is very affordable in offering payments opportunity: in Columbia, provide tool sets.

Nation States vs Corporations: Objective of longevity, security – direct education and regulators involved in education on population. Decentralized systems have longevity vs decentralized systems. Intelligent adaptation of a new technology.

Innovators Under 35 (2:35 p.m. – 3:05 p.m.) – 500 applicants/nominees for 35 to be selected

2:35 p.m.Enabling Digital Transformation in the New Economy – Presented by JPMorgan Chase

The convergence of cloud computing, technology at the edge, and other next-gen computing trends enable digital transformation at speed and scale. Move your organization forward with critical insights from emerging research-to-market solutions contributing to the digital revolution.Lori Beer Global CIO, JPMorgan Chase

Contributors to Computing Power: Quantum computing, AI,

2:40 p.m.Transforming Compute Power

Significant improvements in energy, efficiency, and speed are needed to transform AI. Memristor technology has that potential, though to date no one has been able to convert the theory into practice. Have we reached a new breakthrough that will accelerate AI at lower power? As featured in the 2021 Innovators Under 35.

Adnan Mehonic Assistant Professor, University College London

>>> Training an AI Model using Memistore silicon oxide for digital memory it can be used for In memory computing, Neuromorphic Computing:

Digital CMOS, xxx, Neuromorphic Computing

2:55 p.m.Connecting at the Edge

A low-cost global network of tiny satellites for internet-of-things devices can transform  business, providing connectivity to the edge and  from anywhere on the planet. As featured in the 2021 Innovators Under 35.

Sara Spangelo CEO & Cofounder, Swarm Technologies

>>> 150 satellites offering for $5 per month IoT Global Network connectivity

Risks: Collision among tiny satellite, encryption technology for the communication been transmitted

MIT Inside Track (3:05 p.m. – 3:40 p.m.)

Join the Inside Track sessions to engage more deeply with our content, speakers, and your fellow attendees during mainstage programming breaks.

3:05 p.m.Networking Break3:15 p.m.The Soul of a Robot

To date, much of the work in robotics has focused on the mechanical engineering of physical movement. But as interactive technologies are applied in more social settings, it’s imperative that the technologies be socially engaging, and connect with humans.Randi WilliamsGraduate Research Assistant, MIT Media LabAndy Lippman Associate Director, MIT Media Lab

Living on the Edge (3:40 p.m. – 5:15 p.m.)

Together, the cloud, edge computing, and 5G are altering what’s possible. Grasp the tangible benefits of real-world intelligent cloud computing and learn how it’s transforming business.

3:40 p.m.Capturing Value from the Cloud – Presented by McKinsey Technology

More companies are starting to see the real benefits of cloud, which has been heralded as a catalyst for innovation and digital transformation. Across a range of industries, organizations have successfully implemented cloud to achieve impressive results. This discussion will explore best practices these companies follow and recent research that identifies the pools of value for adoption and drivers of that value.

Aamer Baig Senior Partner, McKinsey Technology Ghada Ijam CIO, Federal Reserve System

Aamer Baig Senior Partner, McKinsey Technology

>>> Cloud:

Enabler and catalist (a) Strategy & Management (b) Business domain adoption (c) Processes and risk postures

1. Innovate

2. Rejuvenate

3. Pioneer adoption of New technologies: Blockchain,

Aamer Baig Senior Partner, McKinsey Technology Cloud migration Scale and where the value comes from CIO, CFO, CEO Cloud has cost components Business opportunity that business process and business transformation

Create evangelists in the organization Top management transparency how an organization work

4:05 p.m.Robotics at the Edge

Robotics accelerate the supply chain by enabling warehouses and machinery to think, sense, and act. Learn how robotics at the edge moves AI from the cloud to independent devices.

Daniel Theobald Founder and Chief Innovation Officer, Vecna Robotics

>>> Where the Optimization will come from? Supply Chain problem solving. Edge computing like Cloud computing allows to collect data Robots collect data – automated guided vehicles, now for optimization the opportunity arrived. Robots navigate and make decisions an obstacle or challenge one individual robot transmit data collected from each robot to the Cloud for analysis for quick processing. Place compute on the Robot before transmitting to the Cloud about where to deploy robots, collect data and improve performance. Data goes in many directions. Local Servers vs the Cloud: Resilience

Interoperability Standard – Robots sharing information in a Standard Open API way.

In the Edge: IoT and Robots – it is a continuum, Only Robots move and sense – standard API to the Cloud autonomy and sensors on top to operate on fire doors, elevators, conveyers. Robots sense around them – deal with obstacles in real time. Three MMM will be done by robots in the future, massive labor shortages. Practical approach. Massive value to be capture in the warehouse.

4:30 p.m.Internet of Things: Batteries Not Included

Internet-of-things sensors can provide 24/7 monitoring of facilities and locations, but the power they require is not always available in the locations where monitoring is required. Explore the latest advances in battery-free, low-maintenance devices that enable monitoring in previously unreachable areas.

David Wentzloff Cofounder & Co-CTO, Everactive

>>> Evolution of computing, wireless communications New Paradigm: Pervasive Computing: Machine Health Monitoring, adoption by EM and ABB, Nasdac, Localization and computing at the EDGE. 1Billion data points collected. Partnering beyond manufacturing: Logistics, agriculture, consumer applications and verticals. Move from the Cloud to the Edge. Computations on the nodes. AI involved power level.

5:00 p.m.Beyond GPS: Hyper-accurate Positioning

New hyper-accurate positioning technologies have brought the world into dramatically sharper focus than GPS with accuracies within a few millimeters, which opens new opportunities in the way we farm, transport goods, and navigate our world. As featured in the 10 Breakthrough Technologies 2021.

Judith Olson Head of Atomic Clock Division, ColdQuanta

>>> Next generation of GPS

SUMMARY

Polls of Blockchain: many (34%) said it change the World. Few said will invest in it or will use it. Call to have more regulations Congress try to regulate the Internet may e coming Technology & Ingenuity gap robots can empower humans unfamiliar

Read Full Post »

#TUBiol5227: Biomarkers & Biotargets: Genetic Testing and Bioethics

Curator: Stephen J. Williams, Ph.D.

The advent of direct to consumer (DTC) genetic testing and the resultant rapid increase in its popularity as well as companies offering such services has created some urgent and unique bioethical challenges surrounding this niche in the marketplace. At first, most DTC companies like 23andMe and Ancestry.com offered non-clinical or non-FDA approved genetic testing as a way for consumers to draw casual inferences from their DNA sequence and existence of known genes that are linked to disease risk, or to get a glimpse of their familial background. However, many issues arose, including legal, privacy, medical, and bioethical issues. Below are some articles which will explain and discuss many of these problems associated with the DTC genetic testing market as well as some alternatives which may exist.

‘Direct-to-Consumer (DTC) Genetic Testing Market to hit USD 2.5 Bn by 2024’ by Global Market Insights

This post has the following link to the market analysis of the DTC market (https://www.gminsights.com/pressrelease/direct-to-consumer-dtc-genetic-testing-market). Below is the highlights of the report.

As you can see,this market segment appears to want to expand into the nutritional consulting business as well as targeted biomarkers for specific diseases.

Rising incidence of genetic disorders across the globe will augment the market growth

Increasing prevalence of genetic disorders will propel the demand for direct-to-consumer genetic testing and will augment industry growth over the projected timeline. Increasing cases of genetic diseases such as breast cancer, achondroplasia, colorectal cancer and other diseases have elevated the need for cost-effective and efficient genetic testing avenues in the healthcare market.
 

For instance, according to the World Cancer Research Fund (WCRF), in 2018, over 2 million new cases of cancer were diagnosed across the globe. Also, breast cancer is stated as the second most commonly occurring cancer. Availability of superior quality and advanced direct-to-consumer genetic testing has drastically reduced the mortality rates in people suffering from cancer by providing vigilant surveillance data even before the onset of the disease. Hence, the aforementioned factors will propel the direct-to-consumer genetic testing market overt the forecast timeline.
 

DTC Genetic Testing Market By Technology

Get more details on this report – Request Free Sample PDF
 

Nutrigenomic Testing will provide robust market growth

The nutrigenomic testing segment was valued over USD 220 million market value in 2019 and its market will witness a tremendous growth over 2020-2028. The growth of the market segment is attributed to increasing research activities related to nutritional aspects. Moreover, obesity is another major factor that will boost the demand for direct-to-consumer genetic testing market.
 

Nutrigenomics testing enables professionals to recommend nutritional guidance and personalized diet to obese people and help them to keep their weight under control while maintaining a healthy lifestyle. Hence, above mentioned factors are anticipated to augment the demand and adoption rate of direct-to-consumer genetic testing through 2028.
 

Browse key industry insights spread across 161 pages with 126 market data tables & 10 figures & charts from the report, “Direct-To-Consumer Genetic Testing Market Size By Test Type (Carrier Testing, Predictive Testing, Ancestry & Relationship Testing, Nutrigenomics Testing), By Distribution Channel (Online Platforms, Over-the-Counter), By Technology (Targeted Analysis, Single Nucleotide Polymorphism (SNP) Chips, Whole Genome Sequencing (WGS)), Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2020 – 2028” in detail along with the table of contents:
https://www.gminsights.com/industry-analysis/direct-to-consumer-dtc-genetic-testing-market
 

Targeted analysis techniques will drive the market growth over the foreseeable future

Based on technology, the DTC genetic testing market is segmented into whole genome sequencing (WGS), targeted analysis, and single nucleotide polymorphism (SNP) chips. The targeted analysis market segment is projected to witness around 12% CAGR over the forecast period. The segmental growth is attributed to the recent advancements in genetic testing methods that has revolutionized the detection and characterization of genetic codes.
 

Targeted analysis is mainly utilized to determine any defects in genes that are responsible for a disorder or a disease. Also, growing demand for personalized medicine amongst the population suffering from genetic diseases will boost the demand for targeted analysis technology. As the technology is relatively cheaper, it is highly preferred method used in direct-to-consumer genetic testing procedures. These advantages of targeted analysis are expected to enhance the market growth over the foreseeable future.
 

Over-the-counter segment will experience a notable growth over the forecast period

The over-the-counter distribution channel is projected to witness around 11% CAGR through 2028. The segmental growth is attributed to the ease in purchasing a test kit for the consumers living in rural areas of developing countries. Consumers prefer over-the-counter distribution channel as they are directly examined by regulatory agencies making it safer to use, thereby driving the market growth over the forecast timeline.
 

Favorable regulations provide lucrative growth opportunities for direct-to-consumer genetic testing

Europe direct-to-consumer genetic testing market held around 26% share in 2019 and was valued at around USD 290 million. The regional growth is due to elevated government spending on healthcare to provide easy access to genetic testing avenues. Furthermore, European regulatory bodies are working on improving the regulations set on the direct-to-consumer genetic testing methods. Hence, the above-mentioned factors will play significant role in the market growth.
 

Focus of market players on introducing innovative direct-to-consumer genetic testing devices will offer several growth opportunities

Few of the eminent players operating in direct-to-consumer genetic testing market share include Ancestry, Color Genomics, Living DNA, Mapmygenome, Easy DNA, FamilytreeDNA (Gene By Gene), Full Genome Corporation, Helix OpCo LLC, Identigene, Karmagenes, MyHeritage, Pathway genomics, Genesis Healthcare, and 23andMe. These market players have undertaken various business strategies to enhance their financial stability and help them evolve as leading companies in the direct-to-consumer genetic testing industry.
 

For example, in November 2018, Helix launched a new genetic testing product, DNA discovery kit, that allows customer to delve into their ancestry. This development expanded the firm’s product portfolio, thereby propelling industry growth in the market.

The following posts discuss bioethical issues related to genetic testing and personalized medicine from a clinicians and scientisit’s perspective

Question: Each of these articles discusses certain bioethical issues although focuses on personalized medicine and treatment. Given your understanding of the robust process involved in validating clinical biomarkers and the current state of the DTC market, how could DTC testing results misinform patients and create mistrust in the physician-patient relationship?

Personalized Medicine, Omics, and Health Disparities in Cancer:  Can Personalized Medicine Help Reduce the Disparity Problem?

Diversity and Health Disparity Issues Need to be Addressed for GWAS and Precision Medicine Studies

Genomics & Ethics: DNA Fragments are Products of Nature or Patentable Genes?

The following posts discuss the bioethical concerns of genetic testing from a patient’s perspective:

Ethics Behind Genetic Testing in Breast Cancer: A Webinar by Laura Carfang of survivingbreastcancer.org

Ethical Concerns in Personalized Medicine: BRCA1/2 Testing in Minors and Communication of Breast Cancer Risk

23andMe Product can be obtained for Free from a new app called Genes for Good: UMich’s Facebook-based Genomics Project

Question: If you are developing a targeted treatment with a companion diagnostic, what bioethical concerns would you address during the drug development process to ensure fair, equitable and ethical treatment of all patients, in trials as well as post market?

Articles on Genetic Testing, Companion Diagnostics and Regulatory Mechanisms

Centers for Medicare & Medicaid Services announced that the federal healthcare program will cover the costs of cancer gene tests that have been approved by the Food and Drug Administration

Real Time Coverage @BIOConvention #BIO2019: Genome Editing and Regulatory Harmonization: Progress and Challenges

New York Times vs. Personalized Medicine? PMC President: Times’ Critique of Streamlined Regulatory Approval for Personalized Treatments ‘Ignores Promising Implications’ of Field

Live Conference Coverage @Medcitynews Converge 2018 Philadelphia: Early Diagnosis Through Predictive Biomarkers, NonInvasive Testing

Protecting Your Biotech IP and Market Strategy: Notes from Life Sciences Collaborative 2015 Meeting

Question: What type of regulatory concerns should one have during the drug development process in regards to use of biomarker testing? From the last article on Protecting Your IP how important is it, as a drug developer, to involve all payers during the drug development process?

Read Full Post »

2021 EmTech Next

AGENDA for June 19, 2021

Thursday, June 1011:30 AM EDT

https://emtechnext21.pathable.co/agenda#/?limit=20&scroll=item,TwBc42y546R75hXJY,TwBc42y546R75hXJY,370.44482421875,18&sortByFields[0]=startsAt&sortByOrders[0]=1&uid=DFwuJhrAAFrqvN6jv

Reporter: Aviva Lev-Ari, PhD, RN

12:00 PM EDT

  • MAINSTAGEThe Future of Productivity12:00 PM – 1:30 PM EDTErik BrynjolfssonStanford UniversityProfessor and Director, Stanford Digital Economy LabAnthony Chang, MD, MBA, MPH, MSChildren’s Hospital of Orange CountyChief Intelligence and Innovation Officer, Medical DirectorAashima GuptaGoogle CloudDirector, Global Healthcare Strategy and SolutionsDavid RotmanMIT Technology ReviewEditor at LargeJulie ShahMITProfessor of Aeronautics and Astronautics, CSAILJennifer StrongMIT Technology ReviewSenior Editor for Podcasts and Live Journalism

REAL TIME COVERAGE

  • Erik Brynjolfsson Stanford UniversityProfessor and Director, Stanford Digital Economy Lab
  • AI –>>> Productivity and Future of Work

    • Rethink processes x10 bigger than technology
    • Top Decile lead the the rest 90% lag.
    • productivity has a J – shape curve
    • Technology & wages: Substitution, Complementarity,
    • 950 Occupations: Radiology – threat from automation, 27 task they do many are not to be done by the amchine
    • Not entire occupations will disappear; Top 1% will will benefit more cashiers: ML will do the job
    • Technologies very powerful ready for deployment
    • changes in business processes
    • Wellbeing and Productivity by Type
    • GDP – nominator and # Hours of Work is the denominator

  • Julie Shah MIT Professor of Aeronautics and Astronautics, CSAIL
  • Reverse Engineer the human mind in robot design

    use of robot in automotive and electronics is prevalent

    economic competitiveness depends on robotics at OEM

    Automation engineers are expensive for medium size firms

    Collaborative robots are not well accounted in the equation of labor replacement

    Human-Robot Integration Models are a challenge: Step by Step understanding

    1:30 PM EDT

    • Aashima Gupta Google Cloud Director, Global Healthcare Strategy and Solutions

    2:00 PM EDT

    • MAINSTAGEAI Productivity vs Privacy2:00 PM – 3:20 PM EDT
    • Prasad AkellaDrishtiFounder and CEO
    • Elizabeth Bramson-BoudreauMIT Technology ReviewCEO and Publisher
    • Will Douglas HeavenMIT Technology ReviewSenior Editor for AI
    • Suzanne KopchaSiemensVice President, Consumer Products & Retai
    • lArun NairRetailNextFounder and CTO

    3:20 PM EDT

    3:50 PM EDT

    • MAINSTAGELeading with Innovation3:50 PM – 5:00 PM EDTWill Douglas HeavenMIT Technology ReviewSenior Editor for AIAdi IgnatiusHarvard Business ReviewEditor in ChiefHubert JolyHarvard UniversityFormer Chairman & CEO, Best Buy; Senior Lecturer, Harvard Business SchoolAndrew McAfeeSloan School of Management, MITCofounder and Co-Director, Initiative on the Digital Economy; Principal Research ScientistMichael ReillyMIT Technology ReviewExecutive EditorDavid RotmanMIT Technology ReviewEditor at LargeJennifer StrongMIT Technology ReviewSenior Editor for Podcasts and Live Journalism

    Read Full Post »

    2021 Virtual World Medical Innovation Forum, Mass General Brigham, Gene and Cell Therapy, VIRTUAL May 19–21, 2021

    The 2021 Virtual World Medical Innovation Forum will focus on the growing impact of gene and cell therapy. Senior healthcare leaders from all over look to shape and debate the area of gene and cell therapy. Our shared belief: no matter the magnitude of change, responsible healthcare is centered on a shared commitment to collaborative innovation–industry, academia, and practitioners working together to improve patients’ lives.

    About the World Medical Innovation Forum

    Mass General Brigham is pleased to present the World Medical Innovation Forum (WMIF) virtual event Wednesday, May 19 – Friday, May 21. This interactive web event features expert discussions of gene and cell therapy (GCT) and its potential to change the future of medicine through its disease-treating and potentially curative properties. The agenda features 150+ executive speakers from the healthcare industry, venture, startups, life sciences manufacturing, consumer health and the front lines of care, including many Harvard Medical School-affiliated researchers and clinicians. The annual in-person Forum will resume live in Boston in 2022. The World Medical Innovation Forum is presented by Mass General Brigham Innovation, the global business development unit supporting the research requirements of 7,200 Harvard Medical School faculty and research hospitals including Massachusetts General, Brigham and Women’s, Massachusetts Eye and Ear, Spaulding Rehab and McLean Hospital. Follow us on Twitter: twitter.com/@MGBInnovation

    Accelerating the Future of Medicine with Gene and Cell Therapy What Comes Next

    https://worldmedicalinnovation.org/agenda/

    Virtual | May 19–21, 2021

    #WMIF2021

    @MGBInnovation

    Leaders in Pharmaceutical Business Intelligence (LPBI) Group

    will cover the event in Real Time

    Aviva Lev-Ari, PhD, RN

    Founder LPBI 1.0 & LPBI 2.0

    member_60221522 copy

    will be in virtual attendance producing the e-Proceedings

    and the Tweet Collection of this Global event expecting +15,000 attendees

    @pharma_BI

    @AVIVA1950

    LPBI’s Eighteen Books in Medicine

    https://lnkd.in/ekWGNqA

    Among them, books on Gene and Cell Therapy include the following:

    Topics for May 19 – 21 include:

    Impact on Patient Care – Therapeutic and Potentially Curative GCT Developments

    GCT Delivery, Manufacturing – What’s Next

    GCT Platform Development

    Oncolytic Viruses – Cancer applications, start-ups

    Regenerative Medicine/Stem Cells

    Future of CAR-T

    M&A Shaping GCT’s Future

    Market Priorities

    Venture Investing in GCT

    China’s GCT Juggernaut

    Disease and Patient Focus: Benign blood disorders, diabetes, neurodegenerative diseases

    Click here for the current WMIF agenda  

    Plus:

    Fireside Chats: 1:1 interviews with industry CEOs/C-Suite leaders including Novartis Gene Therapies, ThermoFisher, Bayer AG, FDA

    First Look: 18 briefings on emerging GCT research from Mass General Brigham scientists

    Virtual Poster Session: 40 research posters and presenters on potential GCT discoveries from Mass General Brigham

    Announcement of the Disruptive Dozen, 12 GCT technologies likely to break through in the next few years

    AGENDA

    Wednesday, May 19, 2021

    8:00 AM – 8:10 AM

    Opening Remarks

    Welcome and the vision for Gene and Cell Therapy and why it is a top Mass General Brigham priority. Introducer: Scott Sperling

    • Co-President, Thomas H. Lee Partners
    • Chairman of the Board of Directors, PHS

    Presenter: Anne Klibanski, MD

    • CEO, Mass General Brigham

    3,000 people joined 5/19 morning

    30 sessions: Lab to Clinic,  academia, industry, investment community

    May 22,23,24, 2022 – in Boston, in-person 2022 WMIF on CGT 8:10 AM – 8:30 AM

    The Grand Challenge of Widespread GCT Patient Benefits

    Co-Chairs identify the key themes of the Forum –  set the stage for top GCT opportunities, challenges, and where the field might take medicine in the future. Moderator: Susan Hockfield, PhD

    • President Emerita and Professor of Neuroscience, MIT

    GCT – poised to deliver therapies

    Inflection point as Panel will present

    Doctors and Patients – Promise for some patients 

    Barriers for Cell & Gene

    Access for patients to therapies like CGT Speakers: Nino Chiocca, MD, PhD

    • Neurosurgeon-in-Chief and Chairman, Neurosurgery, BWH
    • Harvey W. Cushing Professor of Neurosurgery, HMS

    Oncolytic virus triple threat: Toxic, immunological, combine with anti cancer therapies

    Polygenic therapy – multiple genes involved, plug-play, Susan Slaugenhaupt, PhD

    • Scientific Director and Elizabeth G. Riley and Daniel E. Smith Jr., Endowed Chair, Mass General Research Institute
    • Professor, Neurology, HMS

    Ravi Thadhani, MD

    • CAO, Mass General Brigham
    • Professor, Medicine and Faculty Dean, HMS

    Role of academia special to spear head the Polygenic therapy – multiple genes involved, plug-play, 

    Access critical, relations with IndustryLuk Vandenberghe, PhD

    • Grousbeck Family Chair, Gene Therapy, MEE
    • Associate Professor, Ophthalmology, HMS

    Pharmacology Gene-Drug, Interface academic centers and industry

    many CGT drugs emerged in Academic center 8:35 AM – 8:50 AM FIRESIDE

    Gene and Cell Therapy 2.0 – What’s Next as We Realize their Potential for Patients

    Dave Lennon, PhD

    • President, Novartis Gene Therapies

    Hope that CGT emerging, how the therapies work, neuro, muscular, ocular, genetic diseases of liver and of heart revolution for the industry 900 IND application 25 approvals Economic driver Skilled works, VC disease. Modality one time intervention, long duration of impart, reimbursement, ecosystem to be built around CGT

    FDA works by indications and risks involved, Standards and expectations for streamlining manufacturing, understanding of process and products 

    payments over time payers and Innovators relations Moderator: Julian Harris, MD

    • Partner, Deerfield

    Promise of CGT realized, what part?

    FDA role and interaction in CGT

    Manufacturing aspects which is critical Speaker: Dave Lennon, PhD

    • President, Novartis Gene Therapies

    Hope that CGT emerging, how the therapies work, neuro, muscular, ocular, genetic diseases of liver and of heart revolution for the industry 900 IND application 25 approvals Economic driver Skilled works, VC disease. Modality one time intervention, long duration of impart, reimbursement, ecosystem to be built around CGT

    FDA works by indications and risks involved, Standards and expectations for streamlining manufacturing, understanding of process and products 

    payments over time payers and Innovators relations

    • Q&A 8:55 AM – 9:10 AM  

    8:55 AM – 9:20 AM

    The Patient and GCT

    GCT development for rare diseases is driven by patient and patient-advocate communities. Understanding their needs and perspectives enables biomarker research, the development of value-driving clinical trial endpoints and successful clinical trials. Industry works with patient communities that help identify unmet needs and collaborate with researchers to conduct disease natural history studies that inform the development of biomarkers and trial endpoints. This panel includes patients who have received cutting-edge GCT therapy as well as caregivers and patient advocates. Moderator: Patricia Musolino, MD, PhD

    • Co-Director Pediatric Stroke and Cerebrovascular Program, MGH
    • Assistant Professor of Neurology, HMS

    What is the Power of One – the impact that a patient can have on their own destiny by participating in Clinical Trials Contacting other participants in same trial can be beneficial Speakers: Jack Hogan

    • Patient, MEE

    Jeanette Hogan

    • Parent of Patient, MEE

    Jim Holland

    • CEO, Backcountry.com

    Parkinson patient Constraints by regulatory on participation in clinical trial advance stage is approved participation Patients to determine the level of risk they wish to take Information dissemination is critical Barbara Lavery

    • Chief Program Officer, ACGT Foundation

    Advocacy agency beginning of work Global Genes educational content and out reach to access the information 

    Patient has the knowledge of the symptoms and recording all input needed for diagnosis by multiple clinicians Early application for CGTDan Tesler

    • Clinical Trial Patient, BWH/DFCC

    Experimental Drug clinical trial patient participation in clinical trial is very important to advance the state of scienceSarah Beth Thomas, RN

    • Professional Development Manager, BWH

    Outcome is unknown, hope for good, support with resources all advocacy groups, 

    • Q&A 9:25 AM – 9:40 AM  

    9:25 AM – 9:45 AM FIRESIDE

    GCT Regulatory Framework | Why Different?

      Moderator: Vicki Sato, PhD

    • Chairman of the Board, Vir Biotechnology

    Diversity of approaches

    Process at FDA generalize from 1st entry to rules more generalizable  Speaker: Peter Marks, MD, PhD

    • Director, Center for Biologics Evaluation and Research, FDA

    Last Spring it became clear that something will work a vaccine by June 2020 belief that enough candidates the challenge manufacture enough and scaling up FDA did not predicted the efficacy of mRNA vaccine vs other approaches expected to work

    Recover Work load for the pandemic will wean & clear, Gene Therapies IND application remained flat in the face of the pandemic Rare diseases urgency remains Consensus with industry advisory to get input gene therapy Guidance  T-Cell therapy vs Regulation best thinking CGT evolve speedily flexible gained by Guidance

    Immune modulators, Immunotherapy Genome editing can make use of viral vectors future technologies nanoparticles and liposome encapsulation 

    • Q&A 9:50 AM – 10:05 AM  

    9:50 AM – 10:15 AM

    Building a GCT Platform for Mainstream Success

    This panel of GCT executives, innovators and investors explore how to best shape a successful GCT strategy. Among the questions to be addressed:

    • How are GCT approaches set around defining and building a platform?
    • Is AAV the leading modality and what are the remaining challenges?
    • What are the alternatives?
    • Is it just a matter of matching modalities to the right indications?

    Moderator: Jean-François Formela, MD

    • Partner, Atlas Venture

    Established core components of the Platform Speakers: Katherine High, MD

    • President, Therapeutics, AskBio

    Three drugs approved in Europe in the Gene therapy space

    Regulatory Infrastructure exists for CGT drug approval – as new class of therapeutics

    Participants investigators, regulators, patients i. e., MDM 

    Hemophilia in male most challenging

    Human are natural hosts for AV safety signals Dave Lennon, PhD

    • President, Novartis Gene Therapies

    big pharma has portfolios of therapeutics not one drug across Tx areas: cell, gene iodine therapy 

    collective learning infrastructure features manufacturing at scale early in development Acquisitions strategy for growth # applications for scaling Rick Modi

    • CEO, Affinia Therapeutics

    Copy, paste EDIT from product A to B novel vectors leverage knowledge varient of vector, coder optimization choice of indication is critical exploration on larger populations Speed to R&D and Speed to better gene construct get to clinic with better design vs ASAP 

    Data sharing clinical experience with vectors strategies patients selection, vector selection, mitigation, patient type specific Louise Rodino-Klapac, PhD

    • EVP, Chief Scientific Officer, Sarepta Therapeutics

    AAV based platform 15 years in development same disease indication vs more than one indication stereotype, analytics as hurdle 1st was 10 years 2nd was 3 years

    Safety to clinic vs speed to clinic, difference of vectors to trust

    • Q&A 10:20 AM – 10:35 AM  

    10:20 AM – 10:45 AM

    AAV Success Studies | Retinal Dystrophy | Spinal Muscular Atrophy

    Recent AAV gene therapy product approvals have catalyzed the field. This new class of therapies has shown the potential to bring transformative benefit to patients. With dozens of AAV treatments in clinical studies, all eyes are on the field to gauge its disruptive impact.

    The panel assesses the largest challenges of the first two products, the lessons learned for the broader CGT field, and the extent to which they serve as a precedent to broaden the AAV modality.

    • Is AAV gene therapy restricted to genetically defined disorders, or will it be able to address common diseases in the near term?
    • Lessons learned from these first-in-class approvals.
    • Challenges to broaden this modality to similar indications.
    • Reflections on safety signals in the clinical studies?

    Moderator: Joan Miller, MD

    • Chief, Ophthalmology, MEE
    • Cogan Professor & Chair of Ophthalmology, HMS

    Retina specialist, Luxturna success FMA condition cell therapy as solution

    Lessons learned

    Safety Speakers: Ken Mills

    • CEO, RegenXBio

    Tissue types additional administrations, tech and science, address additional diseases, more science for photoreceptors a different tissue type underlying pathology novelties in last 10 years 

    Cell therapy vs transplant therapy no immunosuppressionEric Pierce, MD, PhD

    • Director, Ocular Genomics Institute, MEE
    • Professor of Ophthalmology, HMS

    Laxterna success to be replicated platform, paradigms measurement visual improved

    More science is needed to continue develop vectors reduce toxicity,

    AAV can deliver different cargos reduce adverse events improve vectorsRon Philip

    • Chief Operating Officer, Spark Therapeutics

    The first retinal gene therapy, voretigene neparvovec-rzyl (Luxturna, Spark Therapeutics), was approved by the FDA in 2017.Meredith Schultz, MD

    • Executive Medical Director, Lead TME, Novartis Gene Therapies

    Impact of cell therapy beyond muscular dystrophy, translational medicine, each indication, each disease, each group of patients build platform unlock the promise

    Monitoring for Safety signals real world evidence remote markers, home visits, clinical trial made safer, better communication of information

    • Q&A 10:50 AM – 11:05 AM  

    10:45 AM – 10:55 AM

    Break

      10:55 AM – 11:05 AM FIRST LOOK

    Control of AAV pharmacology by Rational Capsid Design

    Luk Vandenberghe, PhD

    • Grousbeck Family Chair, Gene Therapy, MEE
    • Associate Professor, Ophthalmology, HMS

    AAV a complex driver in Pharmacology durable, vector of choice, administer in vitro, gene editing tissue specificity, pharmacokinetics side effects and adverse events manufacturability site variation diversify portfolios,

    Pathway for rational AAV rational design, curated smart variant libraries, AAV  sequence screen multiparametric , data enable liver (de-) targeting unlock therapeutics areas: cochlea 

    • Q&A 11:05 AM – 11:25 AM  

    11:05 AM – 11:15 AM FIRST LOOK

    Enhanced gene delivery and immunoevasion of AAV vectors without capsid modification

    Casey Maguire, PhD

    • Associate Professor of Neurology, MGH & HMS

    Virus Biology: Enveloped (e) or not 

    enveloped for gene therapy eAAV platform technology: tissue targets and Indications commercialization of eAAV 

    • Q&A 11:15 AM – 11:35 AM  

    11:20 AM – 11:45 AM HOT TOPICS

    AAV Delivery

    This panel will address the advances in the area of AAV gene therapy delivery looking out the next five years. Questions that loom large are: How can biodistribution of AAV be improved? What solutions are in the wings to address immunogenicity of AAV? Will patients be able to receive systemic redosing of AAV-based gene therapies in the future? What technical advances are there for payload size? Will the cost of manufacturing ever become affordable for ultra-rare conditions? Will non-viral delivery completely supplant viral delivery within the next five years?What are the safety concerns and how will they be addressed? Moderators: Xandra Breakefield, PhD

    • Geneticist, MGH, MGH
    • Professor, Neurology, HMS

    Florian Eichler, MD

    • Director, Center for Rare Neurological Diseases, MGH
    • Associate Professor, Neurology, HMS

    Speakers: Jennifer Farmer

    • CEO, Friedreich’s Ataxia Research Alliance

    Ataxia requires therapy targeting multiple organ with one therapy, brain, spinal cord, heart several IND, clinical trials in 2022Mathew Pletcher, PhD

    • SVP, Head of Gene Therapy Research and Technical Operations, Astellas

    Work with diseases poorly understood, collaborations needs example of existing: DMD is a great example explain dystrophin share placedo data 

    Continue to explore large animal guinea pig not the mice, not primates (ethical issues) for understanding immunogenicity and immune response Manny Simons, PhD

    • CEO, Akouos

    AAV Therapy for the fluid of the inner ear, CGT for the ear vector accessible to surgeons translational work on the inner ear for gene therapy right animal model 

    Biology across species nerve ending in the cochlea

    engineer out of the caspid, lowest dose possible, get desired effect by vector use, 2022 new milestones

    • Q&A 11:50 AM – 12:05 PM  

    11:50 AM – 12:15 PM

    M&A | Shaping GCT Innovation

    The GCT M&A market is booming – many large pharmas have made at least one significant acquisition. How should we view the current GCT M&A market? What is its impact of the current M&A market on technology development? Are these M&A trends new are just another cycle? Has pharma strategy shifted and, if so, what does it mean for GCT companies? What does it mean for patients? What are the long-term prospects – can valuations hold up? Moderator: Adam Koppel, MD, PhD

    • Managing Director, Bain Capital Life Sciences

    What acquirers are looking for??

    What is the next generation vs what is real where is the industry going? Speakers:

    Debby Baron,

    • Worldwide Business Development, Pfizer 

    CGT is an important area Pfizer is active looking for innovators, advancing forward programs of innovation with the experience Pfizer has internally 

    Scalability and manufacturing  regulatory conversations, clinical programs safety in parallel to planning getting drug to patients

    Kenneth Custer, PhD

    • Vice President, Business Development and Lilly New Ventures, Eli Lilly and Company

    Marianne De Backer, PhD

    Head of Strategy, Business Development & Licensing, and Member of the Executive Committee, Bayer

    Absolute Leadership in Gene editing, gene therapy, via acquisition and strategic alliance 

    Operating model of the acquired company discussed , company continue independence

    Sean Nolan

    • Board Chairman, Encoded Therapeutics & Affinia

    Executive Chairman, Jaguar Gene Therapy & Istari Oncology

    As acquiree multiple M&A: How the acquirer looks at integration and cultures of the two companies 

    Traditional integration vs jump start by external acquisition 

    AAV – epilepsy, next generation of vectors 

    • Q&A 12:20 PM – 12:35 PM  

    12:15 PM – 12:25 PM FIRST LOOK

    Gene Therapies for Neurological Disorders: Insights from Motor Neuron Disorders

    Merit Cudkowicz, MD

    • Chief of Neurology, MGH

    ALS – Man 1in 300, Women 1 in 400, next decade increase 7% 

    10% ALS is heredity 160 pharma in ALS space, diagnosis is late 1/3 of people are not diagnosed, active community for clinical trials Challenges: disease heterogeneity cases of 10 years late in diagnosis. Clinical Trials for ALS in Gene Therapy targeting ASO1 protein therapies FUS gene struck youngsters 

    Q&A

    • 12:25 PM – 12:45 PM  

    12:25 PM – 12:35 PM FIRST LOOK

    Gene Therapy for Neurologic Diseases

    Patricia Musolino, MD, PhD

    • Co-Director Pediatric Stroke and Cerebrovascular Program, MGH
    • Assistant Professor of Neurology, HMS

    Cerebral Vascular disease – ACTA2 179H gene smooth muscle cell proliferation disorder

    no surgery or drug exist –

    Cell therapy for ACTA2 Vasculopathy  in the brain and control the BP and stroke – smooth muscle intima proliferation. Viral vector deliver aiming to change platform to non-viral delivery rare disease , gene editing, other mutations of ACTA2 gene target other pathway for atherosclerosis 

    • Q&A 12:35 PM – 12:55 PM  

    12:35 PM – 1:15 PM

    Lunch

      1:15 PM – 1:40 PM

    Oncolytic Viruses in Cancer | Curing Melanoma and Beyond

    Oncolytic viruses represent a powerful new technology, but so far an FDA-approved oncolytic (Imlygic) has only occurred in one area – melanoma and that what is in 2015. This panel involves some of the protagonists of this early success story.  They will explore why and how Imlygic became approved and its path to commercialization.  Yet, no other cancer indications exist for Imlygic, unlike the expansion of FDA-approved indication for immune checkpoint inhibitors to multiple cancers.  Why? Is there a limitation to what and which cancers can target?  Is the mode of administration a problem?

    No other oncolytic virus therapy has been approved since 2015. Where will the next success story come from and why?  Will these therapies only be beneficial for skin cancers or other easily accessible cancers based on intratumoral delivery?

    The panel will examine whether the preclinical models that have been developed for other cancer treatment modalities will be useful for oncolytic viruses.  It will also assess the extent pre-clinical development challenges have slowed the development of OVs. Moderator: Nino Chiocca, MD, PhD

    • Neurosurgeon-in-Chief and Chairman, Neurosurgery, BWH
    • Harvey W. Cushing Professor of Neurosurgery, HMS

    Challenges of manufacturing at Amgen what are they? Speakers: Robert Coffin, PhD

    • Chief Research & Development Officer, Replimune

    2002 in UK promise in oncolytic therapy GNCSF

    Phase III melanoma 2015 M&A with Amgen

    oncolytic therapy remains non effecting on immune response 

    data is key for commercialization 

    do not belief in systemic therapy achieve maximum immune response possible from a tumor by localized injection Roger Perlmutter, MD, PhD

    • Chairman, Merck & Co.

    response rates systemic therapy like PD1, Keytruda, OPTIVA well tolerated combination of Oncolytic with systemic 

    GMP critical for manufacturing David Reese, MD

    • Executive Vice President, Research and Development, Amgen

    Inter lesion injection of agent vs systemic therapeutics 

    cold tumors immune resistant render them immune susceptible 

    Oncolytic virus is a Mono therapy

    addressing the unknown Ann Silk, MD

    • Physician, Dana Farber-Brigham and Women’s Cancer Center
    • Assistant Professor of Medicine, HMS

    Which person gets oncolytics virus if patient has immune suppression due to other indications

    Safety of oncolytic virus greater than Systemic treatment

    series biopsies for injected and non injected tissue and compare Suspect of hot tumor and cold tumors likely to have sme response to agent unknown all potential 

    • Q&A 1:45 PM – 2:00 PM  

    1:45 PM – 2:10 PM

    Market Interest in Oncolytic Viruses | Calibrating

    There are currently two oncolytic virus products on the market, one in the USA and one in China.  As of late 2020, there were 86 clinical trials 60 of which were in phase I with just 2 in Phase III the rest in Phase I/II or Phase II.   Although global sales of OVs are still in the ramp-up phase, some projections forecast OVs will be a $700 million market by 2026. This panel will address some of the major questions in this area:

    What regulatory challenges will keep OVs from realizing their potential? Despite the promise of OVs for treating cancer only one has been approved in the US. Why has this been the case? Reasons such have viral tropism, viral species selection and delivery challenges have all been cited. However, these are also true of other modalities. Why then have oncolytic virus approaches not advanced faster and what are the primary challenges to be overcome?

    • Will these need to be combined with other agents to realize their full efficacy and how will that impact the market?
    • Why are these companies pursuing OVs while several others are taking a pass?

    Moderators: Martine Lamfers, PhD

    • Visiting Scientist, BWH

    Challenged in development of strategies 

    Demonstrate efficacyRobert Martuza, MD

    • Consultant in Neurosurgery, MGH
    • William and Elizabeth Sweet Distinguished Professor of Neurosurgery, HMS

    Modulation mechanism Speakers: Anlong Li, MD, PhD

    • Clinical Director, Oncology Clinical Development, Merck Research Laboratories

    IV delivery preferred – delivery alternative are less aggereable Jeffrey Infante, MD

    • Early development Oncolytic viruses, Oncology, Janssen Research & Development

    oncologic virus if it will generate systemic effects the adoption will accelerate

    What areas are the best efficacious 

    Direct effect with intra-tumor single injection with right payload 

    Platform approach  Prime with 1 and Boost with 2 – not yet experimented with 

    Do not have the data at trial design for stratification of patients 

    Turn off strategy not existing yetLoic Vincent, PhD

    • Head of Oncology Drug Discovery Unit, Takeda

    R&D in collaboration with Academic

    Vaccine platform to explore different payload

    IV administration may not bring sufficient concentration to the tumor is administer  in the blood stream

    Classification of Patients by prospective response type id UNKNOWN yet, population of patients require stratification

    • Q&A 2:15 PM – 2:30 PM  

    2:10 PM – 2:20 PM FIRST LOOK

    Oncolytic viruses: turning pathogens into anticancer agents

    Nino Chiocca, MD, PhD

    • Neurosurgeon-in-Chief and Chairman, Neurosurgery, BWH
    • Harvey W. Cushing Professor of Neurosurgery, HMS

    Oncolytic therapy DID NOT WORK Pancreatic Cancer and Glioblastoma 

    Intra- tumoral heterogeniety hinders success 

    Solution: Oncolytic VIRUSES – Immunological “coldness”

    GADD-34 20,000 GBM 40,000 pancreatic cancer

    • Q&A 2:25 PM – 2:40 PM  

    2:20 PM – 2:45 PM

    Entrepreneurial Growth | Oncolytic Virus

    In 2020 there were a total of 60 phase I trials for Oncolytic Viruses. There are now dozens of companies pursuing some aspect of OV technology. This panel will address:

    •  How are small companies equipped to address the challenges of developing OV therapies better than large pharma or biotech?
    • Will the success of COVID vaccines based on Adenovirus help the regulatory environment for small companies developing OV products in Europe and the USA?
    • Is there a place for non-viral delivery and other immunotherapy companies to engage in the OV space?  Would they bring any real advantages?

    Moderator: Reid Huber, PhD

    • Partner, Third Rock Ventures

    Critical milestones to observe Speakers: Caroline Breitbach, PhD

    • VP, R&D Programs and Strategy, Turnstone Biologics

    Trying Intra-tumor delivery and IV infusion delivery oncolytic vaccine pushing dose 

    translation biomarkers program 

    transformation tumor microenvironment Brett Ewald, PhD

    • SVP, Development & Corporate Strategy, DNAtrix

    Studies gets larger, kicking off Phase III multiple tumors Paul Hallenbeck, PhD

    • President and Chief Scientific Officer, Seneca Therapeutics

    Translation: Stephen Russell, MD, PhD

    • CEO, Vyriad

    Systemic delivery Oncolytic Virus IV delivery woman in remission

    Collaboration with Regeneron

    Data collection: Imageable reporter secretable reporter, gene expression

    Field is intense systemic oncolytic delivery is exciting in mice and in human, response rates are encouraging combination immune stimulant, check inhibitors 

    • Q&A 2:50 PM – 3:05 PM  

    2:45 PM – 3:00 PM

    Break

      3:00 PM – 3:25 PM

    CAR-T | Lessons Learned | What’s Next

    Few areas of potential cancer therapy have had the attention and excitement of CAR-T. This panel of leading executives, developers, and clinician-scientists will explore the current state of CAR-T and its future prospects. Among the questions to be addressed are:

    • Is CAR-T still an industry priority – i.e. are new investments being made by large companies? Are new companies being financed? What are the trends?
    • What have we learned from first-generation products, what can we expect from CAR-T going forward in novel targets, combinations, armored CAR’s and allogeneic treatment adoption?
    • Early trials showed remarkable overall survival and progression-free survival. What has been observed regarding how enduring these responses are?
    • Most of the approvals to date have targeted CD19, and most recently BCMA. What are the most common forms of relapses that have been observed?
    • Is there a consensus about what comes after these CD19 and BCMA trials as to additional targets in liquid tumors? How have dual-targeted approaches fared?
    • Moderator:
    • Marcela Maus, MD, PhD
      • Director, Cellular Immunotherapy Program, Cancer Center, MGH
      • Associate Professor, Medicine, HMSIs CAR-T Industry priority
    • Speakers:
    • Head of R&D, Atara BioTherapeutics
    • Phyno-type of the cells for hematologic cancers 
    • solid tumor 
    • inventory of Therapeutics for treating patients in the future 
    • Progressive MS program
    • EBBT platform B-Cells and T-Cells
      • Stefan Hendriks
        • Gobal Head, Cell & Gene, Novartis
        • yes, CGT is a strategy in the present and future
        • Journey started years ago 
        • Confirmation the effectiveness of CAR-T therapies, 1 year response prolonged to 5 years 26 months
        • Patient not responding – a lot to learn
        • Patient after 8 months of chemo can be helped by CAR-T
      • Christi Shaw
        • CEO, Kite
        • CAR-T is priority 120 companies in the space
        • Manufacturing consistency 
        • Patients respond with better quality of life
        • Blood cancer – more work to be done

    Q&A

    • 3:30 PM – 3:45 PM  

    3:30 PM – 3:55 PM HOT TOPICS

    CAR-T | Solid Tumors Success | When?

    The potential application of CAR-T in solid tumors will be a game-changer if it occurs. The panel explores the prospects of solid tumor success and what the barriers have been. Questions include:

    •  How would industry and investor strategy for CAR-T and solid tumors be characterized? Has it changed in the last couple of years?
    •  Does the lack of tumor antigen specificity in solid tumors mean that lessons from liquid tumor CAR-T constructs will not translate well and we have to start over?
    •  Whether due to antigen heterogeneity, a hostile tumor micro-environment, or other factors are some specific solid tumors more attractive opportunities than others for CAR-T therapy development?
    •  Given the many challenges that CAR-T faces in solid tumors, does the use of combination therapies from the start, for example, to mitigate TME effects, offer a more compelling opportunity.

    Moderator: Oladapo Yeku, MD, PhD

    • Clinical Assistant in Medicine, MGH

    window of opportunities studies  Speakers: Jennifer Brogdon

    • Executive Director, Head of Cell Therapy Research, Exploratory Immuno-Oncology, NIBR

    2017 CAR-T first approval

    M&A and research collaborations

    TCR tumor specific antigens avoid tissue toxicity Knut Niss, PhD

    • CTO, Mustang Bio

    tumor hot start in 12 month clinical trial solid tumors , theraties not ready yet. Combination therapy will be an experimental treatment long journey checkpoint inhibitors to be used in combination maintenance Lipid tumor Barbra Sasu, PhD

    • CSO, Allogene

    T cell response at prostate cancer 

    tumor specific 

    cytokine tumor specific signals move from solid to metastatic cell type for easier infiltration

    Where we might go: safety autologous and allogeneic Jay Short, PhD

    • Chairman, CEO, Cofounder, BioAlta, Inc.

    Tumor type is not enough for development of therapeutics other organs are involved in the periphery

    difficult to penetrate solid tumors biologics activated in the tumor only, positive changes surrounding all charges, water molecules inside the tissue acidic environment target the cells inside the tumor and not outside 

    Combination staggered key is try combination

    • Q&A 4:00 PM – 4:15 PM  

    4:00 PM – 4:25 PM

    GCT Manufacturing | Vector Production | Autologous and Allogeneic | Stem Cells | Supply Chain | Scalability & Management

    The modes of GCT manufacturing have the potential of fundamentally reordering long-established roles and pathways. While complexity goes up the distance from discovery to deployment shrinks. With the likelihood of a total market for cell therapies to be over $48 billion by 2027,  groups of products are emerging.  Stem cell therapies are projected to be $28 billion by 2027 and non-stem cell therapies such as CAR-T are projected be $20 billion by 2027. The manufacturing challenges for these two large buckets are very different. Within the CAR-T realm there are diverging trends of autologous and allogeneic therapies and the demands on manufacturing infrastructure are very different. Questions for the panelists are:

    • Help us all understand the different manufacturing challenges for cell therapies. What are the trade-offs among storage cost, batch size, line changes in terms of production cost and what is the current state of scaling naïve and stem cell therapy treatment vs engineered cell therapies?
    • For cell and gene therapy what is the cost of Quality Assurance/Quality Control vs. production and how do you think this will trend over time based on your perspective on learning curves today?
    • Will point of care production become a reality? How will that change product development strategy for pharma and venture investors? What would be the regulatory implications for such products?
    • How close are allogeneic CAR-T cell therapies? If successful what are the market implications of allogenic CAR-T? What are the cost implications and rewards for developing allogeneic cell therapy treatments?

    Moderator: Michael Paglia

    • VP, ElevateBio

    Speakers:

    • Dannielle Appelhans
      • SVP TechOps and Chief Technical Officer, Novartis Gene Therapies
    • Thomas Page, PhD
      • VP, Engineering and Asset Development, FUJIFILM Diosynth Biotechnologies
    • Rahul Singhvi, ScD
      • CEO and Co-Founder, National Resilience, Inc.
    • Thomas VanCott, PhD
      • Global Head of Product Development, Gene & Cell Therapy, Catalent
      • 2/3 autologous 1/3 allogeneic  CAR-T high doses and high populations scale up is not done today quality maintain required the timing logistics issues centralized vs decentralized  allogeneic are health donors innovations in cell types in use improvements in manufacturing

    Ropa Pike, Director,  Enterprise Science & Partnerships, Thermo Fisher Scientific 

    Centralized biopharma industry is moving  to decentralized models site specific license 

    • Q&A 4:30 PM – 4:45 PM  

    4:30 PM – 4:40 PM FIRST LOOK

    CAR-T

    Marcela Maus, MD, PhD

    • Director, Cellular Immunotherapy Program, Cancer Center, MGH
    • Assistant Professor, Medicine, HMS 

    Fit-to-purpose CAR-T cells: 3 lead programs

    Tr-fill 

    CAR-T induce response myeloma and multiple myeloma GBM

    27 patents on CAR-T

    +400 patients treaded 40 Clinical Trials 

    • Q&A 4:40 PM – 5:00 PM  

    4:40 PM – 4:50 PM FIRST LOOK

    Repurposed Tumor Cells as Killers and Immunomodulators for Cancer Therapy

    Khalid Shah, PhD

    • Vice Chair, Neurosurgery Research, BWH
    • Director, Center for Stem Cell Therapeutics and Imaging, HMS

    Solid tumors are the hardest to treat because: immunosuppressive, hypoxic, Acidic Use of autologous tumor cells self homing ThTC self targeting therapeutic cells Therapeutic tumor cells efficacy pre-clinical models GBM 95% metastesis ThTC translation to patient settings

    • Q&A 4:50 PM – 5:10 PM  

    4:50 PM – 5:00 PM FIRST LOOK

    Other Cell Therapies for Cancer

    David Scadden, MD

    • Director, Center for Regenerative Medicine; Co-Director, Harvard Stem Cell Institute, Director, Hematologic Malignancies & Experimental Hematology, MGH
    • Jordan Professor of Medicine, HMS

    T-cell are made in bone marrow create cryogel  can be an off-the-shelf product repertoire on T Receptor CCL19+ mesenchymal cells mimic Tymus cells –

    inter-tymic injection. Non human primate validation

    Q&A

     

    5:00 PM – 5:20 PM   5:00 PM – 5:20 PM FIRESIDE

    Fireside with Mikael Dolsten, MD, PhD

      Introducer: Jonathan Kraft Moderator: Daniel Haber, MD, PhD

    • Chair, Cancer Center, MGH
    • Isselbacher Professor of Oncology, HMS

    Vaccine Status Mikael Dolsten, MD, PhD

    • Chief Scientific Officer and President, Worldwide Research, Development and Medical, Pfizer

    Deliver vaccine around the Globe, Israel, US, Europe.

    3BIL vaccine in 2022 for all Global vaccination 

    Bio Ntech in Germany

    Experience with Biologics immuneoncology & allogeneic antibody cells – new field for drug discovery 

    mRNA curative effort and cancer vaccine 

    Access to drugs developed by Pfizer to underdeveloped countries 

    • Q&A 5:25 PM – 5:40 AM  

    5:20 PM – 5:30 PM

    Closing Remarks

    Thursday, May 20, 2021

    8:00 AM – 8:25 AM

    GCT | The China Juggernaut

    China embraced gene and cell therapies early. The first China gene therapy clinical trial was in 1991. China approved the world’s first gene therapy product in 2003—Gendicine—an oncolytic adenovirus for the treatment of advanced head and neck cancer.  Driven by broad national strategy, China has become a hotbed of GCT development, ranking second in the world with more than 1,000 clinical trials either conducted or underway and thousands of related patents.  It has a booming GCT biotech sector, led by more than 45 local companies with growing IND pipelines.

    In late 1990, a T cell-based immunotherapy, cytokine-induced killer (CIK) therapy became a popular modality in the clinic in China for tumor treatment.  In early 2010, Chinese researchers started to carry out domestic CAR T trials inspired by several important reports suggested the great antitumor function of CAR T cells. Now, China became the country with the most registered CAR T trials, CAR T therapy is flourishing in China.

    The Chinese GCT ecosystem has increasingly rich local innovation and growing complement of development and investment partnerships – and also many subtleties.

    This panel, consisting of leaders from the China GCT corporate, investor, research and entrepreneurial communities, will consider strategic questions on the growth of the gene and cell therapy industry in China, areas of greatest strength, evolving regulatory framework, early successes and products expected to reach the US and world market. Moderator: Min Wu, PhD

    • Managing Director, Fosun Health Fund

    What are the area of CGT in China, regulatory similar to the US Speakers: Alvin Luk, PhD

    • CEO, Neuropath Therapeutics

    Monogenic rare disease with clear genomic target

    Increase of 30% in patient enrollment 

    Regulatory reform approval is 60 days no delayPin Wang, PhD

    • CSO, Jiangsu Simcere Pharmaceutical Co., Ltd.

    Similar starting point in CGT as the rest of the World unlike a later starting point in other biologicalRichard Wang, PhD

    • CEO, Fosun Kite Biotechnology Co., Ltd

    Possibilities to be creative and capitalize the new technologies for innovating drug

    Support of the ecosystem by funding new companie allowing the industry to be developed in China

    Autologous in patients differences cost challengeTian Xu, PhD

    • Vice President, Westlake University

    ICH committee and Chinese FDA -r regulation similar to the US

    Difference is the population recruitment, in China patients are active participants in skin disease 

    Active in development of transposome 

    Development of non-viral methods, CRISPR still in D and transposome

    In China price of drugs regulatory are sensitive Shunfei Yan, PhD

    • Investment Manager, InnoStar Capital

    Indication driven: Hymophilia, 

    Allogogenic efficiency therapies

    Licensing opportunities 

    • Q&A 8:30 AM – 8:45 AM  

    8:30 AM – 8:55 AM

    Impact of mRNA Vaccines | Global Success Lessons

    The COVID vaccine race has propelled mRNA to the forefront of biomedicine. Long considered as a compelling modality for therapeutic gene transfer, the technology may have found its most impactful application as a vaccine platform. Given the transformative industrialization, the massive human experience, and the fast development that has taken place in this industry, where is the horizon? Does the success of the vaccine application, benefit or limit its use as a therapeutic for CGT?

    • How will the COVID success impact the rest of the industry both in therapeutic and prophylactic vaccines and broader mRNA lessons?
    • How will the COVID success impact the rest of the industry both on therapeutic and prophylactic vaccines and broader mRNA lessons?
    • Beyond from speed of development, what aspects make mRNA so well suited as a vaccine platform?
    • Will cost-of-goods be reduced as the industry matures?
    • How does mRNA technology seek to compete with AAV and other gene therapy approaches?

    Moderator: Lindsey Baden, MD

    • Director, Clinical Research, Division of Infectious Diseases, BWH
    • Associate Professor, HMS

    In vivo delivery process regulatory cooperation new opportunities for same platform for new indication Speakers:

    Many years of mRNA pivoting for new diseases, DARPA, nucleic Acids global deployment of a manufacturing unit on site where the need arise Elan Musk funds new directions at Moderna

    How many mRNA can be put in one vaccine: Dose and tolerance to achieve efficacy 

    45 days for Personalized cancer vaccine one per patient

    1.6 Billion doses produced rare disease monogenic correct mRNA like CF multiple mutation infection disease and oncology applications

    Platform allowing to swap cargo reusing same nanoparticles address disease beyond Big Pharma options for biotech

    WHat strain of Flu vaccine will come back in the future when people do not use masks 

    • Kate Bingham, UK Vaccine Taskforce

    July 2020, AAV vs mRNA delivery across UK local centers administered both types supply and delivery uplift 

    • Q&A 9:00 AM – 9:15 AM  

    9:00 AM – 9:25 AM HOT TOPICS

    Benign Blood Disorders

    Hemophilia has been and remains a hallmark indication for the CGT. Given its well-defined biology, larger market, and limited need for gene transfer to provide therapeutic benefit, it has been at the forefront of clinical development for years, however, product approval remains elusive. What are the main hurdles to this success? Contrary to many indications that CGT pursues no therapeutic options are available to patients, hemophiliacs have an increasing number of highly efficacious treatment options. How does the competitive landscape impact this field differently than other CGT fields? With many different players pursuing a gene therapy option for hemophilia, what are the main differentiators? Gene therapy for hemophilia seems compelling for low and middle-income countries, given the cost of currently available treatments; does your company see opportunities in this market? Moderator: Nancy Berliner, MD

    • Chief, Division of Hematology, BWH
    • H. Franklin Bunn Professor of Medicine, HMS

    Speakers: Theresa Heggie

    • CEO, Freeline Therapeutics

    Safety concerns, high burden of treatment CGT has record of safety and risk/benefit adoption of Tx functional cure CGT is potent Tx relative small quantity of protein needs be delivered 

    Potency and quality less quantity drug and greater potency

    risk of delivery unwanted DNA, capsules are critical 

    analytics is critical regulator involvement in potency definition

    Close of collaboration is excitingGallia Levy, MD, PhD

    • Chief Medical Officer, Spark Therapeutics

    Hemophilia CGT is the highest potential for Global access logistics in underdeveloped countries working with NGOs practicality of the Tx

    Roche reached 120 Counties great to be part of the Roche GroupAmir Nashat, PhD

    • Managing Partner, Polaris Ventures

    Suneet Varma

    • Global President of Rare Disease, Pfizer

    Gene therapy at Pfizer small molecule, large molecule and CGT – spectrum of choice allowing Hemophilia patients to marry 

    1/3 internal 1/3 partnership 1/3 acquisitions 

    Learning from COVID-19 is applied for other vaccine development

    review of protocols and CGT for Hemophelia

    You can’t buy Time

    With MIT Pfizer is developing a model for Hemopilia CGT treatment

    • Q&A 9:30 AM – 9:45 AM  

    9:25 AM – 9:35 AM FIRST LOOK

    Treating Rett Syndrome through X-reactivation

    Jeannie Lee, MD, PhD

    • Molecular Biologist, MGH
    • Professor of Genetics, HMS

    200 disease X chromosome unlock for neurological genetic diseases: Rett Syndromeand other autism spectrum disorders female model vs male mice model

    deliver protein to the brain 

    restore own missing or dysfunctional protein

    Epigenetic not CGT – no exogent intervention Xist ASO drug

    Female model

    • Q&A 9:35 AM – 9:55 AM  

    9:35 AM – 9:45 AM FIRST LOOK

    Rare but mighty: scaling up success in single gene disorders

    Florian Eichler, MD

    • Director, Center for Rare Neurological Diseases, MGH
    • Associate Professor, Neurology, HMS

    Single gene disorder NGS enable diagnosis, DIagnosis to Treatment How to know whar cell to target, make it available and scale up Address gap: missing components Biomarkers to cell types lipid chemistry cell animal biology 

    crosswalk from bone marrow matter 

    New gene discovered that causes neurodevelopment of stagnant genes Examining new Biology cell type specific biomarkers 

    • Q&A 9:45 AM – 10:05 AM  

    9:50 AM – 10:15 AM HOT TOPICS

    Diabetes | Grand Challenge

    The American Diabetes Association estimates 30 million Americans have diabetes and 1.5 million are diagnosed annually. GCT offers the prospect of long-sought treatment for this enormous cohort and their chronic requirements. The complexity of the disease and its management constitute a grand challenge and highlight both the potential of GCT and its current limitations.

    •  Islet transplantation for type 1 diabetes has been attempted for decades. Problems like loss of transplanted islet cells due to autoimmunity and graft site factors have been difficult to address. Is there anything different on the horizon for gene and cell therapies to help this be successful?
    • How is the durability of response for gene or cell therapies for diabetes being addressed? For example, what would the profile of an acceptable (vs. optimal) cell therapy look like?

    Moderator: Marie McDonnell, MD

    • Chief, Diabetes Section and Director, Diabetes Program, BWH
    • Lecturer on Medicine, HMS

    Type 1 Diabetes cost of insulin for continuous delivery of drug

    alternative treatments: 

    The Future: neuropotent stem cells 

    What keeps you up at night  Speakers: Tom Bollenbach, PhD

    • Chief Technology Officer, Advanced Regenerative Manufacturing Institute

    Data managment sterility sensors, cell survival after implantation, stem cells manufacturing, process development in manufacturing of complex cells

    Data and instrumentation the Process is the Product

    Manufacturing tight schedules Manasi Jaiman, MD

    • Vice President, Clinical Development, ViaCyte
    • Pediatric Endocrinologist

    continous glucose monitoring Bastiano Sanna, PhD

    • EVP, Chief of Cell & Gene Therapies and VCGT Site Head, Vertex Pharmaceuticals

    100 years from discovering Insulin, Insulin is not a cure in 2021 – asking patients to partner more 

    Produce large quantities of the Islet cells encapsulation technology been developed 

    Scaling up is a challengeRogerio Vivaldi, MD

    • CEO, Sigilon Therapeutics

    Advanced made, Patient of Type 1 Outer and Inner compartments of spheres (not capsule) no immune suppression continuous secretion of enzyme Insulin independence without immune suppression 

    Volume to have of-the-shelf inventory oxegenation in location lymphatic and vascularization conrol the whole process modular platform learning from others

    • Q&A 10:20 AM – 10:35 AM  

    10:20 AM – 10:40 AM FIRESIDE

    Building A Unified GCT Strategy

      Introducer: John Fish

    • CEO, Suffolk
    • Chairman of Board Trustees, Brigham Health

    Moderator: Meg Tirrell

    • Senior Health and Science Reporter, CNBC

    Last year, what was it at Novartis Speaker: Jay Bradner, MD

    • President, NIBR

    Keep eyes open, waiting the Pandemic to end and enable working back on all the indications 

    Portfolio of MET, Mimi Emerging Therapies 

    Learning from the Pandemic – operationalize the practice science, R&D leaders, new collaboratives at NIH, FDA, Novartis

    Pursue programs that will yield growth, tropic diseases with Gates Foundation, Rising Tide pods for access CGT within Novartis Partnership with UPenn in Cell Therapy 

    Cost to access to IP from Academia to a Biotech CRISPR accessing few translations to Clinic

    Protein degradation organization constraint valuation by parties in a partnership 

    Novartis: nuclear protein lipid nuclear particles, tamplate for Biotech to collaborate

    Game changing: 10% of the Portfolio, New frontiers human genetics in Ophthalmology, CAR-T, CRISPR, Gene Therapy Neurological and payloads of different matter

    • Q&A 10:45 AM – 11:00 AM  

    10:40 AM – 10:50 AM

    Break

      10:50 AM – 11:00 AM FIRST LOOK

    Getting to the Heart of the Matter: Curing Genetic Cardiomyopathy

    Christine Seidman, MD

    • Director, Cardiovascular Genetics Center, BWH
    • Smith Professor of Medicine & Genetics, HMS

    The Voice of Dr. Seidman – Her abstract is cited below

    The ultimate opportunity presented by discovering the genetic basis of human disease is accurate prediction and disease prevention. To enable this achievement, genetic insights must enable the identification of at-risk

    individuals prior to end-stage disease manifestations and strategies that delay or prevent clinical expression. Genetic cardiomyopathies provide a paradigm for fulfilling these opportunities. Hypertrophic cardiomyopathy (HCM) is characterized by left ventricular hypertrophy, diastolic dysfunction with normal or enhanced systolic performance and a unique histopathology: myocyte hypertrophy, disarray and fibrosis. Dilated cardiomyopathy (DCM) exhibits enlarged ventricular volumes with depressed systolic performance and nonspecific histopathology. Both HCM and DCM are prevalent clinical conditions that increase risk for arrhythmias, sudden death, and heart failure. Today treatments for HCM and DCM focus on symptoms, but none prevent disease progression. Human molecular genetic studies demonstrated that these pathologies often result from dominant mutations in genes that encode protein components of the sarcomere, the contractile unit in striated muscles. These data combined with the emergence of molecular strategies to specifically modulate gene expression provide unparalleled opportunities to silence or correct mutant genes and to boost healthy gene expression in patients with genetic HCM and DCM. Many challenges remain, but the active and vital efforts of physicians, researchers, and patients are poised to ensure success.

    Hypertrophic and Dilated Cardiomyopaies ‘

    10% receive heart transplant 12 years survival 

    Mutation puterb function

    TTN: contribute 20% of dilated cardiomyopaty

    Silence gene 

    pleuripotential cells deliver therapies 

    • Q&A 11:00 AM – 11:20 AM  

    11:00 AM – 11:10 AM FIRST LOOK

    Unlocking the secret lives of proteins in health and disease

    Anna Greka, MD, PhD

    • Medicine, BWH
    • Associate Professor, Medicine, HMS

    Cyprus Island, kidney disease by mutation causing MUC1 accumulation and death BRD4780 molecule that will clear the misfolding proteins from the kidney organoids: pleuripotent stem cells small molecule developed for applications in the other cell types in brain, eye, gene mutation build mechnism for therapy clinical models transition from Academia to biotech 

    Q&A

    • 11:10 AM – 11:30 AM  

    11:10 AM – 11:35 AM

    Rare and Ultra Rare Diseases | GCT Breaks Through

    One of the most innovative segments in all of healthcare is the development of GCT driven therapies for rare and ultra-rare diseases. Driven by a series of insights and tools and funded in part by disease focused foundations, philanthropists and abundant venture funding disease after disease is yielding to new GCT technology. These often become platforms to address more prevalent diseases. The goal of making these breakthroughs routine and affordable is challenged by a range of issues including clinical trial design and pricing.

    • What is driving the interest in rare diseases?
    • What are the biggest barriers to making breakthroughs ‘routine and affordable?’
    • What is the role of retrospective and prospective natural history studies in rare disease?  When does the expected value of retrospective disease history studies justify the cost?
    • Related to the first question, what is the FDA expecting as far as controls in clinical trials for rare diseases?  How does this impact the collection of natural history data?

    Moderator: Susan Slaugenhaupt, PhD

    • Scientific Director and Elizabeth G. Riley and Daniel E. Smith Jr., Endowed Chair, Mass General Research Institute
    • Professor, Neurology, HMS

    Speakers: Leah Bloom, PhD

    • SVP, External Innovation and Strategic Alliances, Novartis Gene Therapies

    Ultra rare (less than 100) vs rare difficulty to recruit patients and to follow up after treatment Bobby Gaspar, MD, PhD

    • CEO, Orchard Therapeutics

    Study of rare condition have transfer to other larger diseases – delivery of therapeutics genes, like immune disorders 

    Patient testimonials just to hear what a treatment can make Emil Kakkis, MD, PhD

    • CEO, Ultragenyx

    Do 100 patient study then have information on natural history to develop a clinical trial Stuart Peltz, PhD

    • CEO, PTC Therapeutics

    Rare disease, challenge for FDA approval and after market commercialization follow ups

    Justification of cost for Rare disease – demonstration of Change is IP in value patients advocacy is helpful

    • Q&A 11:40 AM – 11:55 AM  

    11:40 AM – 12:00 PM FIRESIDE

    Partnering Across the GCT Spectrum

      Moderator: Erin Harris

    • Chief Editor, Cell & Gene

    Perspective & professional tenure

    Partnership in manufacturing what are the recommendations?

    Hospital systems: Partnership Challenges  Speaker: Marc Casper

    • CEO, ThermoFisher

    25 years in Diagnostics last 20 years at ThermoFisher 

    products used in the Lab for CAR-T research and manufacture 

    CGT Innovations: FDA will have a high level of approval each year

    How move from research to clinical trials to manufacturing Quicker process

    Best practices in Partnerships: the root cause if acceleration to market service providers to deliver highest standards

    Building capacity by acquisition to avoid the waiting time

    Accelerate new products been manufactured 

    Collaborations with Academic Medical center i.e., UCSF in CGT joint funding to accelerate CGT to clinics’

    Customers are extremely knowledgable, scale the capital investment made investment

    150MIL a year to improve the Workflow 

    • Q&A 12:05 PM – 12:20 PM  

    12:05 PM – 12:30 PM

    • 12:05 PM – 12:20 PM  

    12:05 PM – 12:30 PM

    CEO Panel | Anticipating Disruption | Planning for Widespread GCT

    The power of GCT to cure disease has the prospect of profoundly improving the lives of patients who respond. Planning for a disruption of this magnitude is complex and challenging as it will change care across the spectrum. Leading chief executives shares perspectives on how the industry will change and how this change should be anticipated. Moderator: Meg Tirrell

    • Senior Health and Science Reporter, CNBC

    CGT becoming staple therapy what are the disruptors emerging Speakers: Lisa Dechamps

    • SVP & Chief Business Officer, Novartis Gene Therapies

    Reimagine medicine with collaboration at MGH, MDM condition in children 

    The Science is there, sustainable processes and systems impact is transformational

    Value based pricing, risk sharing Payers and Pharma for one time therapy with life span effect

    Collaboration with FDAKieran Murphy

    • CEO, GE Healthcare

    Diagnosis of disease to be used in CGT

    2021 investment in CAR-T platform 

    Investment in several CGT frontier

    Investment in AI, ML in system design new technologies 

    GE: Scale and Global distributions, sponsor companies in software 

    Waste in Industry – Healthcare % of GDP, work with MGH to smooth the workflow faster entry into hospital and out of Hospital

    Telemedicine during is Pandemic: Radiologist needs to read remotely 

    Supply chain disruptions slow down all ecosystem 

    Production of ventilators by collaboration with GM – ingenuity 

    Scan patients outside of hospital a scanner in a Box Christian Rommel, PhD

    • Head, Pharmaceuticals Research & Development, Bayer AG

    CGT – 2016 and in 2020 new leadership and capability 

    Disease Biology and therapeutics

    Regenerative Medicine: CGT vs repair building pipeline in ophthalmology and cardiovascular 

    During Pandemic: Deliver Medicines like Moderna, Pfizer – collaborations between competitors with Government Bayer entered into Vaccines in 5 days, all processes had to change access innovations developed over decades for medical solutions 

    • Q&A 12:35 PM – 12:50 PM  

    12:35 PM – 12:55 PM FIRESIDE

    Building a GCT Portfolio

    GCT represents a large and growing market for novel therapeutics that has several segments. These include Cardiovascular Disease, Cancer, Neurological Diseases, Infectious Disease, Ophthalmology, Benign Blood Disorders, and many others; Manufacturing and Supply Chain including CDMO’s and CMO’s; Stem Cells and Regenerative Medicine; Tools and Platforms (viral vectors, nano delivery, gene editing, etc.). Bayer’s pharma business participates in virtually all of these segments. How does a Company like Bayer approach the development of a portfolio in a space as large and as diverse as this one? How does Bayer approach the support of the production infrastructure with unique demands and significant differences from its historical requirements? Moderator:

    Shinichiro Fuse, PhD

    • Managing Partner, MPM Capital

    Speaker: Wolfram Carius, PhD

    • EVP, Pharmaceuticals, Head of Cell & Gene Therapy, Bayer AG

    CGT will bring treatment to cure, delivery of therapies 

    Be a Leader repair, regenerate, cure

    Technology and Science for CGT – building a portfolio vs single asset decision criteria development of IP market access patients access acceleration of new products

    Bayer strategy: build platform for use by four domains  

    Gener augmentation

    Autologeneic therapy, analytics

    Gene editing

    Oncology Cell therapy tumor treatment: What kind of cells – the jury is out

    Of 23 product launch at Bayer no prediction is possible some high some lows 

    • Q&A 1:00 PM – 1:15 PM  

    12:55 PM – 1:35 PM

    Lunch

      1:40 PM – 2:05 PM

    GCT Delivery | Perfecting the Technology

    Gene delivery uses physical, chemical, or viral means to introduce genetic material into cells. As more genetically modified therapies move closer to the market, challenges involving safety, efficacy, and manufacturing have emerged. Optimizing lipidic and polymer nanoparticles and exosomal delivery is a short-term priority. This panel will examine how the short-term and long-term challenges are being tackled particularly for non-viral delivery modalities. Moderator: Natalie Artzi, PhD

    • Assistant Professor, BWH

    Speakers: Geoff McDonough, MD

    • CEO, Generation Bio

    Sonya Montgomery

    • CMO, Evox Therapeutics

    Laura Sepp-Lorenzino, PhD

    • Chief Scientific Officer, Executive Vice President, Intellia Therapeutics

    Doug Williams, PhD

    • CEO, Codiak BioSciences
    • Q&A 2:10 PM – 2:25 PM  

    2:05 PM – 2:10 PM

    Invention Discovery Grant Announcement

      2:10 PM – 2:20 PM FIRST LOOK

    Enhancing vesicles for therapeutic delivery of bioproducts

    Xandra Breakefield, PhD

    • Geneticist, MGH, MGH
    • Professor, Neurology, HMS
    • Q&A 2:20 PM – 2:35 PM  

    2:20 PM – 2:30 PM FIRST LOOK

    Versatile polymer-based nanocarriers for targeted therapy and immunomodulation

    Natalie Artzi, PhD

    • Assistant Professor, BWH
    • Q&A 2:30 PM – 2:45 PM  

    2:55 PM – 3:20 PM HOT TOPICS

    Gene Editing | Achieving Therapeutic Mainstream

    Gene editing was recognized by the Nobel Committee as “one of gene technology’s sharpest tools, having a revolutionary impact on life sciences.” Introduced in 2011, gene editing is used to modify DNA. It has applications across almost all categories of disease and is also being used in agriculture and public health.

    Today’s panel is made up of pioneers who represent foundational aspects of gene editing.  They will discuss the movement of the technology into the therapeutic mainstream.

    • Successes in gene editing – lessons learned from late-stage assets (sickle cell, ophthalmology)
    • When to use what editing tool – pros and cons of traditional gene-editing v. base editing.  Is prime editing the future? Specific use cases for epigenetic editing.
    • When we reach widespread clinical use – role of off-target editing – is the risk real?  How will we mitigate? How practical is patient-specific off-target evaluation?

    Moderator: J. Keith Joung, MD, PhD

    • Robert B. Colvin, M.D. Endowed Chair in Pathology & Pathologist, MGH
    • Professor of Pathology, HMS

    Speakers: John Evans

    • CEO, Beam Therapeutics

    Lisa Michaels

    • EVP & CMO, Editas Medicine
    • Q&A 3:25 PM – 3:50 PM  

    3:25 PM – 3:50 PM HOT TOPICS

    Common Blood Disorders | Gene Therapy

    There are several dozen companies working to develop gene or cell therapies for Sickle Cell Disease, Beta Thalassemia, and  Fanconi Anemia. In some cases, there are enzyme replacement therapies that are deemed effective and safe. In other cases, the disease is only managed at best. This panel will address a number of questions that are particular to this class of genetic diseases:

    • What are the pros and cons of various strategies for treatment? There are AAV-based editing, non-viral delivery even oligonucleotide recruitment of endogenous editing/repair mechanisms. Which approaches are most appropriate for which disease?
    • How can companies increase the speed of recruitment for clinical trials when other treatments are available? What is the best approach to educate patients on a novel therapeutic?
    • How do we best address ethnic and socio-economic diversity to be more representative of the target patient population?
    • How long do we have to follow up with the patients from the scientific, patient’s community, and payer points of view? What are the current FDA and EMA guidelines for long-term follow-up?
    • Where are we with regards to surrogate endpoints and their application to clinically meaningful endpoints?
    • What are the emerging ethical dilemmas in pediatric gene therapy research? Are there challenges with informed consent and pediatric assent for trial participation?
    • Are there differences in reimbursement policies for these different blood disorders? Clearly durability of response is a big factor. Are there other considerations?

    Moderator: David Scadden, MD

    • Director, Center for Regenerative Medicine; Co-Director, Harvard Stem Cell Institute, Director, Hematologic Malignancies & Experimental Hematology, MGH
    • Jordan Professor of Medicine, HMS

    Speakers: Samarth Kukarni, PhDNick Leschly

    • Chief Bluebird, Bluebird Bio

    Mike McCune, MD, PhD

    • Head, HIV Frontiers, Global Health Innovative Technology Solutions, Bill & Melinda Gates Foundation
    • Q&A 3:55 PM – 4:15 PM  

    3:50 PM – 4:00 PM FIRST LOOK

    Gene Editing

    J. Keith Joung, MD, PhD

    • Robert B. Colvin, M.D. Endowed Chair in Pathology & Pathologist, MGH
    • Professor of Pathology, HMS
    • Q&A 4:00 PM – 4:20 PM  

    4:20 PM – 4:45 PM HOT TOPICS

    Gene Expression | Modulating with Oligonucleotide-Based Therapies

    Oligonucleotide drugs have recently come into their own with approvals from companies such as Biogen, Alnylam, Novartis and others. This panel will address several questions:

    How important is the delivery challenge for oligonucleotides? Are technological advancements emerging that will improve the delivery of oligonucleotides to the CNS or skeletal muscle after systemic administration?

    • Will oligonucleotides improve as a class that will make them even more effective?   Are further advancements in backbone chemistry anticipated, for example.
    • Will oligonucleotide based therapies blaze trails for follow-on gene therapy products?
    • Are small molecules a threat to oligonucleotide-based therapies?
    • Beyond exon skipping and knock-down mechanisms, what other roles will oligonucleotide-based therapies take mechanistically — can genes be activating oligonucleotides?  Is there a place for multiple mechanism oligonucleotide medicines?
    • Are there any advantages of RNAi-based oligonucleotides over ASOs, and if so for what use?

    Moderator: Jeannie Lee, MD, PhD

    • Molecular Biologist, MGH
    • Professor of Genetics, HMS

    Speakers: Bob Brown, PhD

    • CSO, EVP of R&D, Dicerna

    Brett Monia, PhD

    • CEO, Ionis

    Alfred Sandrock, MD, PhD

    • EVP, R&D and CMO, Biogen
    • Q&A 4:50 PM – 5:05 PM  

    4:45 PM – 4:55 PM FIRST LOOK

    RNA therapy for brain cancer

    Pierpaolo Peruzzi, MD, PhD

    • Nuerosurgery, BWH
    • Assistant Professor of Neurosurgery, HMS
    • Q&A 4:55 PM – 5:15 PM  

    Friday, May 21, 2021

    8:30 AM – 8:55 AM

    Venture Investing | Shaping GCT Translation

    What is occurring in the GCT venture capital segment? Which elements are seeing the most activity? Which areas have cooled? How is the investment market segmented between gene therapy, cell therapy and gene editing? What makes a hot GCT company? How long will the market stay frothy? Some review of demographics — # of investments, sizes, etc. Why is the market hot and how long do we expect it to stay that way? Rank the top 5 geographic markets for GCT company creation and investing? Are there academic centers that have been especially adept at accelerating GCT outcomes? Do the business models for the rapid development of coronavirus vaccine have any lessons for how GCT technology can be brought to market more quickly? Moderator: Meredith Fisher, PhD

    • Partner, Mass General Brigham Innovation Fund

    Speakers: David Berry, MD, PhD

    • CEO, Valo Health
    • General Partner, Flagship Pioneering

    Robert Nelsen

    • Managing Director, Co-founder, ARCH Venture Partners

    Kush Parmar, MD, PhD

    • Managing Partner, 5AM Ventures
    • Q&A 9:00 AM – 9:15 AM  

    9:00 AM – 9:25 AM

    Regenerative Medicine | Stem Cells

    The promise of stem cells has been a highlight in the realm of regenerative medicine. Unfortunately, that promise remains largely in the future. Recent breakthroughs have accelerated these potential interventions in particular for treating neurological disease. Among the topics the panel will consider are:

    • Stem cell sourcing
    • Therapeutic indication growth
    • Genetic and other modification in cell production
    • Cell production to final product optimization and challenges
    • How to optimize the final product

    Moderator: Ole Isacson, MD, PhD

    • Director, Neuroregeneration Research Institute, McLean
    • Professor, Neurology and Neuroscience, HMS

    Speakers: Kapil Bharti, PhD

    • Senior Investigator, Ocular and Stem Cell Translational Research Section, NIH

    Joe Burns, PhD

    • VP, Head of Biology, Decibel Therapeutics

    Erin Kimbrel, PhD

    • Executive Director, Regenerative Medicine, Astellas

    Nabiha Saklayen, PhD

    • CEO and Co-Founder, Cellino
    • Q&A 9:30 AM – 9:45 AM  

    9:25 AM – 9:35 AM FIRST LOOK

    Stem Cells

    Bob Carter, MD, PhD

    • Chairman, Department of Neurosurgery, MGH
    • William and Elizabeth Sweet, Professor of Neurosurgery, HMS
    • Q&A 9:35 AM – 9:55 AM  

    9:35 AM – 10:00 AM

    Capital Formation ’21-30 | Investing Modes Driving GCT Technology and Timing

    The dynamics of venture/PE investing and IPOs are fast evolving. What are the drivers – will the number of investors grow will the size of early rounds continue to grow? How is this reflected in GCT target areas, company design, and biotech overall? Do patients benefit from these trends? Is crossover investing a distinct class or a little of both? Why did it emerge and what are the characteristics of the players?  Will SPACs play a role in the growth of the gene and cell therapy industry. What is the role of corporate investment arms eg NVS, Bayer, GV, etc. – has a category killer emerged?  Are we nearing the limit of what the GCT market can absorb or will investment capital continue to grow unabated? Moderator: Roger Kitterman

    • VP, Venture, Mass General Brigham

    Speakers: Ellen Hukkelhoven, PhD

    • Managing Director, Perceptive Advisors

    Peter Kolchinsky, PhD

    • Founder and Managing Partner, RA Capital Management

    Deep Nishar

    • Senior Managing Partner, SoftBank Investment Advisors

    Oleg Nodelman

    • Founder & Managing Partner, EcoR1 Capital
    • Q&A 10:05 AM – 10:20 AM  

    10:00 AM – 10:10 AM FIRST LOOK

    New scientific and clinical developments for autologous stem cell therapy for Parkinson’s disease patients

    Penelope Hallett, PhD

    • NRL, McLean
    • Assistant Professor Psychiatry, HMS
    • Q&A 10:10 AM – 10:30 AM  

    10:10 AM – 10:35 AM HOT TOPICS

    Neurodegenerative Clinical Outcomes | Achieving GCT Success

    Can stem cell-based platforms become successful treatments for neurodegenerative diseases?

    •  What are the commonalities driving GCT success in neurodegenerative disease and non-neurologic disease, what are the key differences?
    • Overcoming treatment administration challenges
    • GCT impact on degenerative stage of disease
    • How difficult will it be to titrate the size of the cell therapy effect in different neurological disorders and for different patients?
    • Demonstrating clinical value to patients and payers
    • Revised clinical trial models to address issues and concerns specific to GCT

    Moderator: Bob Carter, MD, PhD

    • Chairman, Department of Neurosurgery, MGH
    • William and Elizabeth Sweet, Professor of Neurosurgery, HMS

    Speakers: Erwan Bezard, PhD

    • INSERM Research Director, Institute of Neurodegenerative Diseases

    Nikola Kojic, PhD

    • CEO and Co-Founder, Oryon Cell Therapies

    Geoff MacKay

    • President & CEO, AVROBIO

    Viviane Tabar, MD

    • Founding Investigator, BlueRock Therapeutics
    • Chair of Neurosurgery, Memorial Sloan Kettering
    • Q&A 10:40 AM – 10:55 AM  

    10:35 AM – 11:35 AM

    Disruptive Dozen: 12 Technologies that Will Reinvent GCT

    Nearly one hundred senior Mass General Brigham Harvard faculty contributed to the creation of this group of twelve GCT technologies that they believe will breakthrough in the next two years. The Disruptive Dozen identifies and ranks the GCT technologies that will be available on at least an experimental basis to have the chance of significantly improving health care. 11:35 AM – 11:45 AM

    Concluding Remarks

    Friday, May 21, 2021

    Computer connection to the iCloud of WordPress.com FROZE completely at 10:30AM EST and no file update was possible. COVERAGE OF MAY 21, 2021 IS RECORDED BELOW FOLLOWING THE AGENDA BY COPY AN DPASTE OF ALL THE TWEETS I PRODUCED ON MAY 21, 2021 8:30 AM – 8:55 AM

    Venture Investing | Shaping GCT Translation

    What is occurring in the GCT venture capital segment? Which elements are seeing the most activity? Which areas have cooled? How is the investment market segmented between gene therapy, cell therapy and gene editing? What makes a hot GCT company? How long will the market stay frothy? Some review of demographics — # of investments, sizes, etc. Why is the market hot and how long do we expect it to stay that way? Rank the top 5 geographic markets for GCT company creation and investing? Are there academic centers that have been especially adept at accelerating GCT outcomes? Do the business models for the rapid development of coronavirus vaccine have any lessons for how GCT technology can be brought to market more quickly? Moderator: Meredith Fisher, PhD

    • Partner, Mass General Brigham Innovation Fund

    Speakers: David Berry, MD, PhD

    • CEO, Valo Health
    • General Partner, Flagship Pioneering

    Robert Nelsen

    • Managing Director, Co-founder, ARCH Venture Partners

    Kush Parmar, MD, PhD

    • Managing Partner, 5AM Ventures
    • Q&A 9:00 AM – 9:15 AM  

    9:00 AM – 9:25 AM

    Regenerative Medicine | Stem Cells

    The promise of stem cells has been a highlight in the realm of regenerative medicine. Unfortunately, that promise remains largely in the future. Recent breakthroughs have accelerated these potential interventions in particular for treating neurological disease. Among the topics the panel will consider are:

    • Stem cell sourcing
    • Therapeutic indication growth
    • Genetic and other modification in cell production
    • Cell production to final product optimization and challenges
    • How to optimize the final product

    Moderator: Ole Isacson, MD, PhD

    • Director, Neuroregeneration Research Institute, McLean
    • Professor, Neurology and Neuroscience, HMS

    Speakers: Kapil Bharti, PhD

    • Senior Investigator, Ocular and Stem Cell Translational Research Section, NIH

    Joe Burns, PhD

    • VP, Head of Biology, Decibel Therapeutics

    Erin Kimbrel, PhD

    • Executive Director, Regenerative Medicine, Astellas

    Nabiha Saklayen, PhD

    • CEO and Co-Founder, Cellino
    • Q&A 9:30 AM – 9:45 AM  

    9:25 AM – 9:35 AM FIRST LOOK

    Stem Cells

    Bob Carter, MD, PhD

    • Chairman, Department of Neurosurgery, MGH
    • William and Elizabeth Sweet, Professor of Neurosurgery, HMS
    • Q&A 9:35 AM – 9:55 AM  

    9:35 AM – 10:00 AM

    Capital Formation ’21-30 | Investing Modes Driving GCT Technology and Timing

    The dynamics of venture/PE investing and IPOs are fast evolving. What are the drivers – will the number of investors grow will the size of early rounds continue to grow? How is this reflected in GCT target areas, company design, and biotech overall? Do patients benefit from these trends? Is crossover investing a distinct class or a little of both? Why did it emerge and what are the characteristics of the players?  Will SPACs play a role in the growth of the gene and cell therapy industry. What is the role of corporate investment arms eg NVS, Bayer, GV, etc. – has a category killer emerged?  Are we nearing the limit of what the GCT market can absorb or will investment capital continue to grow unabated? Moderator: Roger Kitterman

    • VP, Venture, Mass General Brigham

    Speakers: Ellen Hukkelhoven, PhD

    • Managing Director, Perceptive Advisors

    Peter Kolchinsky, PhD

    • Founder and Managing Partner, RA Capital Management

    Deep Nishar

    • Senior Managing Partner, SoftBank Investment Advisors

    Oleg Nodelman

    • Founder & Managing Partner, EcoR1 Capital
    • Q&A 10:05 AM – 10:20 AM  

    10:00 AM – 10:10 AM FIRST LOOK

    New scientific and clinical developments for autologous stem cell therapy for Parkinson’s disease patients

    Penelope Hallett, PhD

    • NRL, McLean
    • Assistant Professor Psychiatry, HMS
    • Q&A 10:10 AM – 10:30 AM  

    10:10 AM – 10:35 AM HOT TOPICS

    Neurodegenerative Clinical Outcomes | Achieving GCT Success

    Can stem cell-based platforms become successful treatments for neurodegenerative diseases?

    •  What are the commonalities driving GCT success in neurodegenerative disease and non-neurologic disease, what are the key differences?
    • Overcoming treatment administration challenges
    • GCT impact on degenerative stage of disease
    • How difficult will it be to titrate the size of the cell therapy effect in different neurological disorders and for different patients?
    • Demonstrating clinical value to patients and payers
    • Revised clinical trial models to address issues and concerns specific to GCT

    Moderator: Bob Carter, MD, PhD

    • Chairman, Department of Neurosurgery, MGH
    • William and Elizabeth Sweet, Professor of Neurosurgery, HMS

    Speakers: Erwan Bezard, PhD

    • INSERM Research Director, Institute of Neurodegenerative Diseases

    Nikola Kojic, PhD

    • CEO and Co-Founder, Oryon Cell Therapies

    Geoff MacKay

    • President & CEO, AVROBIO

    Viviane Tabar, MD

    • Founding Investigator, BlueRock Therapeutics
    • Chair of Neurosurgery, Memorial Sloan Kettering
    • Q&A 10:40 AM – 10:55 AM  

    10:35 AM – 11:35 AM

    Disruptive Dozen: 12 Technologies that Will Reinvent GCT

    Nearly one hundred senior Mass General Brigham Harvard faculty contributed to the creation of this group of twelve GCT technologies that they believe will breakthrough in the next two years. The Disruptive Dozen identifies and ranks the GCT technologies that will be available on at least an experimental basis to have the chance of significantly improving health care. 11:35 AM – 11:45 AM

    Concluding Remarks

    The co-chairs convene to reflect on the insights shared over the three days. They will discuss what to expect at the in-person GCT focused May 2-4, 2022 World Medical Innovation Forum.

     

    The co-chairs convene to reflect on the insights shared over the three days. They will discuss what to expect at the in-person GCT focused May 2-4, 2022 World Medical Innovation Forum.Christine Seidman, MD

    Hypertrophic and Dilated Cardiomyopaies ‘

    10% receive heart transplant 12 years survival 

    Mutation puterb function

    TTN: contribute 20% of dilated cardiomyopaty

    Silence gene 

    pleuripotential cells deliver therapies 

    • Q&A 11:00 AM – 11:20 AM  

    11:00 AM – 11:10 AM FIRST LOOK

    Unlocking the secret lives of proteins in health and disease

    Anna Greka, MD, PhD

    • Medicine, BWH
    • Associate Professor, Medicine, HMS

    Cyprus Island, kidney disease by mutation causing MUC1 accumulation and death BRD4780 molecule that will clear the misfolding proteins from the kidney organoids: pleuripotent stem cells small molecule developed for applications in the other cell types in brain, eye, gene mutation build mechnism for therapy clinical models transition from Academia to biotech 

    Q&A

    • 11:10 AM – 11:30 AM  

    11:10 AM – 11:35 AM

    Rare and Ultra Rare Diseases | GCT Breaks Through

    One of the most innovative segments in all of healthcare is the development of GCT driven therapies for rare and ultra-rare diseases. Driven by a series of insights and tools and funded in part by disease focused foundations, philanthropists and abundant venture funding disease after disease is yielding to new GCT technology. These often become platforms to address more prevalent diseases. The goal of making these breakthroughs routine and affordable is challenged by a range of issues including clinical trial design and pricing.

    • What is driving the interest in rare diseases?
    • What are the biggest barriers to making breakthroughs ‘routine and affordable?’
    • What is the role of retrospective and prospective natural history studies in rare disease?  When does the expected value of retrospective disease history studies justify the cost?
    • Related to the first question, what is the FDA expecting as far as controls in clinical trials for rare diseases?  How does this impact the collection of natural history data?

    Moderator: Susan Slaugenhaupt, PhD

    • Scientific Director and Elizabeth G. Riley and Daniel E. Smith Jr., Endowed Chair, Mass General Research Institute
    • Professor, Neurology, HMS

    Speakers: Leah Bloom, PhD

    • SVP, External Innovation and Strategic Alliances, Novartis Gene Therapies

    Ultra rare (less than 100) vs rare difficulty to recruit patients and to follow up after treatment Bobby Gaspar, MD, PhD

    • CEO, Orchard Therapeutics

    Study of rare condition have transfer to other larger diseases – delivery of therapeutics genes, like immune disorders 

    Patient testimonials just to hear what a treatment can make Emil Kakkis, MD, PhD

    • CEO, Ultragenyx

    Do 100 patient study then have information on natural history to develop a clinical trial Stuart Peltz, PhD

    • CEO, PTC Therapeutics

    Rare disease, challenge for FDA approval and after market commercialization follow ups

    Justification of cost for Rare disease – demonstration of Change is IP in value patients advocacy is helpful

    • Q&A 11:40 AM – 11:55 AM  

    11:40 AM – 12:00 PM FIRESIDE

    Partnering Across the GCT Spectrum

      Moderator: Erin Harris

    • Chief Editor, Cell & Gene

    Perspective & professional tenure

    Partnership in manufacturing what are the recommendations?

    Hospital systems: Partnership Challenges  Speaker: Marc Casper

    • CEO, ThermoFisher

    25 years in Diagnostics last 20 years at ThermoFisher 

    products used in the Lab for CAR-T research and manufacture 

    CGT Innovations: FDA will have a high level of approval each year

    How move from research to clinical trials to manufacturing Quicker process

    Best practices in Partnerships: the root cause if acceleration to market service providers to deliver highest standards

    Building capacity by acquisition to avoid the waiting time

    Accelerate new products been manufactured 

    Collaborations with Academic Medical center i.e., UCSF in CGT joint funding to accelerate CGT to clinics’

    Customers are extremely knowledgable, scale the capital investment made investment

    150MIL a year to improve the Workflow 

    • Q&A 12:05 PM – 12:20 PM  

    12:05 PM – 12:30 PM

    CEO Panel | Anticipating Disruption | Planning for Widespread GCT

    The power of GCT to cure disease has the prospect of profoundly improving the lives of patients who respond. Planning for a disruption of this magnitude is complex and challenging as it will change care across the spectrum. Leading chief executives shares perspectives on how the industry will change and how this change should be anticipated. Moderator: Meg Tirrell

    • Senior Health and Science Reporter, CNBC

    CGT becoming staple therapy what are the disruptors emerging Speakers: Lisa Dechamps

    • SVP & Chief Business Officer, Novartis Gene Therapies

    Reimagine medicine with collaboration at MGH, MDM condition in children 

    The Science is there, sustainable processes and systems impact is transformational

    Value based pricing, risk sharing Payers and Pharma for one time therapy with life span effect

    Collaboration with FDAKieran Murphy

    • CEO, GE Healthcare

    Diagnosis of disease to be used in CGT

    2021 investment in CAR-T platform 

    Investment in several CGT frontier

    Investment in AI, ML in system design new technologies 

    GE: Scale and Global distributions, sponsor companies in software 

    Waste in Industry – Healthcare % of GDP, work with MGH to smooth the workflow faster entry into hospital and out of Hospital

    Telemedicine during is Pandemic: Radiologist needs to read remotely 

    Supply chain disruptions slow down all ecosystem 

    Production of ventilators by collaboration with GM – ingenuity 

    Scan patients outside of hospital a scanner in a Box Christian Rommel, PhD

    • Head, Pharmaceuticals Research & Development, Bayer AG

    CGT – 2016 and in 2020 new leadership and capability 

    Disease Biology and therapeutics

    Regenerative Medicine: CGT vs repair building pipeline in ophthalmology and cardiovascular 

    During Pandemic: Deliver Medicines like Moderna, Pfizer – collaborations between competitors with Government Bayer entered into Vaccines in 5 days, all processes had to change access innovations developed over decades for medical solutions 

    • Q&A 12:35 PM – 12:50 PM  

    12:35 PM – 12:55 PM FIRESIDE

    Building a GCT Portfolio

    GCT represents a large and growing market for novel therapeutics that has several segments. These include Cardiovascular Disease, Cancer, Neurological Diseases, Infectious Disease, Ophthalmology, Benign Blood Disorders, and many others; Manufacturing and Supply Chain including CDMO’s and CMO’s; Stem Cells and Regenerative Medicine; Tools and Platforms (viral vectors, nano delivery, gene editing, etc.). Bayer’s pharma business participates in virtually all of these segments. How does a Company like Bayer approach the development of a portfolio in a space as large and as diverse as this one? How does Bayer approach the support of the production infrastructure with unique demands and significant differences from its historical requirements? Moderator:

    Shinichiro Fuse, PhD

    • Managing Partner, MPM Capital

    Speaker: Wolfram Carius, PhD

    • EVP, Pharmaceuticals, Head of Cell & Gene Therapy, Bayer AG

    CGT will bring treatment to cure, delivery of therapies 

    Be a Leader repair, regenerate, cure

    Technology and Science for CGT – building a portfolio vs single asset decision criteria development of IP market access patients access acceleration of new products

    Bayer strategy: build platform for use by four domains  

    Gener augmentation

    Autologeneic therapy, analytics

    Gene editing

    Oncology Cell therapy tumor treatment: What kind of cells – the jury is out

    Of 23 product launch at Bayer no prediction is possible some high some lows 

    • Q&A 1:00 PM – 1:15 PM  

    12:55 PM – 1:35 PM

    Lunch

      1:40 PM – 2:05 PM

    GCT Delivery | Perfecting the Technology

    Gene delivery uses physical, chemical, or viral means to introduce genetic material into cells. As more genetically modified therapies move closer to the market, challenges involving safety, efficacy, and manufacturing have emerged. Optimizing lipidic and polymer nanoparticles and exosomal delivery is a short-term priority. This panel will examine how the short-term and long-term challenges are being tackled particularly for non-viral delivery modalities. Moderator: Natalie Artzi, PhD

    • Assistant Professor, BWH

    Speakers: Geoff McDonough, MD

    • CEO, Generation Bio

    Sonya Montgomery

    • CMO, Evox Therapeutics

    Laura Sepp-Lorenzino, PhD

    • Chief Scientific Officer, Executive Vice President, Intellia Therapeutics

    Doug Williams, PhD

    • CEO, Codiak BioSciences
    • Q&A 2:10 PM – 2:25 PM  

    2:05 PM – 2:10 PM

    Invention Discovery Grant Announcement

      2:10 PM – 2:20 PM FIRST LOOK

    Enhancing vesicles for therapeutic delivery of bioproducts

    Xandra Breakefield, PhD

    • Geneticist, MGH, MGH
    • Professor, Neurology, HMS
    • Q&A 2:20 PM – 2:35 PM  

    2:20 PM – 2:30 PM FIRST LOOK

    Versatile polymer-based nanocarriers for targeted therapy and immunomodulation

    Natalie Artzi, PhD

    • Assistant Professor, BWH
    • Q&A 2:30 PM – 2:45 PM  

    2:55 PM – 3:20 PM HOT TOPICS

    Gene Editing | Achieving Therapeutic Mainstream

    Gene editing was recognized by the Nobel Committee as “one of gene technology’s sharpest tools, having a revolutionary impact on life sciences.” Introduced in 2011, gene editing is used to modify DNA. It has applications across almost all categories of disease and is also being used in agriculture and public health.

    Today’s panel is made up of pioneers who represent foundational aspects of gene editing.  They will discuss the movement of the technology into the therapeutic mainstream.

    • Successes in gene editing – lessons learned from late-stage assets (sickle cell, ophthalmology)
    • When to use what editing tool – pros and cons of traditional gene-editing v. base editing.  Is prime editing the future? Specific use cases for epigenetic editing.
    • When we reach widespread clinical use – role of off-target editing – is the risk real?  How will we mitigate? How practical is patient-specific off-target evaluation?

    Moderator: J. Keith Joung, MD, PhD

    • Robert B. Colvin, M.D. Endowed Chair in Pathology & Pathologist, MGH
    • Professor of Pathology, HMS

    Speakers: John Evans

    • CEO, Beam Therapeutics

    Lisa Michaels

    • EVP & CMO, Editas Medicine
    • Q&A 3:25 PM – 3:50 PM  

    3:25 PM – 3:50 PM HOT TOPICS

    Common Blood Disorders | Gene Therapy

    There are several dozen companies working to develop gene or cell therapies for Sickle Cell Disease, Beta Thalassemia, and  Fanconi Anemia. In some cases, there are enzyme replacement therapies that are deemed effective and safe. In other cases, the disease is only managed at best. This panel will address a number of questions that are particular to this class of genetic diseases:

    • What are the pros and cons of various strategies for treatment? There are AAV-based editing, non-viral delivery even oligonucleotide recruitment of endogenous editing/repair mechanisms. Which approaches are most appropriate for which disease?
    • How can companies increase the speed of recruitment for clinical trials when other treatments are available? What is the best approach to educate patients on a novel therapeutic?
    • How do we best address ethnic and socio-economic diversity to be more representative of the target patient population?
    • How long do we have to follow up with the patients from the scientific, patient’s community, and payer points of view? What are the current FDA and EMA guidelines for long-term follow-up?
    • Where are we with regards to surrogate endpoints and their application to clinically meaningful endpoints?
    • What are the emerging ethical dilemmas in pediatric gene therapy research? Are there challenges with informed consent and pediatric assent for trial participation?
    • Are there differences in reimbursement policies for these different blood disorders? Clearly durability of response is a big factor. Are there other considerations?

    Moderator: David Scadden, MD

    • Director, Center for Regenerative Medicine; Co-Director, Harvard Stem Cell Institute, Director, Hematologic Malignancies & Experimental Hematology, MGH
    • Jordan Professor of Medicine, HMS

    Speakers: Samarth Kukarni, PhDNick Leschly

    • Chief Bluebird, Bluebird Bio

    Mike McCune, MD, PhD

    • Head, HIV Frontiers, Global Health Innovative Technology Solutions, Bill & Melinda Gates Foundation
    • Q&A 3:55 PM – 4:15 PM  

    3:50 PM – 4:00 PM FIRST LOOK

    Gene Editing

    J. Keith Joung, MD, PhD

    • Robert B. Colvin, M.D. Endowed Chair in Pathology & Pathologist, MGH
    • Professor of Pathology, HMS
    • Q&A 4:00 PM – 4:20 PM  

    4:20 PM – 4:45 PM HOT TOPICS

    Gene Expression | Modulating with Oligonucleotide-Based Therapies

    Oligonucleotide drugs have recently come into their own with approvals from companies such as Biogen, Alnylam, Novartis and others. This panel will address several questions:

    How important is the delivery challenge for oligonucleotides? Are technological advancements emerging that will improve the delivery of oligonucleotides to the CNS or skeletal muscle after systemic administration?

    • Will oligonucleotides improve as a class that will make them even more effective?   Are further advancements in backbone chemistry anticipated, for example.
    • Will oligonucleotide based therapies blaze trails for follow-on gene therapy products?
    • Are small molecules a threat to oligonucleotide-based therapies?
    • Beyond exon skipping and knock-down mechanisms, what other roles will oligonucleotide-based therapies take mechanistically — can genes be activating oligonucleotides?  Is there a place for multiple mechanism oligonucleotide medicines?
    • Are there any advantages of RNAi-based oligonucleotides over ASOs, and if so for what use?

    Moderator: Jeannie Lee, MD, PhD

    • Molecular Biologist, MGH
    • Professor of Genetics, HMS

    Speakers: Bob Brown, PhD

    • CSO, EVP of R&D, Dicerna

    Brett Monia, PhD

    • CEO, Ionis

    Alfred Sandrock, MD, PhD

    • EVP, R&D and CMO, Biogen
    • Q&A 4:50 PM – 5:05 PM  

    4:45 PM – 4:55 PM FIRST LOOK

    RNA therapy for brain cancer

    Pierpaolo Peruzzi, MD, PhD

    • Nuerosurgery, BWH
    • Assistant Professor of Neurosurgery, HMS
    • Q&A 4:55 PM – 5:15 PM  

    Friday, May 21, 2021

    Computer connection to the iCloud of WordPress.com FROZE completely at 10:30AM EST and no file update was possible. COVERAGE OF MAY 21, 2021 IS RECORDED BELOW FOLLOWING THE AGENDA BY COPY AN DPASTE OF ALL THE TWEETS I PRODUCED ON MAY 21, 2021

    8:30 AM – 8:55 AM

    Venture Investing | Shaping GCT Translation

    What is occurring in the GCT venture capital segment? Which elements are seeing the most activity? Which areas have cooled? How is the investment market segmented between gene therapy, cell therapy and gene editing? What makes a hot GCT company? How long will the market stay frothy? Some review of demographics — # of investments, sizes, etc. Why is the market hot and how long do we expect it to stay that way? Rank the top 5 geographic markets for GCT company creation and investing? Are there academic centers that have been especially adept at accelerating GCT outcomes? Do the business models for the rapid development of coronavirus vaccine have any lessons for how GCT technology can be brought to market more quickly? Moderator:   Meredith Fisher, PhD

    • Partner, Mass General Brigham Innovation Fund

    Strategies, success what changes are needed in the drug discovery process   Speakers:  

    Bring disruptive frontier as a platform with reliable delivery CGT double knock out disease cure all change efficiency and scope human centric vs mice centered right scale of data converted into therapeutics acceleratetion 

    Innovation in drugs 60% fails in trial because of Toxicology system of the future deal with big diseases

    Moderna is an example in unlocking what is inside us Microbiome and beyond discover new drugs epigenetics  

    • Robert Nelsen
      • Managing Director, Co-founder, ARCH Venture Partners

    Manufacturing change is not a new clinical trial FDA need to be presented with new rethinking for big innovations Drug pricing cheaper requires systematization How to systematically scaling up systematize the discovery and the production regulatory innovations

    Responsibility mismatch should be and what is “are”

    Long term diseases Stack holders and modalities risk benefir for populations 

    • Q&A 9:00 AM – 9:15 AM  

    9:00 AM – 9:25 AM

    Regenerative Medicine | Stem Cells

    The promise of stem cells has been a highlight in the realm of regenerative medicine. Unfortunately, that promise remains largely in the future. Recent breakthroughs have accelerated these potential interventions in particular for treating neurological disease. Among the topics the panel will consider are:

    • Stem cell sourcing
    • Therapeutic indication growth
    • Genetic and other modification in cell production
    • Cell production to final product optimization and challenges
    • How to optimize the final product
    • Moderator:
      • Ole Isacson, MD, PhD
        • Director, Neuroregeneration Research Institute, McLean
        • Professor, Neurology and Neuroscience, MGH, HMS

    Opportunities in the next generation of the tactical level Welcome the oprimism and energy level of all Translational medicine funding stem cells enormous opportunities 

    • Speakers:
    • Kapil Bharti, PhD
      • Senior Investigator, Ocular and Stem Cell Translational Research Section, NIH
      • first drug required to establish the process for that innovations design of animal studies not done before
      • Off-th-shelf one time treatment becoming cure 
      •  Intact tissue in a dish is fragile to maintain metabolism
      Joe Burns, PhD
      • VP, Head of Biology, Decibel Therapeutics
      • Ear inside the scall compartments and receptors responsible for hearing highly differentiated tall ask to identify cell for anticipated differentiation
      • multiple cell types and tissue to follow
      Erin Kimbrel, PhD
      • Executive Director, Regenerative Medicine, Astellas
      • In the ocular space immunogenecity
      • regulatory communication
      • use gene editing for immunogenecity Cas1 and Cas2 autologous cells
      • gene editing and programming big opportunities 
      Nabiha Saklayen, PhD
      • CEO and Co-Founder, Cellino
      • scale production of autologous cells foundry using semiconductor process in building cassettes
      • solution for autologous cells
    • Q&A 9:30 AM – 9:45 AM  

    9:25 AM – 9:35 AM FIRST LOOK

    Stem Cells

    Bob Carter, MD, PhD

    • Chairman, Department of Neurosurgery, MGH
    • William and Elizabeth Sweet, Professor of Neurosurgery, HMS
    • Cell therapy for Parkinson to replace dopamine producing cells lost ability to produce dopamin
    • skin cell to become autologous cells reprograms to become cells producing dopamine
    • transplantation fibroblast cells metabolic driven process lower mutation burden 
    • Quercetin inhibition elimination undifferentiated cells graft survival oxygenation increased 
    • Q&A 9:35 AM – 9:55 AM  

    9:35 AM – 10:00 AM

    Capital Formation ’21-30 | Investing Modes Driving GCT Technology and Timing

    The dynamics of venture/PE investing and IPOs are fast evolving. What are the drivers – will the number of investors grow will the size of early rounds continue to grow? How is this reflected in GCT target areas, company design, and biotech overall? Do patients benefit from these trends? Is crossover investing a distinct class or a little of both? Why did it emerge and what are the characteristics of the players?  Will SPACs play a role in the growth of the gene and cell therapy industry. What is the role of corporate investment arms eg NVS, Bayer, GV, etc. – has a category killer emerged?  Are we nearing the limit of what the GCT market can absorb or will investment capital continue to grow unabated? Moderator: Roger Kitterman

    • VP, Venture, Mass General Brigham
    • Saturation reached or more investment is coming in CGT 

    Speakers: Ellen Hukkelhoven, PhD

    • Managing Director, Perceptive Advisors
    • Cardiac area transduct cells
    • matching tools
    • 10% success of phase 1 in drug development next phase matters more 

    Peter Kolchinsky, PhD

    • Founder and Managing Partner, RA Capital Management
    • Future proof for new comers disruptors 
    • Ex Vivo gene therapy to improve funding products what tool kit belongs to 
    • company insulation from next instability vs comapny stabilizing themselves along few years
    • Company interested in SPAC 
    • cross over investment vs SPAC
    • Multi Omics in cancer early screening metastatic diseas will be wiped out 

    Deep Nishar

    • Senior Managing Partner, SoftBank Investment Advisors
    • Young field vs CGT started in the 80s 
    • high payloads is a challenge
    • cost effective fast delivery to large populations
    • Mission oriented by the team and management  
    • Multi Omics disease modality 

    Oleg Nodelman

    • Founder & Managing Partner, EcoR1 Capital
    • Invest in company next round of investment will be IPO
    • Help company raise money cross over investment vs SPAC
    • Innovating ideas from academia in need for funding 
    • Q&A 10:05 AM – 10:20 AM  

    10:00 AM – 10:10 AM FIRST LOOK

    New scientific and clinical developments for autologous stem cell therapy for Parkinson’s disease patients

    Penelope Hallett, PhD

    • NRL, McLean
    • Assistant Professor Psychiatry, HMS
    • Pharmacologic agent in existing cause another disorders locomo-movement related 
    • efficacy Autologous cell therapy transplantation approach program T cells into dopamine generating neurons greater than Allogeneic cell transplantation 
    • Q&A 10:10 AM – 10:30 AM  

    10:10 AM – 10:35 AM HOT TOPICS

    Neurodegenerative Clinical Outcomes | Achieving GCT Success

    Can stem cell-based platforms become successful treatments for neurodegenerative diseases?

    •  What are the commonalities driving GCT success in neurodegenerative disease and non-neurologic disease, what are the key differences?
    • Overcoming treatment administration challenges
    • GCT impact on degenerative stage of disease
    • How difficult will it be to titrate the size of the cell therapy effect in different neurological disorders and for different patients?
    • Demonstrating clinical value to patients and payers
    • Revised clinical trial models to address issues and concerns specific to GCT

    Moderator: Bob Carter, MD, PhD

    • Chairman, Department of Neurosurgery, MGH
    • William and Elizabeth Sweet, Professor of Neurosurgery, HMS
    • Neurogeneration REVERSAL or slowing down 

    Speakers: Erwan Bezard, PhD

    • INSERM Research Director, Institute of Neurodegenerative Diseases
    • Cautious on reversal 
    • Early intervantion versus late

    Nikola Kojic, PhD

    • CEO and Co-Founder, Oryon Cell Therapies
    • Autologus cell therapy placed focal replacing missing synapses reestablishment of neural circuitary

    Geoff MacKay

    • President & CEO, AVROBIO
    • Prevent condition to be manifested in the first place 
    • clinical effect durable single infusion preventions of symptoms to manifest 
    • Cerebral edema – stabilization
    • Gene therapy know which is the abnormal gene grafting the corrected one 
    • More than biomarker as end point functional benefit not yet established  

    Viviane Tabar, MD

    • Founding Investigator, BlueRock Therapeutics
    • Chair of Neurosurgery, Memorial Sloan Kettering
    • Current market does not have delivery mechanism that a drug-delivery is the solution Trials would fail on DELIVERY
    • Immune suppressed patients during one year to avoid graft rejection Autologous approach of Parkinson patient genetically mutated reprogramed as dopamine generating neuron – unknowns are present
    • Circuitry restoration
    • Microenvironment disease ameliorate symptoms – education of patients on the treatment 
    • Q&A 10:40 AM – 10:55 AM  

    10:35 AM – 11:35 AM

    Disruptive Dozen: 12 Technologies that Will Reinvent GCT

    Nearly one hundred senior Mass General Brigham Harvard faculty contributed to the creation of this group of twelve GCT technologies that they believe will breakthrough in the next two years. The Disruptive Dozen identifies and ranks the GCT technologies that will be available on at least an experimental basis to have the chance of significantly improving health care. 11:35 AM – 11:45 AM

    Concluding Remarks

    The co-chairs convene to reflect on the insights shared over the three days. They will discuss what to expect at the in-person GCT focused May 2-4, 2022 World Medical Innovation Forum.

    ALL THE TWEETS PRODUCED ON MAY 21, 2021 INCLUDE THE FOLLOWING:

    Aviva Lev-Ari

    @AVIVA1950

    • @AVIVA1950_PIcs

    4h

    #WMIF2021

    @MGBInnovation

    Erwan Bezard, PhD INSERM Research Director, Institute of Neurodegenerative Diseases Cautious on reversal

    @pharma_BI

    @AVIVA1950

    Aviva Lev-Ari

    @AVIVA1950

    • @AVIVA1950_PIcs

    4h

    #WMIF2021

    @MGBInnovation

    Nikola Kojic, PhD CEO and Co-Founder, Oryon Cell Therapies Autologus cell therapy placed focal replacing missing synapses reestablishment of neural circutary

    @pharma_BI

    @AVIVA1950

    @AVIVA1950_PIcs

    Aviva Lev-Ari

    @AVIVA1950

    4h

    #WMIF2021

    @MGBInnovation

    Bob Carter, MD, PhD Chairman, Department of Neurosurgery, MGH William and Elizabeth Sweet, Professor of Neurosurgery, HMS Neurogeneration REVERSAL or slowing down? 

    @pharma_BI

    @AVIVA1950

    @AVIVA1950_PIcs

    Aviva Lev-Ari

    @AVIVA1950

    4h

    #WMIF2021

    @MGBInnovation

    Penelope Hallett, PhD NRL, McLean Assistant Professor Psychiatry, HMS efficacy Autologous cell therapy transplantation approach program T cells into dopamine genetating cells greater than Allogeneic cell transplantation 

    @pharma_BI

    @AVIVA1950

    @AVIVA1950_PIcs

    Aviva Lev-Ari

    @AVIVA1950

    4h

    #WMIF2021

    @MGBInnovation

    Penelope Hallett, PhD NRL, McLean Assistant Professor Psychiatry, HMS Pharmacologic agent in existing cause another disorders locomo-movement related 

    @pharma_BI

    @AVIVA1950

    @AVIVA1950_PIcs

    Aviva Lev-Ari

    @AVIVA1950

    @AVIVA1950_PIcs

    4h

    #WMIF2021

    @MGBInnovation

    Roger Kitterman VP, Venture, Mass General Brigham Saturation reached or more investment is coming in CGT Multi OMICS and academia originated innovations are the most attractive areas

    @pharma_BI

    @AVIVA1950

    1

    3

    @AVIVA1950_PIcs

    Aviva Lev-Ari

    @AVIVA1950

    @AVIVA1950_PIcs

    4h

    #WMIF2021

    @MGBInnovation

    Roger Kitterman VP, Venture, Mass General Brigham Saturation reached or more investment is coming in CGT 

    @pharma_BI

    @AVIVA1950

    1

    @AVIVA1950_PIcs

    Aviva Lev-Ari

    @AVIVA1950

    4h

    #WMIF2021

    @MGBInnovation

    Oleg Nodelman Founder & Managing Partner, EcoR1 Capital Invest in company next round of investment will be IPO 20% discount

    @pharma_BI

    @AVIVA1950

    @AVIVA1950_PIcs

    Aviva Lev-Ari

    @AVIVA1950

    @AVIVA1950_PIcs

    4h

    #WMIF2021

    @MGBInnovation

    Peter Kolchinsky, PhD Founder and Managing Partner, RA Capital Management Future proof for new comers disruptors  Ex Vivo gene therapy to improve funding products what tool kit belongs to 

    @pharma_BI

    @AVIVA1950

    @AVIVA1950_PIcs

    Aviva Lev-Ari

    @AVIVA1950

    4h

    #WMIF2021

    @MGBInnovation

    Deep Nishar Senior Managing Partner, SoftBank Investment Advisors Young field vs CGT started in the 80s  high payloads is a challenge 

    @pharma_BI

    @AVIVA1950

    @AVIVA1950_PIcs

    Aviva Lev-Ari

    @AVIVA1950

    5h

    #WMIF2021

    @MGBInnovation

    Bob Carter, MD, PhD MGH, HMS cells producing dopamine transplantation fibroblast cells metabolic driven process lower mutation burden  Quercetin inhibition elimination undifferentiated cells graft survival oxygenation increased 

    @pharma_BI

    @AVIVA1950

    @AVIVA1950_PIcs

    Aviva Lev-Ari

    @AVIVA1950

    5h

    #WMIF2021

    @MGBInnovation

    Chairman, Department of Neurosurgery, MGH, Professor of Neurosurgery, HMS Cell therapy for Parkinson to replace dopamine producing cells lost ability to produce dopamine skin cell to become autologous cells reprogramed  

    @pharma_BI

    @AVIVA1950

    #WMIF2021

    @MGBInnovation

    Kapil Bharti, PhD Senior Investigator, Ocular and Stem Cell Translational Research Section, NIH Off-th-shelf one time treatment becoming cure  Intact tissue in a dish is fragile to maintain metabolism to become like semiconductors

    @pharma_BI

    @AVIVA1950

    @AVIVA1950_PIcs

    Aviva Lev-Ari

    @AVIVA1950

    @AVIVA1950_PIcs

    5h

    #WMIF2021

    @MGBInnovation

    Ole Isacson, MD, PhD Director, Neuroregeneration Research Institute, McLean Professor, Neurology and Neuroscience, MGH, HMS Opportunities in the next generation of the tactical level Welcome the oprimism and energy level of all

    @pharma_BI

    @AVIVA1950

    @AVIVA1950_PIcs

    Aviva Lev-Ari

    @AVIVA1950

    5h

    #WMIF2021

    @MGBInnovation

    Erin Kimbrel, PhD Executive Director, Regenerative Medicine, Astellas In the ocular space immunogenecity regulatory communication use gene editing for immunogenecity Cas1 and Cas2 autologous cells

    @pharma_BI

    @AVIVA1950

    @AVIVA1950_PIcs

    Aviva Lev-Ari

    @AVIVA1950

    5h

    #WMIF2021

    @MGBInnovation

    Nabiha Saklayen, PhD CEO and Co-Founder, Cellino scale production of autologous cells foundry using semiconductor process in building cassettes by optic physicists

    @pharma_BI

    @AVIVA1950

    @AVIVA1950_PIcs

    Aviva Lev-Ari

    @AVIVA1950

    5h

    #WMIF2021

    @MGBInnovation

    Joe Burns, PhD VP, Head of Biology, Decibel Therapeutics Ear inside the scall compartments and receptors responsible for hearing highly differentiated tall ask to identify cell for anticipated differentiation control by genomics

    @pharma_BI

    @AVIVA1950

    Aviva Lev-Ari

    @AVIVA1950

    5h

    #WMIF2021

    @MGBInnovation

    Kapil Bharti, PhD Senior Investigator, Ocular and Stem Cell Translational Research Section, NIH first drug required to establish the process for that innovations design of animal studies not done before 

    @pharma_BI

    @AVIVA1950

    @AVIVA1950_PIcs

    Aviva Lev-Ari

    @AVIVA1950

    5h

    #WMIF2021

    @MGBInnovation

    Meredith Fisher, PhD Partner, Mass General Brigham Innovation Fund Strategies, success what changes are needed in the drug discovery process@pharma_BI

    @AVIVA1950

    @AVIVA1950_PIcs

    Aviva Lev-Ari

    @AVIVA1950

    5h

    #WMIF2021

    @MGBInnovation

    Robert Nelsen Managing Director, Co-founder, ARCH Venture Partners Manufacturing change is not a new clinical trial FDA need to be presented with new rethinking for big innovations Drug pricing cheaper requires systematization

    @pharma_BI

    @AVIVA1950

    1

    @AVIVA1950_PIcs

    Aviva Lev-Ari

    @AVIVA1950

    5h

    #WMIF2021

    @MGBInnovation

    Kush Parmar, MD, PhD Managing Partner, 5AM Ventures Responsibility mismatch should be and what is “are”

    @pharma_BI

    @AVIVA1950

    @AVIVA1950_PIcs

    Aviva Lev-Ari

    @AVIVA1950

    5h

    #WMIF2021

    @MGBInnovation

    David Berry, MD, PhD CEO, Valo Health GP, Flagship Pioneering Bring disruptive frontier platform reliable delivery CGT double knockout disease cure all change efficiency scope human centric vs mice centered right scale acceleration

    @pharma_BI

    @AVIVA1950

    @AVIVA1950_PIcs

    Aviva Lev-Ari

    @AVIVA1950

    6h

    #WMIF2021

    @MGBInnovation

    Kush Parmar, MD, PhD Managing Partner, 5AM Ventures build it yourself, benefit for patients FIrst Look at MGB shows MEE innovation on inner ear worthy investment  

    @pharma_BI

    @AVIVA1950

    @AVIVA1950_PIcs

    Aviva Lev-Ari

    @AVIVA1950

    6h

    #WMIF2021

    @MGBInnovation

    Robert Nelsen Managing Director, Co-founder, ARCH Venture Partners Frustration with supply chain during the Pandemic, GMC anticipation in advance CGT rapidly prototype rethink and invest proactive investor .edu and Pharma

    @pharma_BI

    @AVIVA1950

    Read Full Post »

    World Leaders to meet during Davos Agenda in a crucial year to rebuild trust

    Reporter: Aviva Lev-Ari, PhD, RN

     

    Davos Agenda

    https://www.weforum.org/events/the-davos-agenda-2021

     

    Adrian Monck, Managing Director, Public Engagement, public.affairs@weforum.org

    日本語 | 中文 | عربي

    World Leaders to Meet During Davos Agenda in a Crucial Year to Rebuild Trust

    • The Davos Agenda 2021 will convene under the theme: A Crucial Year to Rebuild Trust
    • The World Economic Forum will gather the world’s foremost leaders to address the economic, environmental, social and technological challenges following the COVID-19 pandemic 
    • More than 1,500 business, government and civil society leaders from over 70 countries will set the agenda for a critical year ahead and discuss how to catalyse impact in the rapidly advancing Fourth Industrial Revolution
    • The conclusions from the Davos Agenda week will feed into task forces working on global issues for the upcoming Special Annual Meeting in Singapore
    • For more information, please visit http://www.weforum.org; share on social media using the hashtag #DavosAgenda

    Geneva, Switzerland, 18 January 2021 – The World Economic Forum Davos Agenda, taking place virtually on 25-29 January, will bring together the foremost leaders of the world to address the new global situation. Heads of state and government, chief executives and leaders from civil society will convene under the theme: A Crucial Year to Rebuild Trust.

    The meeting will focus on creating impact, rebuilding trust and shaping the policies and partnerships needed in 2021.

    “In the context of the COVID-19 pandemic, the need to reset priorities and the urgency to reform systems have been growing stronger around the world,” said Klaus Schwab, Founder and Executive Chairman of the World Economic Forum. “Rebuilding trust and increasing global cooperation are crucial to fostering innovative and bold solutions to stem the pandemic and drive a robust recovery. This unique meeting will be an opportunity for leaders to outline their vision and address the most important issues of our time, such as the need to accelerate job creation and to protect the environment.”

    The COVID-19 pandemic has demonstrated that no institution or individual alone can address the economic, environmental, social and technological challenges of our complex, interdependent world. The pandemic has accelerated systemic changes that were apparent before its inception. The fault lines that emerged in 2020 now appear as critical crossroads in 2021. The Davos Agenda will help leaders choose innovative and bold solutions to stem the pandemic and drive a robust recovery over the next year.

    The five programme themes are:

    1. Designing cohesive, sustainable, resilient economic systems (25 January)
    2. Driving responsible industry transformation and growth (26 January)
    3. Enhancing stewardship of the global commons (27 January)
    4. Harnessing the technologies of the Fourth Industrial Revolution (28 January)
    5. Advancing global and regional cooperation (29 January)

    Special addresses from G20 heads of state and government and international organizations will provide crucial insights into a range of important issues in the year ahead. Participants will hear first-hand how these public figures will demonstrate leadership and drive action in areas such as the environment, jobs, and advances in innovation brought by the Fourth Industrial Revolution.

    Heads of state and government include:

    Xi Jinping, President of the People’s Republic of China; Narendra Modi, Prime Minister of India; Yoshihide Suga, Prime Minister of Japan; Emmanuel Macron, President of France; Angela Merkel, Federal Chancellor of Germany; Ursula von der Leyen, President of the European Commission; Giuseppe Conte, Prime Minister of Italy; Moon Jae-in, President of the Republic of Korea; Alberto Fernández, President of Argentina; Cyril Ramaphosa, President of South Africa; Pedro Sánchez, Prime Minister of Spain; Guy Parmelin, President of the Swiss Confederation and Federal Councillor for Economic Affairs, Education and Research; Ivan Duque, President of Colombia; Carlos Alvarado Quesada, President of Costa Rica; Nana Addo Dankwa Akufo-Addo, President of the Republic of Ghana; Kyriakos Mitsotakis, Prime Minister of Greece; Benjamin Netanyahu, Prime Minister of Israel; Abdullah II ibn Al Hussein, King of the Hashemite Kingdom of Jordan; Paul Kagame, President of Rwanda; Lee Hsien Loong, Prime Minister of Singapore, the host of the World Economic Forum Special Annual Meeting 2021.

    Other world leaders are expected to confirm.

    Leaders from international organizations, government agencies and central banks include:

    António Guterres, Secretary-General, United Nations (UN); Tedros Adhanom Ghebreyesus, Director-General, World Health Organization (WHO); Kristalina Georgieva, Managing Director, International Monetary Fund (IMF); Amina Mohammed, Deputy Secretary-General, United Nations (UN); Achim Steiner, Administrator, United Nations Development Programme (UNDP); Phumzile Mlambo-Ngcuka, Undersecretary-General and Executive Director, United Nations Entity for Gender Equality and the Empowerment of Women (UN WOMEN); Dongyu Qu, Director-General, Food and Agriculture Organization of the United Nations (FAO); Inger Andersen, Executive Director, United Nations Environment Programme (UNEP); Henrietta Fore, Executive Director, United Nations Children’s Fund (UNICEF); David Beasley, Executive Director, United Nations World Food Programme (WFP); Fang Liu, Secretary-General, International Civil Aviation Organization (ICAO); Anthony Fauci, Director, National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA; Angel Gurría, Secretary-General, Organisation for Economic Co-operation and Development (OECD); Mauricio Claver-Carone, President, Inter-American Development Bank (IDB); Guy Ryder, Director-General, International Labour Organization (ILO); Jürgen Stock, Secretary-General, International Criminal Police Organization (INTERPOL); Fatih Birol, Executive Director, International Energy Agency (IEA); Rebecca Fatima Sta Maria, Executive Director, APEC Secretariat (Asia-Pacific Economic Cooperation).

    Christine Lagarde, President, European Central Bank; François Villeroy de Galhau, Governor of the Central Bank of France; Andrew Bailey, Governor of the Bank of England.

    The private sector will be represented by more than 1,000 leaders from the Forum’s member and partner organizations. Seven of the top ten companies by market capitalization are engaged year-round with the Forum and many will participate in The Davos Agenda week. As a working meeting to advance ongoing project work, more than 500 chief executives and chairpersons will take part in sessions throughout the week.

    Leaders from civil society are a critical voice in shaping the agenda. Those taking part in the meeting include:

    Seth Berkley, Chief Executive Officer, Gavi, the Vaccine Alliance; Gabriela Bucher, Executive Director, Oxfam International; Sharan Burrow, General Secretary, International Trade Union Confederation (ITUC); Hindou Oumarou Ibrahim, President, Association for Indigenous Women and Peoples of Chad (AFPAT); Marco Lambertini, Director-General, WWF International; Laura Liswood, Secretary-General, Council of Women World Leaders; Delia Ferreira Rubio, Chair, Transparency International; Peter Sands, Executive Director, Global Fund to Fight AIDS, Tuberculosis and Malaria (GF). 

    Drawn from over 10,000 civic-minded young leaders, members of the World Economic Forum’s Global Shapers, Young Global Leaders, Technology Pioneers and Social Entrepreneurs communities will bring unique perspectives to The Davos Agenda.

    Flagship reports, initiatives, and the latest book on Stakeholder Capitalism 

    On January 25, Professor Schwab will release his latest book, titled “Stakeholder Capitalism: A Global Economy that Works for Progress, People and Planet.” It explores how societies can build the future post-COVID, and builds on the Forum’s 50-year-old advocacy of the stakeholder approach.

    The World Economic Forum will release its Global Risks Report 2021 on 19 January. The flagship report is an important marker for prioritizing action in public and private sectors in the year ahead.

    The Davos Agenda will also mark the launch of several World Economic Forum initiatives to accelerate the race to net-zero emissions, to champion new standards for racial justice, to ensure artificial intelligence is developed ethically and in the global public interest and to close the digital divide. More details on these initiatives and others will be disclosed at the meeting.

    Opening Event and Crystal Awards

    The meeting will be preceded by the Opening Event, available on YouTube on Sunday 24 January at 19.00 CET, featuring a welcome from Klaus Schwab and a special address by Guy Parmelin, President of the Swiss Confederation, just before the 27th Crystal Awards hosted by Hilde Schwab, Chairperson and Co-founder, Schwab Foundation for Social Entrepreneurship, and the photographer Platon.

    The awards will be followed by the world premiere of “See Me: A Global Concert.” The official programme of The Davos Agenda will begin on 25 January.

    Notes to editors

    Media registration and sign-up

    Explore the guide on how to follow and embed sessions on your website here

    Watch the livestreamed sessions here

    Follow the Forum on Twitter via @wef@davos and join the conversation using #DavosAgenda | Instagram | LinkedIn | TikTok | Weibo | Podcasts

    Become a fan of the Forum on Facebook

    Read the Forum Agenda also in French | Spanish | Mandarin | Japanese

    Check out the Forum’s Strategic Intelligence Platform and Transformation Maps

    Watch Forum videos

    Learn about the Forum’s impact

    Subscribe to Forum news releases and Podcasts

    SOURCE

    From: “<Adrian Monck>”, World Economic Forum <Public.Affairs@weforum.org>

    Reply-To: “<Adrian Monck>”, World Economic Forum <Public.Affairs@weforum.org>

    Date: Monday, January 18, 2021 at 9:37 AM

    To: “Aviva Lev-Ari, PhD, RN” <AvivaLev-Ari@alum.berkeley.edu>

    Subject: World Leaders to meet during Davos Agenda in a crucial year to rebuild trust

    Read Full Post »

    REUTERS NEXT (Jan 11-14) kicks off 2021 by gathering global leaders and forward thinkers to reimagine solutions to the challenges the new year brings

    Reporter: Aviva Lev-Ari, PhD, RN

     

    The Virtual Summit Rethinking the Future

    REUTERS NEXT kicks off 2021 by gathering global leaders and forward thinkers to reimagine solutions to the challenges the new year brings.

    After the extraordinary upheavals of 2020, we will come together to look ahead at opportunities for change and growth, as well as how to deal with the rifts and problems that our world and our societies face.

    No country, company or community can tackle the future alone. To build a better world, thinkers and doers must come together to share ideas, collaborate and act.

    REUTERS NEXT draws on Reuters global reach to host diverse voices from around the world who will examine topics from different perspectives, bringing their passion, experience and expertise to find new ways forward.

    Join the conversation at REUTERS NEXT as we look ahead, together.

    https://reutersevents.com/events/next/#about

    https://reutersevents.app.swapcard.com/event/reuters-next

    Leaders in Pharmaceutical Business Intelligence (LPBI) Group

    Announcing Strategic Transition from 1.0 LPBI to 2.0 LPBI on 1/1/2021: New Management, Marketing Communication and New Scientific/Technical Opportunities

     

    Aviva Lev-Ari, PhD, RN, Founder, LPBI Group: 1.0 & 2.0

    will attend REUTERS NEXT on January 13 & 14, 2021 and

    will cover these days in real time

    AGENDA

    https://reutersevents.com/events/next/conference-agenda.php

     

    Day 1: January 11

     RECOVERING GROWTH
    5:30am GMT
    Capturing a Slice of the Boom in High-Net-Worth Banking

    The private banking arm of OCBC Bank is among a handful of Asian banks that have emerged among the biggest serving the region’s growing legion of billionaires. Boasting assets under management of $116 billion, Bank of Singapore has expanded into Europe, India and Dubai as it seeks to serve the family offices of the rich. The private bank, part of Southeast Asia’s second-largest lender, is also exploring setting up an onshore presence in China, the top market for wealth creation.

     

    Bahren Shaari

    Bahren ShaariChief Executive OfficerBank of Singapore

     

    Anshuman Daga

    Anshuman DagaSenior Financial CorrespondentReuters

     POLICY & PROGRESS
    6:00am GMT
    Interview

     

    Dr Reza Baqir

    Dr Reza BaqirGovernorState Bank Pakistan

     

    Simon Robinson

    Simon RobinsonGlobal Managing EditorReuters

     POLICY & PROGRESS
    6:30am GMT
    Interview

     

    Tae Yong-ho

    Tae Yong-hoThe Member of the National Assembly of The Republic of Korea

     

    Jack Kim

    Jack KimCorrespondentReuters

     POLICY & PROGRESS
    7:00am GMT
    Asia’s COVID-19 journey: Swifter Response But Slower Return to Normality?

    Asia has managed to control the spread of the new coronavirus more swiftly and effectively than the rest of the world, but many countries in the region are still battling with a persistent resurgence of new cases and the initial amount of vaccines Asia will receive will be limited. Is Asia likely to lag other regions in ending the pandemic and when will things go back to normal?

     

    Dr. Pandu Riono

    Dr. Pandu RionoEpidemiologist & Senior StaffUniversity of Indonesia, Faculty of Public Health

     

    Irma Hidayana

    Irma HidayanaCo-Founder & Co-LeaderLaporCovid19

     

    Dale Fisher

    Dale FisherProfessor of MedicineNational University of Singapore

     

    Miyoung Kim

    Moderator: Miyoung KimBreaking News Editor, AsiaReuters

     POLICY & PROGRESS
    7:30am GMT
    Interview

     

    Edward Yau Tang-wah

    Edward Yau Tang-wahSecretary for Commerce and Economic DevelopmentHong Kong Special Administrative Region Government

     

    Anne-Marie Roantree

    Anne-Marie RoantreeBureau ChiefReuters

     RADICAL REDESIGN
    9:00am GMT
    Recovering the Travel Bug post-Covid

     

    Deep Kalra

    Deep KalraFounder & Group Executive ChairmanMakeMyTrip Limited

     

    Sabina Fluxa

    Sabina FluxaChief Executive OfficerIberostar

     

    Tony Fernandes

    Tony FernandesChief Executive OfficerAirAsia

     SUSTAINABLE FUTURE
    9:30am GMT
    Urban Mining: Recycling on a Mass Scale

     

    Steve Fisher

    Steve FisherPresident and Chief Executive OfficerNovelis

     

    Yash Lohia

    Yash LohiaChief Sustainability OfficerIndorama Ventures

     SUSTAINABLE FUTURE
    10:00am GMT
    The Measurement Challenge of Carbon Accounting

    How can we cut emissions if we can’t count them?

     

    David Hone

    David HoneChief Climate Change AdviserShell

     

    Nick Stansbury

    Nick StansburyHead of Commodity ResearchLegal & General Investment Management (LGIM)

     

    Sean Kidney

    Sean KidneyChief Executive OfficerClimate Bonds Initiative

     RECOVERING GROWTH
    10:30am GMT
    Powering Economic Growth in Africa

    Look at different investment strategies – infrastructure, digital and trade.

     

    Fola Fagbule

    Fola FagbuleSenior Vice PresidentAfrica Finance Corporation

     

    Juliana Rotich

    Juliana RotichVenture PartnerAtlantica Ventures

     

    Silver Ojakol

    Silver OjakolCommissioner External TradeGhana

     POLICY & PROGRESS
    11:00am GMT
    Interview

     

    Vera Daves de Sousa

    Vera Daves de SousaFinance MinisterMinistry of Finance of Angola

     RADICAL REDESIGN
    11:30am GMT
    Ethnic Diversity at Work: Putting Words into Action

     

    Lanaya Irvin

    Lanaya IrvinPresidentCoqual

     

    John Rice

    John RiceFounder & Chief Executive OfficerManagement Leadership for Tomorrow

     MEDIA & FREE SPEECH
    12:00pm GMT
    Interview

     

    Waad al-Kateab

    Waad al-KateabFilmmaker, Activist & FounderAction For Sama

     RADICAL REDESIGN
    12:30pm GMT
    Ethnic Diversity at Work: Putting Words into Action

    Companies lurched into diversity policies after Floyd’s death. Will they stick?

     

    soon

    Speakers TBC

     MEDIA & FREE SPEECH
    1:00pm GMT
    How to Rebuild Trust in Media

    In a polarised world, news media need to rebuild trust. Impartiality, transparency, representation and listening all play a part. What other strategies are top media executives planning?

     

    Tim Davie

    Tim DavieDirector GeneralBBC

     

    Michael Friedenberg

    Michael FriedenbergPresidentReuters

     

    Jane Barrett

    Moderator: Jane BarrettGlobal Editor Media News StrategyReuters

     SUSTAINABLE FUTURE
    3:00pm GMT
    Interview

     

    Professor Jeffrey Sachs

    Professor Jeffrey SachsEconomist & DirectorCenter for Sustainable Development at Columbia University

     

    soon

    Ann SaphirFinancial ReporterReuters

     SUSTAINABLE FUTURE
    3:20pm GMT
    Nuclear Energy and its Future

     

    Sama Bilbao y Leon

    Sama Bilbao y LeonDirector GeneralWorld Nuclear Association

     

    Dan Poneman

    Dan PonemanPresident & Chief Executive OfficerCentrus Energy Corp.

     

    Jay Wileman

    Jay WilemanPresident & Chief Executive OfficerGE Hitachi

     

    George Borovas

    George BorovasHead of Nuclear and Tokyo Office Managing PartnerHunton Andrews Kurth

     

    soon

    Moderator: Nina ChestneyHead of EMEA Power, Gas, Coal and CarbonReuters

     RECOVERING GROWTH
    4:00pm GMT
    Trade, Doing Business Globally, Challenges

     

    Joe Kaeser

    Joe KaeserPresident & Chief Executive OfficerSiemens AG

     RADICAL REDESIGN
    4:30pm GMT
    Edtech: Making the Most of Online Learning Beyond Covid

     

    Dwayne Matthews

    Dwayne MatthewsEducation Strategist & FounderTomorrowNow Learning Labs

     SUSTAINABLE FUTURE
    5:00pm GMT
    The Arctic Frontier

    Climate change is warming the Arctic faster than the rest of the world, opening long-frozen region to exploration, tourism, mining and shipping. Those crowds and commerce have an impact on the environment and indigenous communities.

     

    Ann Daniels

    Ann DanielsPolar Explorer

     

    Ilarion Merculieff

    Ilarion MerculieffPresidentGlobal Center for Indigenous Leadership and Lifeways

     

    Neil Roberts

    Neil RobertsHead of Marine and AviationLloyd’s of London Market Association

     

    Clare Baldwin

    Moderator: Clare BaldwinSpecial CorrespondentReuters

     SUSTAINABLE FUTURE
    5:30pm GMT
    Managing the Energy Transition from Within

    Top players in the oil industry discuss the challenges and opportunities for their businesses in a transition away from fossil fuels.

     

    Lorenzo Simonelli

    Lorenzo SimonelliChief Executive OfficerBaker Hughes

     

    Jennifer Hiller

    Moderator: Jennifer HillerOil & Gas ReporterReuters

     RADICAL REDESIGN
    6:00pm GMT
    Interview

     

    Salman Khan

    Salman KhanFounder and CEOKhan Academy

     RADICAL REDESIGN
    6:20pm GMT
    Interview

     

    Sheryl Sandberg

    Sheryl SandbergChief Operating OfficerFacebook

    Day 2: January 12

     POLICY & PROGRESS
    5:30am GMT
    India’s Place in a Divided World

     

    Dr. S. Jaishankar

    Dr. S. JaishankarExternal Affairs Minister of India

     POLICY & PROGRESS
    6:00am GMT
    Philippines: On the Road to Recovery?

     

    Benjamin Diokno

    Benjamin DioknoGovernorBangko Sentral ng Pilipinas

     

    Karen Lema

    Karen LemaBureau Chief PhilippinesReuters

     RECOVERING GROWTH
    6:30am GMT
    Where Asia’s Smart Money is Going in 2021

     

    Hugh Young

    Hugh YoungManaging DirectorAberdeen Standard Investments

     

    Elizabeth Allen

    Elizabeth AllenHead of Asian Fixed IncomeHSBC Global Asset Management

     MEDIA & FREE SPEECH
    7:00am GMT
    Political journalism in Asia: new media, old values

     

    Steve Gan

    Steve GanEditor-in-chiefMalaysiakini.com

     

    Najwa Shihab

    Najwa ShihabNewscaster & AnchorMetro TV Indonesia

     

    Cherian George

    Cherian GeorgeProfessor of Media StudiesHong Kong Baptist University

     MEDIA & FREE SPEECH
    7:30am GMT
    Interview

     

    K Shanmugam

    K ShanmugamMinister for Home Affairs & Minister for Law

     RADICAL REDESIGN
    9:00am GMT
    Australia vs Big Tech

    The ACCC’s Sims is spearheading potential changes to Australia’s merger laws early in 2021, putting the country at the front of a global crackdown on antitrust violations from “Big Tech.” The ACCC is due to deliver a report on the app marketplace, with a focus on the market power of Apple and Google, by the end of March. The regulator has already taken legal action against Google twice – for misleading consumers about how much personal information it was tracking and for misleading consumers about its collection of personal location data.

     

    Rod Sims

    Rod SimsChairAustralian Competition and Consumer Commission

     RADICAL REDESIGN
    10:10am GMT
    Interview

     

    Nguyen Thi Phuong Thao

    Nguyen Thi Phuong ThaoPresident & CEOVietJet

     RECOVERING GROWTH
    10:30am GMT
    A New Economy: Africa’s Digital Engine

     

    Jihan Abass

    Jihan AbassFounder & Chief Executive OfficerLami

     

    Iyinoluwa Aboyeji

    Iyinoluwa AboyejiTech Entrepreneur Co-FounderAndela

     MEDIA & FREE SPEECH
    11:00am GMT
    Interview

     

    Sir Tim Berners-Lee

    Sir Tim Berners-LeeInventor of World Wide Web and CTOInrupt

     

    John Bruce

    John BruceChief Executive OfficerInrupt

     RADICAL REDESIGN
    12:00pm GMT
    Banking the Unbanked with New Technology

    Digital taking barriers down and making banking more possible – but also making digital a requirement?

     

    Vijay Shekar Sharma

    Vijay Shekar SharmaChief Executive Officer & FounderPaytm

     POLICY & PROGRESS
    12:30pm GMT
    Interview

     

    Olaf Scholz

    Olaf ScholzFederal Minister of Finance and Vice ChancellorGerman Federal Ministry of Finance

     

    Mark Bendeich

    Mark BendeichEurope News EditorReuters

     SUSTAINABLE FUTURE
    3:00pm GMT
    Interview

     

    Patricia Espinosa

    Patricia EspinosaExecutive SecretaryUnited Nations Framework Convention on Climate Change

     

    Matthew Green

    Matthew GreenClimate Change CorrespondentReuters

     MEDIA & FREE SPEECH
    3:30pm GMT
    Misinformation and New Narratives

    Conspiracy theories and misinformation have spewed out of social media to mainstream narratives. Where does it all come from? How do they proliferate and what can we do about it?

     

    Graham Brookie

    Graham BrookieDirector and Managing Editor, Digital Forensic Research Lab (DFRLab)Atlantic Council

     

    Claire Wardle

    Claire WardleCo-FounderFirst Draft

     

    Christina Anagnostopoulos

    Christina AnagnostopoulosSenior Producer, Reuters Fact CheckReuters

     SUSTAINABLE FUTURE
    4:00pm GMT
    Batteries – Lithium as the New Oil

     

    Eric Norris

    Eric NorrisPresident – Lithium GBUAlbemarle Corporation

     

    Ernest Scheyder

    Ernest ScheyderCorrespondentReuters

     SUSTAINABLE FUTURE
    4:30pm GMT
    The Future of Fossil Fuels in A Green World

    Unlike Shell or BP, Chevron has been unabashed about its commitment to fossil fuels. It’s been smarter than others though, has a stronger balance sheet, and has made more calculated decisions. This has shown up in its market value, which last week surpassed Exxon Mobil for the first time ever. Wirth will have a lot to say about global economies, too, and the global rebound from the Covid-19 crisis.

     

    Michael Wirth

    Michael WirthChief Executive OfficerChevron

     

    Lauren Silva Laughlin

    Lauren Silva LaughlinGlobal Deals EditorReuters

     

    Rob Cox

    Rob CoxGlobal EditorReuters Breakingviews

     RECOVERING GROWTH
    5:00pm GMT
    Rich World, Poor World. How to Close the Gap

    What are the best ways to help the poorer countries of the world and their societies? Is the age of foreign aid over? What about debt relief and keeping more tax in country?

     

    Dambisa Moyo

    Dambisa MoyoGlobal Economist & AuthorVersaca Investments

     SUSTAINABLE FUTURE
    5:30pm GMT
    Keep It In The Ground: A Radical Solution to Climate Change

    Is the best way to lower emissions to keep fossil fuels in the ground? Why environmentalists believe not tapping new oil and gas deposits, and plugging abandoned wells, would benefit investors and society.

     

    Janet Redman

    Janet RedmanClimate Campaign DirectorGreenpeace USA

     

    Kassie Siegel

    Kassie SiegelSenior Counsel and DirectorThe Climate Law Institute

     

    Peter Erickson

    Peter EricksonSenior ScientistStockholm Environment Institute

     RECOVERING GROWTH
    6:00pm GMT
    Interview

     

    Stephen Pagliuca

    Stephen PagliucaCo-chairBain

     

    Lauren Silva Laughlin

    Lauren Silva LaughlinGlobal Deals EditorReuters

     RECOVERING GROWTH
    6:20pm GMT
    Interview

     

    Calvin McDonald

    Calvin McDonaldChief Executive OfficerLululemon

    Day 3: January 13

     RADICAL REDESIGN
    5:30am GMT
    Asia Aviation in a Post-Pandemic World

    The once fast-growing Asian aviation industry has been hit hard by the pandemic, with the region among the slowest to reopen international travel, though domestic travel has begun to rebound. How will the pandemic shape future travel patterns for leisure and business travel? How can airlines like Qantas adapt their product, fleet and route networks for the future passenger mix? How will they restore confidence in international travel before and after a vaccine?

     

    Alan Joyce

    Alan JoyceChief Executive OfficerQantas

     RECOVERING GROWTH
    6:00am GMT
    How to Sell Drinks in a Socially-Distanced World

    Suntory, like all global drinks makers, has been hit hard by the pandemic which has dented sales of its popular beer and global whiskies. Even with the eventual arrival of vaccines, consumers are expected to remain wary of crowding together at bars and restaurants as they used to. How is Suntory riding out the slump? Are there any new growth opportunities in post-pandemic trends (drinking at home, non-alcohol beers etc.)? Has the pandemic, and the global political landscape, changed his views on globalization? Do Japanese companies including Suntory need to be more wary of large-scale, international acquisitions now?

     

    Takeshi Niinami

    Takeshi NiinamiChief Executive OfficerSuntory

     MEDIA & FREE SPEECH
    6:30am GMT
    Silencing the Messenger: The Struggle for Free Speech in Asia

    Over the past three decades, more journalists have been killed in Asia Pacific than any other region on earth, with the Philippines, India, and Afghanistan consistently ranked among the deadliest places to be a journalist. Overall press freedom has worsened in more than a dozen countries across the continent since 2018, according to watchdog Reporters Without Borders, and in a time of pandemic, pervasive online misinformation, and rising authoritarianism, news organizations are facing unprecedented challenges.

     

    Khin Omar

    Khin OmarBurmese Democracy Activist

     

    Nidhi Razdan

    Nidhi RazdanAssociate Professor of JournalismHarvard University

     

    Vergel O. Santos

    Vergel O. SantosMember, Board of TrusteesCenter for Media Freedom and Responsibility

     RECOVERING GROWTH
    7:00am GMT
    China Private Equity: Navigating volatilities and capturing new growth post-COVID (3)

     

    Dr. Fred Hu

    Dr. Fred HuChairmanPrimavera Capital Group

     RECOVERING GROWTH
    7:20am GMT
    China Private Equity: Navigating volatilities and capturing new growth post-COVID (1)

     

    Shan Weijian

    Shan WeijianChairman and Chief Executive OfficerPAG

     POLICY & PROGRESS
    9:00am GMT
    The EU economy post-COVID, post-Brexit, in debt…

     

    Christine Lagarde

    Christine LagardePresidentEuropean Central Bank

     

    Alessandra Galloni

    Alessandra GalloniGlobal Managing EditorReuters

     MEDIA & FREE SPEECH
    9:45am GMT
    How and Why to Fight Threats to Press Freedom Around the World

    A global panel on press freedom around the world. Is it getting generally worse?

     

    Maria Ressa

    Maria RessaFounder, Rapplercompany

     

    Sonny Swe

    Sonny SweCo-Founder & Chief Executive OfficerFrontier Myanmar

     RADICAL REDESIGN
    10:30am GMT
    Telling Africa Stories

    How African storytellers are reshaping the way the world sees the continent.

     

    Bibi Bakare-Yusuf

    Bibi Bakare-YusufFounder & PublisherCassava Republic Press

     

    Mo Abudu

    Mo AbuduChief Executive OfficerEbonylife Media & Ebonylife Place

     RADICAL REDESIGN
    12:00pm GMT
    Managing the Masses and Politicians through the Fog of Covid

     

    Dr. Anders Tegnell

    Dr. Anders TegnellState EpidemiologistSweden

     

    Dr. Chikwe Ihekweazu

    Dr. Chikwe IhekweazuDirector GeneralNigeria Centre for Disease Control (NCDC)

     RADICAL REDESIGN
    1:00pm GMT
    Precious Cargo: Transporting Vaccines and Looking for Recovery

     

    John Pearson

    John PearsonChief Executive OfficerDHL Express

     RECOVERING GROWTH
    1:30pm GMT
    Interview

     

    Alan Jope

    Alan JopeChief Executive OfficerUnilever

     RECOVERING GROWTH
    3:00pm GMT
    Pets and the pandemic: The future of animal science

     

    Kristin Peck

    Kristin PeckChief Executive OfficerZoetis

     POLICY & PROGRESS
    3:30pm GMT
    Public Health Lessons from COVID and Vaccinations

    COVID-19 has laid bare many failings in the public health system. What lessons are there to learn around the world and what are the biggest challenges beyond COVID?

     

    Heidi J Larson

    Heidi J LarsonProfessor of AnthropologyRisk and Decision Science Vaccine Confidence Project

     

    Professor Michelle Williams

    Professor Michelle WilliamsDean of the FacultyHarvard T.H. Chan School of Public Health

    4:00pm GMT
    Interview

     

    soon

    Speaker TBC

     RADICAL REDESIGN
    4:30pm GMT
    Interview

     

    Sandeep Mathrani

    Sandeep MathraniChief Executive OfficerWeWork

     MEDIA & FREE SPEECH
    5:00pm GMT
    The Edelman Trust Barometer 2021

    Richard Edelman discusses the new Trust Barometer for 2021. To discuss trust in journalism, politicians, tech companies etc.

     

    Richard Edelman

    Richard EdelmanChief Executive OfficerEdelman

     SUSTAINABLE FUTURE
    5:30pm GMT
    Climate and Environmental Justice

    What do we do about the unequal impact of climate change?

     

    Dr Friederike Otto

    Dr Friederike OttoAssociate Director, Environmental Change InstituteUniversity of Oxford

     

    Osprey Orielle Lake

    Osprey Orielle LakeFounder and Executive DirectorWomen’s Earth and Climate Action Network (WECAN) International

     

    Mohamed Adow

    Mohamed AdowDirectorPower Shift Africa

     

    Valerie Volcovici

    Valerie VolcoviciCorrespondentReuters

     MEDIA & FREE SPEECH
    6:00pm GMT
    The Changing Nature of Philanthropy in the 2020s

     

    Darren Walker

    Darren WalkerPresidentFord Foundation

     RADICAL REDESIGN
    6:30pm GMT
    Interview

     

    Sundar Pichai

    Sundar PichaiChief Executive OfficerGoogle and Alphabet

    Day 4: January 14

     POLICY & PROGRESS
    5:30am GMT
    Interview

    Mahathir bin Mohamad served twice as Malaysia’s prime minister, from July 1981 to October 2003 and from May 2018 to March 2020. Forming the new Homeland Fighters Party, Mahathir remains a prominent voice in the Southeast Asian nation’s politics.

     

    Mahathir Mohamad

    Mahathir MohamadFormer Prime Minister of Malaysia

     POLICY & PROGRESS
    6:00am GMT
    Interview

     

    soon

    Speaker TBC

     SUSTAINABLE FUTURE
    6:30am GMT
    Palm Oil Production in Asia: Looking For a Sustainable Future

    Global sales of palm oil, used in everything from cookies to soap, reached $43 billion last year, with Southeast Asia responsible for the bulk of production. The industry has come under fire in recent years, including consumer boycotts, for clearing biodiversity-rich tropical rainforests in the region. Yet it also provides hundreds of thousands of jobs as well as substantial foreign income. The major players, Indonesia and Malaysia, are looking at ways to expand coveted green credentials, even as they push for consumer companies to step up purchases of the more expensive sustainable palm oil.

     

    Ravi Muthayah

    Ravi MuthayahSecretary-GeneralMalaysia Plantation & Commodities Ministry

     

    Olivier Tichit

    Olivier TichitLeader of SustainabilityMusim Mas

     

    Mohd Haris Mohd Arshad

    Mohd Haris Mohd ArshadManaging DirectorSime Darby Oils

     RADICAL REDESIGN
    7:10am GMT
    Tech Innovation in China

    Nowhere else in the world has seen more rapid digitization in the past decade than in China, where technological innovation driven by the private sector has transformed all aspects of society, from the way people socialize to how business is done. The commercial outlook for innovators in China is positive, with a ready market of 1.4 billion people, but any new technological offerings and innovation remain beholden to sudden shifts in the mood in Beijing.

     

    Ma Baoli

    Ma BaoliFounder, Chairman & Chief Executive OfficerBlueCity

     POLICY & PROGRESS
    7:30am GMT
    Interview

     

    Taro Kono

    Taro KonoJapan Minister of State for Special Missions

     RECOVERING GROWTH
    9:00am GMT
    The business of vaccinating the world against COVID-19

    India’s Serum Institute is one of the biggest vaccine makers by volume in the world. CEO Poonawalla’s early bet on the AstraZeneca-University of Oxford COVID-19 vaccine candidate during first phase trials appears to have paid off. The institute plans to prioritize distribution in India before providing doses to the COVAX facility, an international initiative aimed at ensuring almost 100 low and middle income economies have access to a vaccine.

     

    Adar Poonawalla

    Adar PoonawallaChief Executive OfficerIndia’s Serum Institute

     RECOVERING GROWTH
    10:00am GMT
    Interview

     

    N Chandrasekaran

    N ChandrasekaranChairmanTata Group

     RADICAL REDESIGN
    10:30am GMT
    The Future of Further Education post-Covid

    How has Covid changed universities and which changes will stick.

     

    Sebastian Thrun

    Sebastian ThrunFounder, President & Executive ChairmanUdacity

     

    Louise Richardson

    Louise RichardsonVice-ChancellorUniversity of Oxford

     SUSTAINABLE FUTURE
    11:30am GMT
    The Amazon and Business. A Delicate Coexistence

    The Amazon rainforest is being destroyed for business but are the two incompatible? Can we save the Amazon and profit from it?

     

    João Paulo Ferreira

    João Paulo FerreiraChief Executive OfficerNatura & Co Latin America

     RECOVERING GROWTH
    12:00pm GMT
    Interview

     

    Peter Wennink

    Peter WenninkPresident & Chief Executive OfficerASML

     RADICAL REDESIGN
    1:00pm GMT
    Break the Mould: Diversity in Tech and Finance

     

    soon

    Speaker TBC

     SUSTAINABLE FUTURE
    3:00pm GMT
    ESG: Should We Really Divest Energy Stocks?

    If big investors dump stocks, there may be less accountability. What to do?

     

    John Flint

    John FlintFormer Group Chief ExecutiveHSBC

     

    Adam Matthews

    Adam MatthewsDirector of Ethics and EngagementChurch of England Pensions Board

     MEDIA & FREE SPEECH
    4:00pm GMT
    Interview

     

    soon

    Speaker TBC

     RADICAL REDESIGN
    5:00pm GMT
    Diversity in Law

    How the US legal profession is pushing greater diversity and where the blockers still are.

     

    Justice Goodwin Liu

    Justice Goodwin LiuAssociate JusticeCalifornia Supreme Court

     

    Anne Robinson

    Anne RobinsonManaging Director, General Counsel and Corporate SecretaryVanguard

     

    Dev Stahlkopf

    Dev StahlkopfCorporate Vice President and General Counsel, Legal AffairsMicrosoft

     RADICAL REDESIGN
    5:30pm GMT
    Equality in Law and the Push for Diversity

     

    Jitse Groen

    Jitse GroenChief Executive OfficerJustEat

     

    Brian Niccol

    Brian NiccolChairman & Chief Executive OfficerChipotle

     RADICAL REDESIGN
    6:00pm GMT
    The Future of Travel – How Airbnb is Changing Post-COVID

    Off the back of its successful IPO, Airbnb’s CEO Brian Chesky shares lessons from the pandemic and how he sees travel returning in 2021.

     

    Brian Chesky

    Brian CheskyChief Executive OfficerAirbnb

     RECOVERING GROWTH
    6:30pm GMT
    The Next Frontiers of Venture Capitalism

    Interview with Y Combinator on where they are putting their trend-setting bets in 2021.

     

    Michael Seibel

    Michael SeibelGroup Partner and Managing DirectorY-Combinator

     

    Jared Friedman

    Jared FriedmanGroup PartnerY-Combinator

     

    Read Full Post »

    Virtual Discover Brigham, November 12, 11AM EST – 3:45PM EST

     

    2020 AGENDA

    http://www.discoverbrigham.org/

    11:00 – 11:45 AM EST

    Poster Session & Demos

    11:45 AM – 12:15 PM EST

    Rock the Mic: Postdoc Fast Pitch

    12:30 – 1:05 PM EST

    What We Know About COVID-19

    1:10 – 1:40 PM EST

    Hey Briggie: The Use of Artificial Intelligence to Improve Patient Safety and Experience

    1:45 – 2:15 PM EST

    Committing to Diversity, Inclusion, and Equity in Clinical Research: The Time is Now

    2:25 – 2:55 PM EST

    Getting Ahead: Advances in Food and Drug Allergy

    3:00 – 3:30 PM EST

    What’s Sex Got to Do with It: Risk and Management of Autoimmune Disease

    3:35 – 3:45 PM EST

    Closing Remarks

    “Kicking off with a keynote, the day-long event featured seven interactive demos, eight scientific sessions, 99 poster presentations, 37 speakers and the announcement of the winner of the $100,000 BRIght Futures Prize.”READ MORE

    SESSION
    SPOTLIGHTS

    Read Full Post »

    Older Posts »